Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds by Nicholson, KG et al.
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 18 ISSUE 36 MAY 2014
ISSN 1366-5278
DOI 10.3310/hta18360
Randomised controlled trial and health economic 
evaluation of the impact of diagnostic testing  
for influenza, respiratory syncytial virus and 
Streptococcus pneumoniae infection on the 
management of acute admissions in the elderly  
and high-risk 18- to 64-year-olds
Karl G Nicholson, Keith R Abrams, Sally Batham, Marie Jo Medina,  
Fiona C Warren, Mike Barer, Alison Bermingham, Tristan W Clark,  
Nicholas Latimer, Maria Fraser, Nelun Perera,  
K Rajakumar and Maria Zambon

Randomised controlled trial and health
economic evaluation of the impact of
diagnostic testing for inﬂuenza,
respiratory syncytial virus and
Streptococcus pneumoniae infection on
the management of acute admissions in
the elderly and high-risk 18- to 64-year-oldsKarl G Nicholson,1* Keith R Abrams,2 Sally Batham,1
Marie Jo Medina,1 Fiona C Warren,3 Mike Barer,4
Alison Bermingham,5 Tristan W Clark,1
Nicholas Latimer,6 Maria Fraser,7 Nelun Perera,7
K Rajakumar4 and Maria Zambon51Infectious Diseases Unit, Vaccine Evaluation Centre, University Hospitals of
Leicester NHS Trust and Department of Infection, Immunity and Inflammation,
University of Leicester, Leicester, UK
2Department of Health Sciences, University of Leicester, Leicester Medical School,
Leicester, UK
3Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK
4Department of Infection, Immunity and Inflammation, University of Leicester,
Leicester, UK
5Health Protection Agency, Centre for Infections, London, UK
6Health Economics and Decision Science (HEDS), School of Health and Related
Research (ScHARR), University of Sheffield, Sheffield, UK
7Department of Microbiology, University Hospitals of Leicester NHS Trust,
Leicester, UK
*Corresponding authorDeclared competing interests of authors: Karl G Nicholson has been an ad hoc consultant to
GlaxoSmithKline and Novartis. He has received funding to speak at meetings organised by Novartis, Baxter,
Berna Biotech, Esteves, and the European Scientiﬁc Working Group on Inﬂuenza, and H5 vaccines
from Novartis to support an MRC-funded research project, and H1N1 vaccines from Baxter AG and
GlaxoSmithKline to support an NIHR-funded research project. A colleague in Karl G Nicholson’s
Department has received research funding from Roche. Maria Zambon has been an investigator of clinical
trials sponsored by Novartis, Baxter, Sanoﬁ Pasteur and CSL Australia Ltd. Keith R Abrams has acted as a
paid consultant to the health-care industry generally (for the provision of advice and short courses), but
speciﬁcally has not advised any organisation as regards diagnostics. Tristan W Clark has been an
investigator of clinical trials sponsored by Novartis and Roche.

Published May 2014
DOI: 10.3310/hta18360This report should be referenced as follows:
Nicholson KG, Abrams KR, Batham S, Medina MJ, Warren FC, Barer M, et al. Randomised
controlled trial and health economic evaluation of the impact of diagnostic testing for inﬂuenza,
respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute
admissions in the elderly and high-risk 18- to 64-year-olds. Health Technol Assess 2014;18(36).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TARISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Five-year impact factor: 5.804
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is
assessed for inclusion in the Database of Abstracts of Reviews of Effects.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: nihredit@southampton.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: www.hta.ac.uk/
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 03/39/18. The contractual start date
was in November 2005. The draft report began editorial review in January 2012 and was accepted for publication in April 2013. The authors
have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher
have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft
document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reﬂect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reﬂect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Nicholson et al. under the terms of a commissioning
contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and
study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement
is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre,
Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR  
Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK
NIHR Journals Library Editors
Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical 
School, UK
Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School,  
University of Warwick, UK
Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK
Dr Peter Davidson Director of NETSCC, HTA, UK
Ms Tara Lamont Scientific Advisor, NETSCC, UK
Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society,  
Newcastle University, UK
Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK
Professor Jane Norman Professor of Maternal and Fetal Health, University of Edinburgh, UK
Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts Professorial Research Associate, University College London, UK
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: nihredit@southampton.ac.ukNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36AbstractRandomised controlled trial and health economic evaluation of
the impact of diagnostic testing for inﬂuenza, respiratory
syncytial virus and Streptococcus pneumoniae infection
on the management of acute admissions in the elderly
and high-risk 18- to 64-year-oldsKarl G Nicholson,1* Keith R Abrams,2 Sally Batham,1 Marie Jo Medina,1
Fiona C Warren,3 Mike Barer,4 Alison Bermingham,5 Tristan W Clark,1
Nicholas Latimer,6 Maria Fraser,7 Nelun Perera,7 K Rajakumar4
and Maria Zambon5
1Infectious Diseases Unit, Vaccine Evaluation Centre, University Hospitals of Leicester NHS Trust and
Department of Infection, Immunity and Inﬂammation, University of Leicester, Leicester, UK
2Department of Health Sciences, University of Leicester, Leicester Medical School, Leicester, UK
3Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK
4Department of Infection, Immunity and Inﬂammation, University of Leicester, Leicester, UK
5Health Protection Agency, Centre for Infections, London, UK
6Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR),
University of Shefﬁeld, Shefﬁeld, UK
7Department of Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK
*Corresponding author karlgnicholson@doctors.org.uk
Background: Western industrialised nations face a large increase in the number of older people. People
over the age of 60 years account for almost half of the 16.8 million hospital admissions in England from
2009 to 2010. During 2009–10, respiratory infections accounted for approximately 1 in 30 hospital
admissions and 1 in 20 of the 51.5 million bed-days.
Objective: To determine the diagnostic accuracy and clinical effectiveness and cost-effectiveness of
rapid molecular and near-patient diagnostic tests for inﬂuenza, respiratory syncytial virus (RSV) and
Streptococcus pneumoniae infections in comparison with traditional laboratory culture.
Methods: We carried out a randomised controlled trial (RCT) to evaluate impact on prescribing and clinical
outcomes of point-of-care tests (POCTs) for inﬂuenza A and B and pneumococcal infection, reverse
transcriptase-polymerase chain reaction (RT-PCR) tests for inﬂuenza A and B and RSV A and B, and
conventional culture for these pathogens. We evaluated diagnostic accuracy of POCTs for inﬂuenza and
pneumococcal infection, RT-PCR for inﬂuenza and sputum culture for S. pneumoniae using samples
collected during the RCT. We did a systematic review and meta-analysis of POCTs for inﬂuenza A and B.
We evaluated ease and speed of use of each test, process outcomes and cost-effectiveness.
Results: There was no evidence of association between diagnostic group and prescribing or clinical
outcomes. Using PCR as ‘gold standard’, Quidel Inﬂuenza A + B POCT detected 24.4% [95% conﬁdence
interval (CI) 16.0% to 34.6%] of inﬂuenza infections (speciﬁcity 99.7%, 95% CI 99.2% to 99.9%); viral
culture detected 21.6% (95% CI 13.5% to 31.6%; speciﬁcity 99.8%, 95% CI 99.4% to 100%). Using
blood culture as ‘gold standard’, BinaxNOW pneumococcal POCT detected 57.1% (95% CI 18.4% tovii
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ABSTRACT
viii90.1%) of pneumococcal infections (speciﬁcity 92.5%; 95% CI 90.6% to 94.1%); sputum culture
detected 100% (95% CI 2.5% to 100%; speciﬁcity 97.2%, 95% CI 94.3% to 98.9%). Overall, pooled
estimates of sensitivity and speciﬁcity of POCTs for inﬂuenza from the literature were 74% (95% CI 67% to
80%) and 99% (95% CI 98% to 99%), respectively. Median intervals from specimen collection to test
result were 15 minutes [interquartile range (IQR) 10–23 minutes) for Quidel Inﬂuenza A + B POCT,
20 minutes (IQR 15–30 minutes) for BinaxNOW pneumococcal POCT, 50.8 hours (IQR 44.3–92.6 hours)
for semi-nested conventional PCR, 29.2 hours (IQR 26–46.9 hours) for real-time PCR, 629.6 hours
(IQR 262.5–846.7 hours) for culture of inﬂuenza and 84.4 hours (IQR 70.7–137.8 hours) and 71.4 hours
(IQR 69.15–84.0 hours) for culture of S. pneumoniae in blood and sputum, respectively. Both POCTs
were rated straightforward and undemanding; blood culture was moderately complex and all other tests
were complex. Costs and quality-adjusted life-years (QALYs) of each diagnostic strategy were similar.
Incrementally, PCR was most cost-effective (78.3% probability at a willingness to pay of £20,000/QALY).
Few patients were admitted within a timescale conducive to treatment with a neuraminidase inhibitor
according to National Institute for Health and Care Excellence guidance.
Limitations: The accuracy study was limited by inadequate gold standards.
Conclusions: All tests had limitations. We found no evidence that POCTs for inﬂuenza or S. pneumoniae,
or PCR for inﬂuenza or RSV inﬂuenced antimicrobial prescribing or clinical outcomes. The total costs and
QALYs of each diagnostic strategy were similar, although, incrementally, PCR was the most cost-effective
strategy. The analysis does not support routine use of POCTs for either inﬂuenza or pneumococcal antigen
for adults presenting with acute cardiopulmonary conditions, but suggests that conventional viral culture
for clinical diagnosis should be replaced by PCR.
Trial registration: Current Controlled Trials ISRCTN21521552.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 18, No. 36. See the NIHR Journals Library website
for further project information.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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In 2007, for the ﬁrst time, the population at state pension age exceeded the number of children. Despite
increases to state pension age, the number of pensioners is projected to exceed the number of children
of < 16 years by over 2 million in 2031. People aged > 60 years accounted for almost half of all the
16.8 million hospital admissions from 2009 to 2010. During 2009–10, infections of the respiratory tract
accounted for about 1 in 20 of the 51.5 million bed-days. Preparation for this population growth and its
effects is of paramount importance.
With increasing severity of acute respiratory infection (ARI) in older people, the number of hospitalisations
for acute lower respiratory infections in England is about three times higher in those > 75 years than in
younger people. The average length of stay for acute respiratory conditions increases progressively with
age. The annual number of pneumonia and inﬂuenza deaths in England and Wales increases with
increasing age. Strategies that prevent acute lower respiratory infections, ameliorate their severity, or
shorten the average duration of stay will have the greatest beneﬁt in the elderly.
In this study, we evaluate rapid diagnostic technologies for three target pathogens: inﬂuenza, respiratory
syncytial virus (RSV) and Streptococcus pneumoniae. Collectively, they are responsible for considerable
morbidity and mortality in the elderly. A number of diagnostic tests are available for these pathogens but
they have drawbacks.
The overall aim of our study was to improve the detection, treatment and control of these respiratory
infections in at-risk people in the hospital setting, using new diagnostics tests to see if they improved
patient care and cut duration of hospital stay. The tests chosen were two promising point-of-care tests
(POCTs) for inﬂuenza A and B, and S. pneumoniae, and polymerase chain reaction (PCR) tests for inﬂuenza
A and B and RSV A and B. The study involved an evaluation of diagnostic accuracy of immunoassays for
the detection of inﬂuenza nucleoproteins, and the C polysaccharide cell wall antigen common to all
S. pneumoniae strains, as well as PCR tests and conventional diagnostic tests in adult at-risk patients who
were hospitalised over a three-winter period with acute cardiopulmonary illness. We evaluated the clinical
effectiveness of three investigation strategies to reduce antibiotic prescribing and improve clinical
outcomes. We carried out a systematic review and meta-analysis of POCTs for inﬂuenza, evaluated the
ease and speed of use of the different tests, evaluated the cost-effectiveness of the three diagnostic
strategies and, ﬁnally, considered the implications of our research for further research.Objectives
1. To determine whether randomisation of patients to one of two study groups – (1) POCTs for inﬂuenza
and pneumococcal antigens and (2) laboratory-based PCRs for inﬂuenza and RSV – has any impact on
prescribing outcomes, clinical outcomes, quality of life (QoL) or use of single-room accommodation in
comparison with (3) traditional culture methods.
2. To compare the diagnostic accuracy of PCR for inﬂuenza and RSV, and POCTs for inﬂuenza, and
S. pneumoniae with the diagnostic accuracy of traditional culture methods.
3. To conduct a systematic review to (1) determine the diagnostic accuracy of POCTs for inﬂuenza;
(2) estimate the heterogeneity of published studies; and (3) conduct subgroup-speciﬁc estimates using
study-level covariates.xxiii
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xxiv4. To evaluate the ease and speed of use of the three diagnostic strategies used in the study: (1) POCTs
for inﬂuenza and pneumococcal antigens; (2) laboratory-based PCRs for inﬂuenza and RSV; and
(3) traditional culture methods.
5. To conduct a trial-based cost-effectiveness analysis.Methods
We conducted the clinical trial in the acute medical admissions units and medical wards of two teaching
hospitals (Glenﬁeld Hospital and Leicester Royal Inﬁrmary) in the University Hospitals of Leicester NHS
Trust. We recruited people with an acute exacerbation of chronic cardiopulmonary illness of ≤ 168 hours’
(7 days’) duration or an acute cardiopulmonary illness of ≤ 7 days’ duration [including pneumonia,
‘inﬂuenza’/inﬂuenza-like illness, exacerbations of chronic obstructive pulmonary disease (COPD), bronchitis,
asthma, congestive heart failure or cardiac arrhythmia], who satisﬁed the study inclusion and exclusion
criteria, and could be recruited to the study within a 16-hour period of initial assessment by the patient’s
medical team. Participants were then randomly allocated to one of three diagnostic study groups:
(1) near-patient tests for pneumococcal infection and inﬂuenza; (2) rapid molecular tests for inﬂuenza and
RSV; or (3) conventional laboratory diagnostic tests. Identical diagnostic samples were taken from each
person but were processed differently depending on the randomisation. We assessed QoL using the
EuroQoL European Quality of Life-5 Dimensions (EQ-5D) tool. We captured basic demographic data
information on prescribed medication, oxygen and intravenous ﬂuids, investigations, isolation status,
complications, transfer to the intensive care unit, duration of stay, deaths, QoL, and the timing of
specimen collection and test results. Eventually, all tests were undertaken on all specimens.
The diagnostic accuracy study used the diagnostic results obtained in the above randomised controlled trial
(RCT). Data on diagnostic performance of the various tests [viral culture, sputum culture, PCR, Quidel
POCT for inﬂuenza A and B (Quidel® QuickVue Inﬂuenza A + B: Quidel, San Diego, CA, USA) and
BinaxNOW® (Portland, ME, USA) POCT for pneumococcal antigen] were summarised as (1) percentage
diagnostic agreement; (2) sensitivity (percentage of true positives correctly identiﬁed); (3) speciﬁcity
(percentage of true-negatives correctly identiﬁed); (4) positive and negative predictive values; or
(5) area under receiver operating characteristic (ROC) curve (the probability that two patients, one
diseased and one not diseased, would be both correctly classiﬁed by the test). We undertook analyses
using different reference standards to enable comparison between the results from our study and those
found in the literature.
We conducted a systematic review to determine the sensitivity and speciﬁcity of POCTs for inﬂuenza.
Pooled sensitivities and speciﬁcities were estimated using a bivariate mixed-effects meta-analysis model.
Heterogeneity was assessed using the I2 measure and explored using subgroup analyses using
study-level covariates.
We examined the speed of use of the tests used in this study from data collected in the RCT. The time of
specimen collection was recorded in the case report forms by the study nurses, as was the time that the
test result was entered into the continuation sheets in the patients’ case-notes. All other times were
derived from the intranet record of test results, and times when details of positive blood culture and virus
culture results were communicated to clinicians. We assessed the ease of use (EoU) of the tests using a
modiﬁcation of the US Clinical Laboratory Improvement Amendments (CLIA) Categorization Criteria, which
grade speciﬁc laboratory test systems, assays and examinations for level of complexity by assigning scores
of 1, 2 or 3 for each of seven criteria: (1) knowledge; (2) training and experience; (3) reagents and
materials preparation; (4) characteristics of operational steps; (5) calibration, quality control and proﬁciency
of testing materials; (6) test system troubleshooting and equipment maintenance; and (7) interpretation
and judgement. We combined (1) and (2) above, and included ﬁve additional criteria: (1) test site
requirements; (2) equipment; (3) storage and disposal of waste test materials and reagents; (4) health and
safety implications; and (5) time to reporting of results. As in the CLIA system, a score of 1 indicates theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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also undertaken.
We analysed resource-use data collected prospectively during the RCT while the patient was in hospital
and retrospectively from a 28-day follow-up. An incremental cost-effectiveness analysis was undertaken,
with cost per quality-adjusted life-year (QALY) using the EQ-5D data recorded during the RCT. Markov
chain Monte Carlo methods were used to estimate the uncertainty surrounding outcome measures, and
calculate the probability of strategies being cost-effective at willingness-to-pay thresholds of £20,000 and
£30,000 per QALY, together with the probability of error for any strategy adopted.Results
The main results reported are based on the ﬁrst admission for 1172 patients. The RCT found no difference
in prescribing outcomes between diagnostic groups for time from admission to ﬁrst narrow-spectrum
antibiotic, time from admission to ﬁrst oral antibiotic, or time from admission to cessation of antibiotics.
Similarly, there was no difference in clinical outcome between groups for length of hospital stay among
survivors, fever duration, supplemental oxygen dependence, continuous positive airway pressure
dependence or deaths. The number of patients requiring intensive treatment unit and ventilator support
was too small for statistical analysis. Use of isolation facilities did not differ between groups, nor was there
a signiﬁcant difference in EQ-5D scores.
The accuracy study found that the Quidel Inﬂuenza A + B POCT detected 24.4% of inﬂuenza infections
compared with PCR but the speciﬁcity was almost 98%. The BinaxNOW pneumococcal POCT detected
57% of pneumococcal infections compared with blood culture, and its speciﬁcity was 92.5%. Sputum
culture detected 100% of pneumococcal infections compared with blood culture, and its speciﬁcity
was 97%.
In the systematic review and meta-analysis study, we found that the headline sensitivity for inﬂuenza
POCTs was 74% [95% conﬁdence interval (CI) 67% to 80%] and speciﬁcity was high [99% (95% CI 98%
to 99%)]. There was a high level of heterogeneity between studies for both outcomes, and further
analyses showed that the pooled estimate of sensitivity was considerably lower for some subgroup
combinations than others. We found that the sensitivity was 86% in children and adolescents but 67% in
populations of mixed age. We found evidence of reduced sensitivity for infection caused by the 2009
H1N1 virus. Finally, analysis of ﬁve studies that included both adults and children and compared the Quidel
POCT with PCR revealed a sensitivity of 34% (95% CI 14% to 62%), which was similar to the result found
in our study [24.4% (95% CI 16% to 31.6%)].
In the ease and speed of use study, we found that both POCTs gave results quickly and were rated as
straightforward and undemanding to use. The median time to reporting the real-time PCR for inﬂuenza A
and B was approximately 29 hours. EoU analysis showed that PCR is complex and demanding in
requirements. Viral culture was extremely slow with a median turnaround time exceeding 3 weeks; it was
also rated as complex. The median times for reporting growth of S. pneumoniae in blood and sputum
culture were similar at 84 hours and 71 hours, respectively. Blood culture was rated as moderately
complex; sputum culture was rated as complex.
There were no statistically signiﬁcant differences in the distributions of total costs, or QALYs associated with
each of the three diagnostic groups. Formal incremental analysis shows that traditional laboratory culture
testing is dominated; PCR has lower average total cost but also lower QALY gain than POCT. The associated
incremental cost-effectiveness ratio of POCT compared with PCR is £734,717, and the probability of POCT
being a cost-effective strategy at a willingness-to-pay threshold of £20,000 per QALY is only 18.3%.
Conversely, the probability of adopting a PCR-based diagnostic strategy as the most cost-effective strategy
when, in fact, either POCT or traditional laboratory culture should be adopted at a willingness-to-payxxv
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xxvithreshold of £20,000 per QALY is only 21.7%. Very few patients were admitted within a period that would
permit treatment with a neuraminidase inhibitor (NI) according to National Institute for Health and Care
Excellence guidance.Conclusions
Although the study was powered to enable both clinical effectiveness (in terms of length of stay) and
diagnostic performance to be evaluated with sufﬁcient power/precision, we found no evidence that POCTs
for inﬂuenza or S. pneumoniae infection, or PCR for inﬂuenza A and B and RSV A and B, inﬂuenced either
the prescribing of antibiotics by clinicians providing care or clinical outcome. All tests had limitations – poor
sensitivity, complexity, demands, test turnaround times or a combination of these. The total costs and
QALYs of each diagnostic strategy were similar, though incrementally PCR was the most cost-effective
strategy with a probability of being so of 78.3% at a willingness-to-pay threshold of £20,000 per QALY.
Results of sensitivity analyses indicated that this conclusion appeared to be warranted. The analysis does
not support routine testing with POCTs for either inﬂuenza or pneumococcal antigen for adults presenting
with acute cardiopulmonary conditions. Our ﬁndings suggest that conventional viral culture for clinical
diagnosis should be replaced by PCR.Recommendations for research
1. We recommend a systematic review and meta-analysis of published data relating to the treatment of
patients hospitalised with inﬂuenza with NIs to assess the evidence in support of treatment of patients
hospitalised with inﬂuenza complications at > 48 hours after symptom onset.
2. Most patients with inﬂuenza complications in this study were unable to receive antiviral therapy
because of delayed presentation. Patients risk serious outcomes from acute respiratory illness unless
they are seen sooner. Research is needed to determine how widespread delayed presentation is, why it
occurs, and whether it can be reduced.
3. Because of the high speciﬁcity of POCTs for inﬂuenza, research is needed to determine their
effectiveness in general practice surgeries (or a commercial pharmacy setting) for people at risk of
serious complications owing to age and chronic ill heath during declared outbreaks.
4. There is good evidence that inﬂuenza virus exacerbates asthma, COPD, cystic ﬁbrosis, and is causally
associated with community-acquired pneumonia and acute bronchitis. Uncertainty about the role of NI
treatment of patients presenting with these complaints during inﬂuenza outbreaks will remain until
trials have shown clear beneﬁts.
5. Controversy about the beneﬁts of treatment with neuraminidase of patients presenting to hospital at
> 48 hours (up to 6 days) after onset of symptoms will remain until clinical trials have established clear
beneﬁts. We recommend that this research includes assessments of quantitative viral shedding and
biomarkers to evaluate their role in guiding patient management.Trial registration
This trial is registered as ISRCTN21521552.Funding
Funding for this project was provided by the NIHR Health Technology Assessment programme for the
National Institute for Health Research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Chapter 1 Background and rationaleElderly demographicsWestern industrialised nations face a large increase in the number of older people. In 2006 there were
about 200,000 more children of < 16 years of age than people at state pension age in the UK. However,
in 2007, for the ﬁrst time ever, the population at state pension age exceeded the number of children.
And, despite increases to state pension age, the population at state pension age is projected to exceed the
number of children of < 16 years by 400,000 in 2016, and by over 2 million in 2031.1 Annual ﬁgures
published by the NHS Information Centre reveal that people aged > 60 years accounted for almost half of
all of the 16.8 million hospital admissions (ﬁnished consultant episodes) in 2009–10.2,3 During 2009–10,
infections of the respiratory tract accounted for about 1 in 30 of all hospital admissions in England and 1
in 20 of the 51.5 million bed-days.4 Preparation for this population growth, including the prevention and
care of illness, is of paramount importance.Acute respiratory illnessIllness surveys conducted in general practice indicate an overwhelming importance of acute respiratory
illness in comparison with other conditions. During the most recent (Fourth) National Morbidity Study,
a higher proportion of people (31%) consulted for respiratory conditions at least once during the year than
for diseases in any other single International Classification of Diseases (ICD) chapter.5 Overall, 67% of
patients who saw their general medical practitioner (GP) with a respiratory condition did so because of an
acute infection, i.e. ≈ 20% of all consultations in primary care occur because of acute respiratory infections
(ARIs), which are mostly viral. The rates of acute respiratory illness were highest among small children.
They were lowest among subjects aged 45–64 years and then increased with age, and the percentage that
was graded as ‘serious’ reached ≈ 25% in those aged > 65 years.
Owing to the increasing severity of acute respiratory illness in older people, the number of hospital
admissions in England for inﬂuenza, pneumonia and other acute lower respiratory infections (ICD-10 codes
J10-J18, J20-J22) is approximately three times higher for people aged ≥ 75 years than in younger people
(Figure 1).4 Annual ﬁgures published by the NHS Information Centre reveal that among those aged
> 75 years the number of admissions for inﬂuenza and pneumonia and other lower respiratory tract
infections has doubled to almost 200,000 in England over the last 10 years (see Figure 1).4
The average length of stay for acute respiratory conditions increases progressively with age.6 Although the
average length of stay for pneumonia has fallen during the last 20 years, it is 10–15% longer in those
aged > 65 years than in younger adults (Figure 2).7 The annual number of pneumonia and inﬂuenza
deaths (ICD-10 codes J10–J18) in England and Wales increases with increasing age and exceeds 1000 per
annum in each of the 5-year age bands in those aged > 70 years (Figure 3). Strategies that prevent acute
lower respiratory infections, ameliorate their severity or shorten the average duration of stay will have the
greatest beneﬁt in the elderly.
In this study, we evaluate rapid diagnostic technologies for three target pathogens – inﬂuenza, respiratory
syncytial virus (RSV) and Streptococcus pneumoniae – which are key aetiological agents of acute
respiratory illness and, collectively, are responsible for considerable morbidity and mortality in the elderly.
There is a paucity of information on the relative incidence of inﬂuenza, RSV and pneumococcal disease
among elderly cardiopulmonary admissions. Falsey et al.8 evaluated the number of hospitalisations for RSV
infection relative to inﬂuenza in several thousand elderly people admitted to six hospitals in New York1
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DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36State between November and April 1989–1992. This and other studies suggest that RSV may be found in
up to 5% of patients hospitalised with acute respiratory disease,9–13 although with molecular diagnostic
tests, the number identiﬁed may be higher. Previous studies8–10,12,13 indicate that about 10% of
cardiopulmonary admissions have inﬂuenza but the number of admissions is inﬂuenced by the severity of
epidemics, which have been generally mild since 1999/2000, including the recent 2009 H1N1 pandemic.
None of these studies was conducted in the UK, and referral and admission practices may differ in the UK
from those elsewhere. About one-third of all patients who are hospitalised in Northern Europe with
community-acquired pneumonia (CAP) have S. pneumoniae infection.14 S. pneumoniae is the most
common microbiological cause of CAP,15,16 including the UK,17 and is the most commonly identiﬁed cause
of CAP death.16Influenza
About 20% of children and 5% of adults worldwide develop symptomatic inﬂuenza A or B each year.18
Although inﬂuenza A and B viruses circulate virtually every winter, quantiﬁcation of the burden of inﬂuenza
on consultations, emergency department examinations, hospital admissions and mortality has been difﬁcult
because inﬂuenza lacks pathognomonic features, it co-circulates with other respiratory pathogens, and it
causes a range of non-speciﬁc complications, such as exacerbations of chronic cardiopulmonary disease.
Indeed, during 2009, many hospital admissions with conﬁrmed inﬂuenza A H1N1 infection presented with
an exacerbation of asthma.19 During outbreaks, sentinel schemes, such as the Royal College of General
Practitioners network in England, report increased consultation rates for inﬂuenza-like illness (ILI) and other
respiratory syndromes that are strongly associated with excess mortality. In England and Wales, an
estimated 6200–29,600 people died during each of the epidemics between 1975–6 and 1989–90.20 These
estimates are about 10 times the number of death certiﬁcations for inﬂuenza, suggesting that inﬂuenza is
responsible for many ‘hidden deaths’. About 90% of inﬂuenza-associated excess deaths are among people
aged ≥ 65 years.18 Although there are age-related increases in deaths from seasonal inﬂuenzal illness in
both ‘at-risk’ and ‘low-risk’ groups,21 most deaths and hospitalisations occur in elderly people with chronic
cardiopulmonary disorders.
The burden of inﬂuenza on winter admissions is poorly reﬂected by hospital activity analysis – as shown by
our recent study of rapid molecular diagnosis of paediatric admissions in Leicester. We found that very few
children with inﬂuenza were diagnosed or coded correctly.22 Moreover, analysis of hospital activity statistics
for Leicester for winters 2002–3 and 2003–4 showed that only 2 of 5614 cardiopulmonary admissions
among the elderly had a conﬁrmed diagnosis of inﬂuenza. These local observations suggest that hospital
activity data may grossly underestimate the true burden of inﬂuenza in hospitals, and the infrequency with
which inﬂuenza is diagnosed may explain why hospital doctors consider conventional diagnostic virology
for respiratory pathogens to be unhelpful.Respiratory syncytial virus
Respiratory syncytial virus infection produces incomplete protection and reinfection is common. Like
inﬂuenza, RSV infection in the elderly has no pathognomonic features, and cannot be distinguished from
other respiratory virus infections clinically. Evidence indicates that RSV may be severe in the elderly, causing
a spectrum of illness including pneumonia.8,23,24 Outbreaks in residential care facilities causing severe
morbidity and mortality are well documented. Pneumonia occurs in 5–55% of cases and mortality of up to
20% is described.8,23 Because RSV has traditionally been considered a paediatric infection, evidence of the
virus in community-dwelling elderly or admissions with cardiopulmonary disorders is usually not sought.Community-acquired pneumonia and Streptococcus pneumoniae
Invasive pneumococcal disease and CAP exhibit a distinct winter seasonality that may be attributed to
climatic conditions, crowding, air pollution, and respiratory virus activity, including inﬂuenza, RSV and
rhinoviruses.25–27 In Leicester, weekly admissions data for 1352 cases of CAP admitted during the winters of
2002–3 and 2003–4 showed two peaks of 5 and 6 weeks’ duration during 2002–3 and a 14-week peak
during 2003–4, conﬁrming the seasonal pattern and its possible association with respiratory virus activity.
Bacterial pneumonia is a well-recognised complication of inﬂuenza, and pneumococcus was the most3
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4common microbe associated with life-threatening and fatal 2009 pandemic H1N1 infection. Between
9.5% and 48% of CAP may involve co-infection of typical and atypical organisms.28 Of the 148 cases of
S. pneumoniae infection identiﬁed by Porath et al.,29 100 had co-pathogens identiﬁed, usually ‘atypicals’.
Although the clinical importance of polymicrobial infection is uncertain, mixed infection may be associated
with a more complicated course.30 The overall mortality from CAP can be substantial – in one meta-analysis
involving 33,148 patients with CAP, it was 12.3% for patients with S. pneumoniae, 9% for inﬂuenza,
and 5% for RSV.16 Treatment cannot await the results of conventional microbiological tests, so an
empiric regimen is necessary, which in the UK typically includes a β-lactam antibiotic, with or without
a macrolide.17
It is possible that a positive point-of-care (POC) pneumococcal antigen test result could lead to the
prescription of a single antimicrobial agent, placing patients with polymicrobial infection that includes
S. pneumoniae at increased risk of death. Oosterheert et al.31 undertook a systematic review to assess
whether treatment with a β-lactam plus macrolide or quinolone monotherapy is truly superior to β-lactam
treatment alone. Eight relevant studies were selected. In six, signiﬁcant reductions in mortality were found;
in one, a reduction in hospital length of stay was found; and in another no beneﬁcial effects could be
demonstrated for treatment regimens with ﬂuoroquinolone monotherapy or combinations of β-lactams
and macrolides. The studies supporting the recommended treatment regimen were designed as
non-experimental cohort studies and confounding may have inﬂuenced the results. The authors concluded
that a randomised controlled trial (RCT) is warranted to circumvent the methodological ﬂaws in the designs
of the available studies.Diagnostic tests
Diagnostic tests for influenza
Viral isolation and haemagglutination inhibition antibody testing are standard methods for inﬂuenza
diagnosis but have drawbacks. Virus isolation by culture from respiratory secretions may take a week or
more – for example, a median of 8 days in one recent study;21 it requires specialised laboratory facilities,
and the results cannot be provided soon enough to inﬂuence treatment decisions or infection control.
Serology provides a retrospective diagnosis.32 Neither test alone is considered a reference standard for
inﬂuenza diagnosis, as each lacks sensitivity, but culture and serology have been used together as the
reference standard in assessment of molecular tests.33
Tests for rapid diagnosis of inﬂuenza A and B virus by immunoﬂuorescence (IF) of exfoliated
nasopharyngeal cells have shown variable sensitivity (40–100%) and speciﬁcity (86–99%);34 they require
specialist equipment and expertise, and are labour intensive. Rapid, near-patient tests (NPTs) for inﬂuenza
vary in complexity, sensitivity and speciﬁcity.18 They can potentially aid clinical management, but their value
in the hospital setting in inﬂuencing prescribing and infection control of adults is unclear. We used the
Quidel® QuickVue Inﬂuenza A + B test (Quidel, San Diego, CA, USA) due to its apparent ease and speed of
use, and reports of its sensitivity and speciﬁcity.18 However, its diagnostic accuracy in the elderly is unclear.
Molecular diagnosis of inﬂuenza by reverse-transcriptase [reverse transcriptase-polymerase chain reaction
(RT-PCR)] provides improved sensitivity and speciﬁcity, allows accurate detection, and facilitates the
subtyping of inﬂuenza.35 Like virus culture, multiplex polymerase chain reaction (PCR) offers the potential
to identify several pathogens (e.g. inﬂuenza subtypes A/H1N1, A/H3N2 and B; RSV types A and B) in one
sample and in one reaction.35,36 The technique is used routinely within the specialist diagnostic facilities of
the Centre for Infections, Colindale, London, where it has a sensitivity of 92% and speciﬁcity of 84%.33Diagnostic tests for respiratory syncytial virus
Factors contributing to underestimations of the incidence and burden of RSV in the elderly include virus
lability; the brief period of virus shedding and low titre of virus in nasal specimens during reinfection; the
relative insensitivity of standard diagnostic tests – including the complement ﬁxation test (CFT), virus
culture (even when performed under rigorous conditions including bedside inoculation),37 and rapidNIHR Journals Library www.journalslibrary.nihr.ac.uk
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USA)] in the elderly,37,38 and the frequent co-circulation of RSV with inﬂuenza.22,24 Multiplex RT-PCR has
emerged as a sensitive and speciﬁc method of detecting RSV infection.36 Examination of nose and throat
swabs by multiplex RT-PCR from 167 elderly subjects (age ≥ 65 years) who presented to their GP with ILI
during the winters of 1995–6, 1996–7 and 1997–8 showed that 15% had RSV.39 These investigators
detected one RSV infection for every two inﬂuenza infections, suggesting that the previously unrecognised
burden of RSV in the elderly may be substantial.Diagnostic tests for Streptococcus pneumoniae
Diagnosis of pneumococcal pneumonia is complicated by the lack of a diagnostic reference standard
that is highly sensitive and speciﬁc. Despite being the single most important pathogen causing CAP,
S. pneumoniae is undoubtedly underdiagnosed owing to limitations of conventional tests. Limitations of
Gram stain and culture of sputum include failure to obtain sputum for culture – a fraction of patients
produce sputum;28 the overall diagnostic yield of sputum examination is very low (< 25%),40 and isolation
of S. pneumoniae from sputum may represent colonisation. Blood cultures have been considered as a
standard in patients with CAP,41 but positive cultures are found in < 10% of patients with CAP, particularly
those with low-severity CAP or have started antibiotics already.17,41,42 The test is often unhelpful, as
positivity becomes evident no earlier than 24 hours after obtaining the specimen, and results typically have
little inﬂuence on therapeutic decisions and outcomes.41,43–45 However, a review of patients with conﬁrmed
pneumococcal pneumonia found that 42% of patients with positive blood culture results had their
treatment changed as a result.46 As the overall prevalence of β-lactam resistance remains low in the UK,
rapid near-patient testing for pneumococcal infection could inﬂuence therapeutic decisions.
Measurement of pneumococcal antibodies has not proven reliable for diagnosing pneumococcal
pneumonia.47 PCR appears to be more sensitive than blood culture but most studies have tested only
a small number of samples, and have not compared different sample types from the same patients.48
Murdoch et al.48 used a nested PCR to target the pneumolysin gene in multiple sample types from
474 adults with CAP. The authors concluded that the pneumolysin PCR adds little to existing diagnostic
tests and that it was less sensitive than the rapid urine antigen test. Other investigators have evaluated
different PCR methods on sputum – in general they have had good sensitivity but poor speciﬁcity, whereas
PCRs that have been developed to evaluate blood have had poor sensitivity but good speciﬁcity.49 The
detection of S. pneumoniae antigens in the urine of patients with pneumonia has been extensively studied
using a variety of techniques. Although the performance of most tests has been somewhat disappointing,
the BinaxNOW® urinary antigen test (Binax, Portland, ME, USA) that we used is simple to perform; it can
detect the C polysaccharide cell wall antigen common to all S. pneumoniae strains and it provides results
within 15 minutes. It has sensitivity of 80% or more in adults and children when positive blood cultures
are used as reference standard.50–54Rationale for the studyThe three respiratory pathogens, inﬂuenza, RSV and S. pneumoniae, are responsible for considerable
morbidity and mortality, and become increasingly important as pathogens with advancing age and
comorbidity. The elderly population of the UK is rapidly increasing in life expectancy and size. People aged
> 60 years now account for almost half of the annual number of all hospital admissions, placing huge
pressure on the health-care system. RSV and inﬂuenza can exacerbate chronic cardiopulmonary disease in
adults of working age, adding to the demand for hospital beds and pressure on health-care providers to
discharge patients at the earliest opportunity, preferably before admission to a hospital ward.
Vaccines and drugs to prevent RSV transmission and illness are unlikely to be available for use within the
next decade. Vaccines against inﬂuenza and pneumococcal infection provide incomplete protection. Many
pathogens can cause CAP, and the appreciable risk of death from CAP demands that treatment is given5
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6empirically at the earliest opportunity. Early treatment with neuraminidase inhibitors (NIs) – within 48 hours
of onset of illness – is considered essential.
Conventional diagnostic tests, especially viral culture, provide information too late to inﬂuence care and
containment decisions. They are expensive and require specialised facilities and expertise. Blood cultures
are often negative in patients with CAP caused by the pneumococcus; the result is also inﬂuenced by
antecedent antimicrobial treatment. Treatment of CAP is usually empirical.
Compared with other diagnostic tests, the rapid point-of-care tests (POCTs) offer the greatest potential to
inﬂuence antibiotic prescribing, ameliorate illness and prevent nosocomial transmission – but only if the
tests are sufﬁciently sensitive and speciﬁc. PCR could provide comparable beneﬁts if its longer turnaround
time is compensated for by better test performance.
This study was designed to evaluate the ease and speed of use of the different tests, assess their costs,
and identify whether they provide clinical and health-economic beneﬁts, and rationalise the use of
single-roomed accommodation.
The three diagnostic strategies assessed in this study were (1) POCTs for inﬂuenza A and B and
pneumococcal infection; (2) RT-PCR tests for inﬂuenza A and B, and RSV A and B; and (3) conventional
culture for these pathogens.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Chapter 2 MethodsStudy designWe undertook a prospective RCT and economic evaluation of rapid POC, molecular and conventional
diagnostic tests for inﬂuenza, RSV and S. pneumoniae in the management and outcome of acute
cardiopulmonary admissions in the elderly (age ≥ 65 years) and ‘high-risk’ individuals with underlying
chronic heart or lung disease, including asthma, who were 18–64-years of age at the time of presentation
in two teaching hospitals in the UK. A summary of the protocol for the study is provided in Appendix 1.
A copy of the full protocol is available from the Principal Investigator, Karl Nicholson.SettingThe participating hospitals were Glenﬁeld General Hospital and Leicester Royal Inﬁrmary in the University
Hospitals of Leicester (UHL) NHS Trust, Leicester, a city in the English East Midlands. The UHL NHS Trust
serves a population of approximately one million subjects of all ages. It is the only facility within the county
of Leicestershire that provides inpatient emergency medical care to the population of Leicestershire.
The laboratory tests were carried out in the Department of Microbiology, Leicester Royal Inﬁrmary.ParticipantsWe recruited people presenting to medical admissions units, or any ward accepting acute medical
admissions, with an acute exacerbation of chronic cardiopulmonary illness of ≤ 168 hours’ (7 days’)
duration or an acute cardiopulmonary illness of ≤ 7 days’ duration [including pneumonia, ‘inﬂuenza’/ILI,
exacerbations of chronic obstructive pulmonary disease (COPD), bronchitis, asthma, congestive heart
failure or cardiac arrhythmia], who satisﬁed the study inclusion and exclusion criteria and could be
recruited to the study within a 16-hour period of initial assessment by the patient’s medical team.
The inclusion and exclusion criteria for participants are shown in Box 1.
Recruitment
Medical and nursing staff on medical admissions units and wards providing acute medical care to patients
with acute cardiopulmonary conditions identiﬁed eligible patients. Research nurses provided trial
information and obtained signed informed consent from the patient or signed informed assent from a
relative or carer.RandomisationParticipants were then randomly allocated to one of three diagnostic study groups: (1) NPTs for
pneumococcal infection and inﬂuenza; (2) rapid molecular tests for inﬂuenza and RSV; or (3) conventional
laboratory diagnostic tests. Their investigations, medical care and discharge planning was provided as
usual by the medical and nursing teams on the medical admissions units and other wards, not by the
investigators. The randomisation process enabled the investigators to evaluate the role of the diagnostic
tests on clinical outcomes. Ultimately, all diagnostic tests were performed on specimens from all subjects,
providing the means to compare diagnostic accuracy.7
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OX 1 Participant inclusion and exclusion criteria
Inclusion criteria
l Written informed consent, or written informed assent by a relative or carer.
l Men or women aged ≥ 65 years, or 18–64 years, with underlying chronic heart or lung disease
including asthma.
l Acute exacerbation of chronic cardiopulmonary illness,* or acute cardiopulmonary illness or ILI of
≤ 168 hours’ duration, including pneumonia, inﬂuenza or ILI, exacerbations of COPD, bronchitis, asthma,
congestive heart failure and cardiac arrhythmia.
l Recruitment within 16 hours of initial medical assessment.
l Able to comply with the study protocol.
l Access to a telephone.
Exclusion criteria
l Angina or suspected myocardial infarction.
l Previously recruited within 28 days of the current admission.
l Enrolment in a trial of antimicrobial therapy.
*These are provisional or suspected clinical diagnoses that have been made either by the referring GP or by
the admitting medical team. In general, participants had at least one respiratory symptom and one systemic
symptom or two or more respiratory symptoms from at least two of the following bullet points:
Respiratory symptoms
l Sore throat and/or hoarseness.
l Nasal symptoms (stufﬁness, and/or runny nose, and/or thick nasal discharge, or sneezing).
l Cough (new or increased).
l Sputum (new or increased).
l Wheezing (new or increased).
l Difﬁculty breathing/shortness of breath (new or increased).
l Chest pain with breathing.
Systemic symptoms
l Feverishness/sweating.
l Chills, shivers or rigors.
l Tiredness or fatigue.
l Decrease or loss of appetite.
l Headache.
l Muscle or body aches.
l Generally feel unwell.
METHODS
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block sizes of 9, 12 or 15, which were not revealed to any person before randomisation. The
randomisation code allocated participants in the ratio 1 : 1 : 1 to one of the three study groups. It was
provided in sequentially numbered sealed study envelopes, which were stored securely (within a locked
ﬁling cabinet, within a locked ofﬁce, within a locked department). The randomisation code for an
individual patient became known to the research nurse only when signed informed consent or assent was
obtained. The randomisation codes were then checked by the trial statistician against the master copy to
ensure that the sequences concurred. It was not revealed to the participants or to the medical and nursing
team providing care.Planned interventionsParticipants were randomised to receive:
l diagnostic assessment using rapid near-patient diagnostic tests (Quidel for inﬂuenza, and BinaxNOW
for the pneumococcal antigen), or
l rapid molecular tests (for inﬂuenza A and B and RSV A and B), plus laboratory pneumococcal antigen
testing, or
l conventional laboratory diagnostic assessment, notably culture for inﬂuenza A and B, RSV A and B,
and S. pneumoniae, and serology for inﬂuenza A and B.
Although all tests were eventually carried out on all participants, clinicians were provided with rapid test
results relating only to their randomisation group.Collection of samples for microbiological analysesIdentical samples were taken from each person but were processed differently depending on the
randomisation (Box 2).BOX 2 Specimen processing
Rapid ‘near-patient’ test group
l Blood culture Undertaken by the admitting medical team or research nurse, and transported to/processed
in the laboratory according to local protocols.
l Paired (acute and convalescent) sera An ‘acute’ venous blood sample was collected and transported to
the laboratory, where the serum was separated and stored. A convalescent sample was collected, where
possible, up to 90 days after admission. Acute and convalescent sera from participants were batched and
tested at the HPA Centre for Infections for antibodies to seasonal strains of inﬂuenza A and B.
l Freshly expectorated sputum Sputum was collected from participants with a productive cough
and cultured in the laboratory using standard operating procedures.
l Freshly voided urine Collected and tested on the ward, by a research nurse, for pneumococcal
soluble antigen using the near-patient BinaxNOW S. pneumoniae test, according to the manufacturer’s
instructions (see Appendix 2).Participants in each group gave a venous blood sample on entry to the study for blood culture if it had not9
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l Nasopharyngeal swabs A nasal swab sample was collected from the nostril that presented the most
secretion (if any) under visual inspection. This specimen was analysed on the ward by a research nurse
for the presence of inﬂuenza A and B antigen using the near-patient QuickVue Inﬂuenza A+B test
(www.cliawaived.com/web/items/pdf/QDL-20183-Quidel_Inﬂuenza_Tests_Insert∼619ﬁle1.pdf).
A nasopharyngeal specimen was collected for deferred molecular testing and conventional virus
culture using the opposite nostril to that used previously. The protocol for collecting and transporting
nasopharyngeal specimens is provided in Appendix 3. The nasopharyngeal specimen was transported to
laboratory (and stored at 4 °C if received after hours), where one aliquot was cultured for inﬂuenza A and
B and RSV using standard operating procedures, and another was stored at –80 °C and analysed by
deferred molecular diagnostic tests for inﬂuenza A and B and RSV A and B.
Molecular diagnostic group
l Blood culture Undertaken and processed as above.
l Paired (acute and convalescent) sera Collected and processed as above.
l Freshly expectorated sputum Collected from participants with a productive cough and processed as for
the ‘near patient test group’.
l Freshly voided urine Collected and transported to laboratory, where it was tested promptly for the
presence of pneumococcal soluble antigen using the near-patient BinaxNOW S. pneumoniae test.
l Nasopharyngeal swabs Nasopharyngeal swabs were collected as for the ‘near-patient test group’. They
were transported to the laboratory and stored at 4 °C if they were received after hours. The nasal swab
sample was stored at –20 °C for deferred testing for the presence of inﬂuenza A and B antigen using the
near-patient QuickVue Inﬂuenza A+B test. An aliquot of the nasopharyngeal specimen was analysed
promptly by molecular diagnostic tests for inﬂuenza A and B and RSV A and B. Another aliquot was
cultured for inﬂuenza A and B and RSV using standard operating procedures.
Conventional test group
l Blood culture Undertaken and processed as for ‘near-patient test group’.
l Paired (acute and convalescent) sera Collected and processed as for ‘near-patient test group’.
l Freshly expectorated sputum Collected from participants with a productive cough and processed as for
the ‘near-patient test group’.
l Freshly voided urine Collected and transported to laboratory where it was stored at –20 °C for
deferred testing for the presence of pneumococcal soluble antigen using the near-patient BinaxNOW
S. pneumoniae test.
l Nasopharyngeal swabs Nasopharyngeal swabs were collected as ‘near-patient test group’ and transported
to the laboratory as above. One aliquot was cultured for inﬂuenza A and B and RSV using standard
operating procedures, and another was stored and analysed by deferred molecular diagnostic tests for
inﬂuenza A and B and RSV A and B. The nasal swab sample was stored at –20 °C for deferred testing for
the presence of inﬂuenza A and B antigen using the near-patient QuickVue Inﬂuenza A+B test.
BOX 2 Specimen processing (continued)
METHODS
10Partcipants in each group gave a venous blood sample on entry to the study for blood culture if it had not
been collected already by the medical team. Blood cultures were processed in the laboratory according to
local protocols. Serum from an ‘acute’ blood sample was collected from participants in each group on entry
to the study and stored for titration of antibodies against inﬂuenza A and B in paired ‘acute’ and
‘convalescent’ sera. It was originally planned that the ‘convalescent’ sample would be collected 10 days
after admission. Because many people were discharged within 10 days of admission, we amended the
protocol to collect ‘convalescent’ sera up to 30 days, and subsequently up to 90 days, after admission.
Acute and convalescent sera were processed in the Inﬂuenza Laboratory at the Health Protection Agency
(HPA) Centre for Infections, Colindale, London.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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participants in each study group with a productive cough. Freshly voided urine was collected from all
participants on entry to the study and processed in the BinaxNOW S. pneumoniae test, as shown in Box 2,
and according to the manufacturer’s instructions (see Appendix 2). One nasal swab (collected from one
nostril only), one nasal swab (collected from the opposite nostril) and one throat swab were collected on
entry to the study (see Appendix 3), and were processed as shown in Box 2.EuroQol quality-of-life assessment (European Quality
of Life-5 Dimensions)We assessed patients using the European quality of life (EuroQol) assessment at baseline on admission, and
7 and 28 days later. The EuroQoL European Quality of Life-5 Dimensions tool (EQ-5D)55 has been used in
many cost-effectiveness studies56,57 and is recommended for use in the economic evaluation of health-care
technologies within the UK in guidance issued by the National Institute for Health and Care Excellence
(NICE).58 It deﬁnes health in ﬁve dimensions: morbidity, self-care, usual activities, pain or discomfort, anxiety
or depression. Each dimension has three levels: no problems, a moderate problem, or a severe problem.
Health states deﬁned by the level chosen for each dimension can be scored using utility weights reﬂecting the
values from a representative sample of the UK population.59 These utilities are scaled so that full health = 1
and death = 0, and they allow for severe health states for which health-related quality of life (HRQoL) is
valued lower than death. The EQ-5D was self-completed by participants or was done by proxy if the
participant was incapable of completing the self-administered questionnaire or providing a verbal response.
Where patients were discharged, the EQ-5D was assessed by telephone interview of the patient, by postal
questionnaire or by proxy.Record-keepingThe mainstay of the record-keeping for this study was the case report form (CRF) (see Appendix 5).
Individual CRFs were stored in locked ﬁling cabinets in a secure University of Leicester research laboratory
within Leicester Royal Inﬁrmary.
The CRFs captured basic demographic data (including details of residential status, smoking habits, alcohol
consumption, household contacts, inﬂuenza and pneumococcus immunisation status during the previous
3 years, and hospital admissions during the period 1 September to 30 April of the previous winter), the
date and time of admission, the randomisation group, GP details, symptoms of the presenting illness,
examination ﬁndings on admission, past medical history, and provisional diagnosis information on
recruitment. The CRFs also recorded information on prescribed medication, oxygen and intravenous (i.v.)
ﬂuids, investigations, isolation status, complications, transfer to the intensive care unit, duration of stay,
deaths, quality of life (QoL), and the timing of specimen collection and test results. Information was
collected from the participant by research staff on recruitment and during follow-up visits, from medical
case notes, computerised hospital records, and by post, and was entered into the CRF. Clinical and QoL
data, together with laboratory ﬁndings, were entered into a database written in Microsoft Access 2000
(Microsoft Corporation, Redmond, WA, USA), which was maintained on University of Leicester mainframe
computers, behind electronic ﬁrewalls allowing limited access with passwords. This proved a secure and
conﬁdential way of maintaining the records.Near-patient tests
BinaxNOW Streptococcus pneumoniae test
Urine was tested for S. pneumoniae antigens using the BinaxNOW S. pneumoniae urinary antigen tests
according to the manufacturer’s instructions. The principles of the test and the test procedure are described in11
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12Appendix 2. Freshly voided urine samples were collected from participants in each study group, as described
in Box 2. Brieﬂy, the test swab provided by the manufacturer was dipped into the urine specimen at room
temperature, so that the specimen completely covered the swab head. The swab was removed from the urine
and then placed into the bottom hole (the swab well) of the test device, and pushed upwards so that the
swab tip was visible in the top hole. Three drops of the reagent was added to the bottom hole and the
adhesive cover was immediately removed from the right edge of the test device, which was then closed
and sealed. A positive-control swab (containing heat-inactivated S. pneumoniae) and an S. pneumoniae
negative-control swab were also provided. The results were read 15 minutes later. A positive test result was
indicated by the appearance of a pink-to-purple coloured line for both the specimen and positive control.
A negative test result was indicated by a colour reaction to only the positive control.Quidel QuickVue Influenza A + B test
Nasopharyngeal specimens collected as described in Box 2 were tested for inﬂuenza type A and type B
antigens using the Quidel QuickVue Inﬂuenza A + B test, according to the manufacturer’s instructions.
The principles of the test and the test procedure are described at www.cliawaived.com/web/items/pdf/
QDL-20183-Quidel_Inﬂuenza_Tests_Insert∼619ﬁle1.pdf.Molecular diagnostic testsWe used molecular diagnostic tests that were developed at the Centre for Infections, HPA (London, UK),
and the HPA Laboratory, Cambridge.Ribonucleic acid extraction from clinical and control samples
Swab samples in virus transport medium (VTM) were vortexed vigorously for 1 minute to dislodge material
attached to the swab. Each sample was mixed with 2 ml of amphotericin B (Fungizone®, Gibco®, New York,
NY, USA) (2.5 µg/ml concentration) then vortexed to mix before removal of an aliquot for nucleic acid
extraction. Viral ribonucleic acid (RNA) was extracted from nasopharyngeal specimens that were collected,
transported and stored, as described in Box 2. During the ﬁrst study season, viral RNA was manually
extracted from 150-µl aliquots of nasopharyngeal specimen using the guanidium isothiocyanate method
described by Boom et al.,60 with a ﬁnal elution volume of 30 µl. Although this method provided high-quality
RNA for PCR, subsequent work was performed using an automated nucleic acid extraction platform
(X-tractorGene, Corbett Robotics, Australia) with a guanidine isothiocyanate reagent pack (Sigma-Aldrich,
St Louis, MO, USA) according to the manufacturer’s speciﬁcations. Brieﬂy, manual cell lysis was performed
by adding 100 µl of sample digest buffer and 360 µl of lysis buffer to a 180-µl nasopharyngeal sample
aliquot. The entire 640-µl volume was then transferred into a lysis block, which was placed in X-tractorGene
for automated processing, providing a ﬁnal elution volume of 50 µl.
Positive-control viruses and two negative controls were included with each extraction. The control viruses
were inﬂuenza strains A/Taiwan/1/86 (H1N1), A/Moscow/10/99 (H3N2) and B/Panama/45/90; RSV strains
Long (RSV A) and N2 (RSV B); and human metapneumovirus (hMPV). The no-template controls were
VTM and deoxyribonuclease (DNAse)/ribonuclease (RNAse)-free water. The controls were made as
quality-controlled batches, stored at –80 °C and then undergoing the same lysis procedure and nucleic
acid extraction described above.Reverse transcription
Synthesis of complementary deoxyribonucleic acid (cDNA) from extracted RNA was primed using random
hexamers and Moloney murine leukaemia virus (MMLV) reverse transcriptase (RT) as described by Stockton
et al.,36 prior to ampliﬁcation by either the multiplex semi-nested conventional PCR or real-time PCR methods.
In a 40-µl reaction, 22.2 µl of RNA was added to a RT mix containing 20mM Tris-HCl, 50mM KCl,
7.5 mM MgCl2, 100mM of each deoxynucleotide triphosphate (dNTP), 5.3 nM of a random hexamerNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36(Promega, Madison, WI, USA), 1.6 U of ribonuclease inhibitor (RNasin) (Promega) and 200U of MMLV
transcriptase (Invitrogen, Carlsbad, CA, USA). The mixture was incubated at room temperature for
10 minutes, at 37 °C for at least 45 minutes, at 95 °C for 5 minutes and then quenched on ice for at
least 1 minute.Polymerase chain reaction tests
Different PCR assays were used to detect inﬂuenza A and B and RSV A and B during the 3-year study that
took into account ongoing technological advances and availability. The method applied during the ﬁrst
year of the study used conventional PCR. Subsequently, real-time PCR methods were applied to facilitate
rapid, high throughput of specimens.
Semi-nested multiplex conventional PCR During the ﬁrst year of the study, detection and subtyping of
inﬂuenza A H1 and H3, inﬂuenza B, and RSV A and RSV B were carried out by conventional, semi-nested
PCR targeting the haemagglutinin (HA) region of the inﬂuenza genome, and the N and P regions of RSV in
a multiplex reaction as described by Stockton et al.36 For primary PCR, 20 µl of cDNA was added to the
master mix to make up a ﬁnal reaction volume of 100 µl. For secondary PCR, 2 µl of the primary PCR
product was added to 48 µl of reaction master mix for a ﬁnal volume of 50 µl. Secondary PCR amplicons
were visualised using ethidium bromide following gel electrophoresis on 1.2% agarose (Roche, Mannheim,
Germany). Band patterns were compared against positive-control viruses for inﬂuenza and RSV. Negative
controls included DNAse/RNAse-free water and VTM.
HPA Cambridge one-step quadriplex real-time RT-PCR During the second year of the study, we used a
one-step quadriplex PCR to detect inﬂuenza A and B according to the National Standard Method virology
standard operating procedure (VSOP) 25.61 This assay ampliﬁed 5 µl of extracted RNA template in a
25-µl reaction volume with generic primers targeting the conserved region of the matrix gene for inﬂuenza
A/B detecting all known inﬂuenza subtypes (H1–H15) and inﬂuenza B, and includes a bacteriophage MS2
internal control. The speciﬁcity of this assay was evaluated against a panel of inﬂuenza A (subtypes H1–H15),
inﬂuenza B strains and a respiratory panel of pathogens to ensure speciﬁcity of the assay for inﬂuenza type A,
inﬂuenza A subtype H5 and inﬂuenza type B. All samples were analysed in duplicate, and both results had to
be concordant for a deﬁnitive positive or negative diagnosis. Data analysis was performed using the Rotor
Gene software versions 6.0.41 and 6.1.71 (Corbett Research, Australia). This method and all other real-time
PCR methods in the study used a Rotor-Gene real-time PCR machine (Corbett Research, Australia), and
master mix and enzyme kits purchased from Invitrogen (Carlsbad, CA, USA). Forward and reverse primers
were obtained from Euroﬁns (London, UK); probes tagged with minor groove binders (MGBs) were
synthesised by Applied Biosystems (ABI, Warrington, UK) and probes labelled with Cy5 and Rox were
purchased from Metabion (Martinsried, Germany).
HPA Colindale, one-step influenza multiplex real-time RT-PCR During the third year of the study, we
detected H1 and H3 subtypes of inﬂuenza A and inﬂuenza B using a one-step multiplex PCR according to
the National Standard Method VSOP 50 as described by Stephenson et al.62 but with minor modiﬁcations.
This assay ampliﬁed 7.5 µl of extracted RNA template in a 25-µl reaction volume, with primers and probes
targeting conserved regions of the HA gene of H1, H3 and B viruses, and includes a soil-borne cereal
mosaic virus (SBCMV) internal control. All samples were analysed in duplicate, and both results had to be
concordant for a deﬁnitive positive or negative diagnosis. Primers and probes tagged with black hole
quencher (BHQ) were obtained from Euroﬁns (London, UK): other probes tagged with MGB were
purchased from ABI. Modiﬁcations included substitution of the ﬂuorophores VIC to JOE and NED to Cy5.
Data analysis was performed using the Rotor-Gene software version 6.1.71.
HPA Colindale, One-step real-time RT-PCR for RSVA and RSVB and hMPV, and two-step real-time,
multiplex PCR for RSVA, RSVB, and hMPV We used one-step real-time RT-PCR for RSVA, RSVB, and hMPV
during the second year of the study, and a two-step RT-PCR for these pathogens, according to the HPA
SOP V-5381/01–06. The same primers and probes were used in both the one-step and two-step assays13
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14and targeted conserved regions of the respective nucleocapsid genes in RSV A, RSV B and hMPV63 and
both assays included an SBCMV internal control. In the one-step method, 7.5 µl of extracted RNA template
was used in a 25 µl total reaction volume. In the two-step assay, 22.2 µl of extracted RNA was added to
17.8 µl RT mix and then 2.5 µl of the cDNA product was added to 22.5 µl reaction mix for a total volume
of 25 µl. All samples were analysed in duplicate with results validated as positive or negative where both
replicates were concordant. Probes tagged with BHQs and primers were purchased from Euroﬁns
(London, UK).Conventional diagnostic tests
Virus culture
Nasopharyngeal samples were processed in the laboratory according to local protocols. Two cell lines were
used for viral culture: primary liver cells (PLC/PRF5) (a continuous primary liver carcinoma line)64 and
Medical Research Council 5 cells (MRC-5) from human fetal lung.65
Approximately 0.25 ml of the nasopharyngeal specimen in VTM was inoculated into monolayered
PLC/PRF5 and MRC-5 cells in culture tubes and incubated, stationary, at 33 °C overnight. Tubes negative
for cytopathic effect (CPE) after 24 hours were reincubated, with rolling at two to three revolutions
per minute, at 33 °C in fresh maintenance medium.
MRC-5 cell culture tubes were observed until 28 days after inoculation. Those that were CPE positive were
conﬁrmed and subtyped by IF using group-speciﬁc antibodies, whereas those that were CPE negative were
reincubated and observed up to 28 days after initial inoculation. If contamination occurred during this
period, the original samples were ﬁltered and reinoculated into fresh culture tubes. If the cell monolayer
sheet appeared to be of poor quality then cells were scraped off the tubes, transferred into a fresh culture
tube and reincubated and analysed for up to another 28 days.
PLC/PRF5 cell culture tubes were observed for CPE twice weekly and haemadsorption (HAd) was
concurrently performed using human red blood cells type O. CPE- and/or HAd-positive tubes were
conﬁrmed and subtyped by IF, whereas those that were negative were reincubated and observed for up to
14 days post initial inoculation. As with MRC-5 tubes, contaminated tubes were ﬁltered and reincubated,
whereas those with poor cell sheets were scraped off and transferred into fresh culture tubes for analysis up
to another 14 days.Haemagglutination inhibition
Antibody responses were titrated by the Respiratory Virus Unit, Centre for Infections, HPA (London, UK), by
haemagglutination inhibition (HAI) assay using established protocols. Sera were tested at an initial dilution
of 1/8 and were given serial two-times dilutions to establish end point titres. Acute and convalescent sera
were tested in parallel, in duplicate, under masked conditions using A/New Caledonia/20/99 (H1N1),
A/California/7/2004 (H3N2), and B/Malaysia/2506/04 (a descendant of the B/Victoria/2/87 lineage) as test
antigens during the 2005–6 season; A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/2005 (H3N2),
B/Malaysia/2506/04 during the 2006–7 season; and A/Solomon Islands/03/2006 (H1N1), A/Brisbane/
10/2007 (H3N2), and B/Florida/4/2006 (a descendant of the B/Yamagata/16/88 lineage) during the
2007–8 season. A fourfold or greater rise in antibody titre was considered a signiﬁcant rise.Blood cultures
Blood cultures bottles were incubated using the BacT/ALERT 3D automated blood culture system
(bioMérieux, Durham, NC, USA) according to local protocols. Bottles ﬂagging positive growth wereNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36removed and a drop of the blood culture broth was Gram stained and examined under the microscope.
Blood culture broth with Gram-positive cocci in chains were inoculated onto blood agar plates and
incubated aerobically and anaerobically at 37 °C. Primary antibiotic susceptibility for streptococci to include
optochin were also set up on blood agar and Iso-sensitest agar (Oxoid, Basingstoke, UK), and incubated
aerobically at 37 °C. The presence of S. pneumoniae was conﬁrmed by demonstrating streptococci in the
Gram stain of colonies, negative catalase test and susceptibility to optochin.Gram stain and microscopy of sputum
Sputum was examined by Gram stain and microscopy according to local protocols. Brieﬂy, sputum smears on
slides were ﬂame heated to ﬁx, and then stained in the following order: Crystal violet, Gram’s iodine, ethanol
and carbol fuchsin. Microscopic analysis was performed using immersion oil and bright-ﬁeld microscopy.
Samples positive for Gram-positive cocci, Gram-positive bacilli, Gram-negative cocci and Gram-negative bacilli
were rated, subjectively, using a ‘+’ system, whereby the lowest copy number receives one + and conﬂuent
samples are given +++. The presence of epithelial cells and white blood cells was also observed and reported.Sputum culture
Sputum was cultured on blood and chocolate agar according to local protocols. Samples were diluted with
equal volume of sterile saline, homogenised and inoculated onto chocolate agar with bacitracin, and
blood agar with optochin. Plates were incubated aerobically in CO2 at 37 °C, were read at 24 hours and
48 hours. S. pneumoniae were identiﬁed by Gram stain showing streptococci, negative catalase test
and susceptibility to optochin.Outcome measures
Clinical
Impact of test result on prescribing:
l Time, from admission to ﬁrst administration of ‘narrow-spectrum’ antibiotics.
l Time, from admission to ﬁrst administration of oral antibiotics.
l Time, from admission to prescription of ‘no antibiotics’ (oral or i.v.) administered to patients with
inﬂuenza or RSV.
l Proportion of patients in each group who are prescribed NIs.
Impact of test result on duration of hospitalisation:
l For all patients in each diagnostic group.
l For patients in each diagnostic group with:
¢ Inﬂuenza.
¢ RSV.
¢ S. pneumoniae infection.Fever duration during ﬁrst 10 days of hospitalisation
l Time, from admission until patients became apyrexial, for:
¢ All patients in each group.
¢ Patients with S. pneumoniae infection.Supplemental oxygen dependence and continuous positive airway pressure dependence during
ﬁrst 10 days of hospitalisation15
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16Admissions to intensive care and ventilator support during ﬁrst 10 days of hospitalisation
Deaths within 28 days of hospitalisation
l For all patients in each diagnostic group.
l Overall, for patients with:
¢ Inﬂuenza.
¢ RSV.
¢ S. pneumoniae infection.Quality of life:
l For all patients in each diagnostic group.
l For patients in each diagnostic group with inﬂuenza, RSV and S. pneumoniae infection.
Use of isolation facilities by patients with inﬂuenza and RSV, and inappropriate use by those
with S. pneumoniae infectionFinancial
Costs of the diagnostic tests
Care costs
Cost savings arising from the use of diagnostic tests
Total NHS costs
Incremental cost per case detected and cost per QALYLaboratory
Diagnostic accuracy: sensitivity, speciﬁcity, and positive and negative predictive values
Ease of use of diagnostic tests
Speed of use of diagnostic tests
Cost per case detectedAntimicrobial spectrum of activity
Broad-spectrum antibiotics
The following antibiotics, or classes of antibiotics, for the purposes of this study, were considered to be
broad-spectrum antibiotics, i.e. having activity against Gram-positive and Gram-negative pathogens, with
or without anaerobic organisms:
l Cephalosporins.
l Co-amoxiclav (Augmentin®, GSK).
l Piperacillin with tazobactam (Tazocin®, Pﬁzer).
l Carbapenems [imepenem with cilastatin (Primaxin®, MSD), meropenem (Meronem®, AstraZeneca),
ertapenem (Invanz®, MSD)].NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36l Quinolones [ciproﬂoxacin (Ciproxin®, Bayer), levoﬂoxacin (Tavanic®, Sanoﬁ-aventis), moxiﬂoxacin
(Avelox®, Bayer), etc.].
l Tetracyclines [doxycycline (non-proprietary), oxytetracycline (non-proprietary), minocycline
(non-proprietary)].
l Cotrimoxazole (non-proprietary).
l Clarithromycin and azithromycin (non-proprietary).
l Clindamycin (non-proprietary).Narrow-spectrum antibiotics
The following antibiotics, or classes of antibiotics, are considered to be narrow-spectrum antibiotics,
i.e. predominantly having activity against either Gram-positive or Gram-negative organisms, or
anaerobic organisms:Gram-positive antibioticsl Benzylpenicillin (and penicillin V).
l Flucloxacillin.
l Amoxicillin (and ampicillin).
l Erythromycin.
l Vancomycin.
l Rifampicin.
l Fusidic acid.
l Linezolid.
l Daptomycin.Gram-negative antibioticsl Gentamicin and other aminoglycosides.
l Aztreonam.
l Trimethoprim.
l Nitrofurantoin.Anaerobic antibioticsl Metronidazole.
Where multiple agents are used together, they are classiﬁed as broad spectrum if either is a broad-spectrum
agent, or if together they cover Gram-negative and Gram-positive organisms, with or without anaerobes.Sample sizeStatistical power of the Three Winters Study (3WS) was estimated for one laboratory end point (sensitivity/
speciﬁcity), the primary clinical end point (i.e. length of stay), and one secondary end point (i.e. appropriate
isolation levels).
The initial sample size calculation proposed that if the average sensitivity/speciﬁcity of the tests is assumed
to be 80% and a 20% dropout rate was assumed then 2752 patients in total would enable the sensitivity/
speciﬁcity to be estimated to within two standard errors (SEs), i.e. 7.6% if the disease prevalence was 5%
and 5.4% if the prevalence was 10%.
In terms of clinical end points, 2752 patients in total would also enable a minimum clinically signiﬁcant
difference (MCSD), between diagnostic policies, of 1 day in the mean length of stay [assuming standard17
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18deviation (SD) = 6 days] to be detected at the 5% signiﬁcance level with over 80% power, assuming a
20% dropout rate and adjusting for the fact that there are three groups. In total 2752 patients would also
enable a MCSD, between diagnostic policies, of an improvement in appropriate use of isolation facilities
from 5% to 15% to be detected at the 1% signiﬁcance level with over 95% power, assuming a 20%
dropout rate and adjusting for the fact that there are three groups.
Clearly, the initial sample size calculation was driven by the desire to estimate the sensitivity/speciﬁcity with
a sufﬁcient level of precision but that this depended crucially upon the disease prevalence. Consequently,
the sample size calculation was revisited in 2007 after the ﬁrst two winters’ data were available. During
2005–6, the overall disease prevalence was 18.7%, and during 2006–7 it was 10.3%, giving a combined
disease prevalence across the ﬁrst two winters of 13.2%. Consequently, if the average sensitivity/speciﬁcity
was 80% and the dropout rate continued to be 20% then 1200 patients in total would enable the
sensitivity/speciﬁcity to be estimated to within, i.e. two SE, 7.8% assuming a prevalence of 13%. Hence,
the required sample size was revised to 1200 patients in total, as this still enabled both a MCSD of 1 day
in mean length of stay (SD = 6 days) to be detected at the 5% signiﬁcance level with over 80% power,
and a MCSD of an improvement in appropriate use of isolation facilities from 5% to 15% to be detected
at the 1% signiﬁcance level with over 95% power, both assuming a 20% dropout rate and allowing for
the fact that there are three groups.Statistical methodsStatistical analyses were carried out using Stata version 11 (StataCorp LP, College Station, TX, USA). The
study was analysed as an intention-to-treat (ITT) study; effectively all patients were analysed according to
the group to which they were randomly allocated, regardless of whether they were in fact managed
according to the results of their designated diagnosis method.
For continuous, non-time-to-event, outcomes the three intervention groups were compared using either
parametric [analysis of variance (ANOVA)] or non-parametric (Kruskal–Wallis) test as appropriate, and
summary statistics were reported as means (SD) and medians [interquartile range (IQR)], respectively. For
categorical outcomes, the three interventions groups were compared using either Pearson’s chi-squared
test or Fisher’s exact test, as appropriate. For time-to-event outcomes, these were reported as median (IQR)
for each of three intervention groups, and compared formally using Cox proportional hazards regression
models to allow for censoring/death and reported as hazard ratios (HRs) [and associated 95% conﬁdence
intervals (CIs)]. For the primary outcome, length of stay, the three intervention groups were also compared
graphically using cumulative probability plots, i.e. one minus the Kaplan–Meier survivor function. EQ-5D
data – collected at baseline, 7 days and 28 days – was initially summarised at each of the three time points
and compared using parametric/non-parametric methods as for other continuous outcomes. Further
analysis using linear mixed-effect regression models to allow for within-patient correlation enabled an
assessment of the change in EQ-5D over time to be made and whether there was evidence of an
intervention group interaction with time.
A number of patients were randomised more than once owing to the nature of their age and clinical
condition. The primary analyses used their first admission/randomisation. However, to assess the impact
that this assumption had on the results, two sensitivity analyses were undertaken – the ﬁrst using all
admissions but assuming that they were independent, i.e. ignoring the fact that some patients appeared
more than once, and the second, perhaps more appropriately, including a random effect in the analyses to
account for the inherent correlation induced by patients being rerandomised.
All statistical tests were reported at the 5% signiﬁcance level, and 95% CIs or credible intervals (CrIs)
were reported throughout as the sample size calculations explicitly made allowance for the fact that there
were three rather two groups and inﬂated the sample size accordingly to maintain an overall 5%
signiﬁcance level.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Ethical arrangementsThis study was sponsored by the University Hospitals of Leicester NHS Trust. It was approved by
Leicestershire, Northamptonshire and Rutland Research Ethics Committee on 20 July 2005,
reference no. 05/Q2502/76.Revisions to the protocolWe requested protocol amendments as outlined below. All requests were approved by the Local Research
Ethics Committee. Protocol amendments that were implemented are outlined below:
1. On 13 January 2006 we requested the following amendments to the protocol in response to
poor recruitment:
¢ Approve a one-page ‘Synopsis’ of the six-page Patient Information Sheet to be used by patients
who are not known to be suffering from dementia but were too unwell to read the full Patient
Information Sheet.
¢ Allow recruitment of subjects with an illness of up to 7 days’ duration (i.e. ≤ 168 hours) rather than
ﬁve days’ duration (i.e. ≤ 120 hours).
¢ Change from 6 hours to 8 hours the interval between initial assessment by the admitting medical
team and recruitment to the trial.
¢ Allow trained medical students to recruit patients to the study during out-of-hours periods.
2. On 14 March 2006, we requested the following protocol amendments.
¢ Change the timing of the convalescent blood sample from day 10 to ‘between day 10 and day 30’.
¢ Approve recruitment of all 18- to 64-year-old subjects with pneumonia and ILI, rather than just
those 18- to 64-year-old subjects with pneumonia and ILI who have underlying chronic heart and
lung disease, including asthma.
¢ Recruit patients until the end of June, rather than the period ‘September to April’.
¢ Approve a 20-ml urine collection and amendments to protocol where the volume was
stated differently.
¢ Change the labelling of the packs to correspond exactly with the trial identiﬁcation numbers. For
patients recruited in the Royal Inﬁrmary, the packs were changed from RI-HTA-0001, RI-HTA-0002,
etc., to 1–0001, 1–0002, etc. For patients recruited at Glenﬁeld Hospital, the packs were changed
from GH-HTA-0001, GH-HTA-0002, etc., to 2–0001, 2–0002, etc.
3. On 21 December 2006 we requested an amendment to aid recruitment:
¢ Change, from 8 hours (originally 6 hours) to 16 hours the interval between initial assessment by
the admitting medical team and recruitment to the trial.
4. On 20 March 2007 we requested an amendment to aid collection of convalescent sera:
¢ Extend from day 10 to day 90 (i.e. 90 days after admission) the period when we could collect
convalescent blood.
5. On 5 November 2007 we requested an amendment to aid recruitment of incapacitated adults:
¢ Allow personal and professional representatives to provide consent for incapacitated adults to take
part in the study.19
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DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Chapter 3 Study populationRecruitment and complianceBetween 14 December 2005 and 23 May 2008, 1253 admissions were enrolled and randomised to the
rapid near-patient test group (n = 418), the molecular diagnostic group (n = 415) and the conventional
diagnosis group (n = 420). One individual withdrew from the study. Altogether a total of 1252 admissions
were randomised as shown in Figure 4, and participated in the study.21
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The data set comprised data relating to 1252 separate hospital inpatient episodes. There were 1172 unique
patients in the study, with 67 individuals having up to four separate inpatients episodes each. The main
analyses and results use the ﬁrst admission for the 1172 patients (see Chapter 2 for other sensitivity analysis
details). The number of admissions per patient is shown in Table 1, together with the frequencies of
inpatient episodes by patient numbers. The 1172 ﬁrst admissions were randomised as shown in Figure 5.
The demographic variables are described for ﬁrst admissions only (1172 patients) and are set out in
Table 2, as well as other patient background information deemed of interest. The baseline demographics
are intended to describe the characteristics of the patients participating in the trial and to assess whether
the randomisation process had been applied successfully.
From Table 2, the only demographic variable that appears to show weak statistically signiﬁcant evidence of
unbalanced distribution across the three trial arms is body mass index (BMI), with a p-value of 0.091.
However, the mean values of BMI across the three groups are very similar, and it is unlikely that any
difference across the groups is clinically signiﬁcant.
Regarding hospital admissions in the previous year, out of the 1140 ﬁrst admission patients with data
available, 727 had zero admissions in the previous year. The maximum number of previous admissions was
20 (one patient).TABLE 1 Number of patients having successive inpatient episodes
Admission No. of patients (% out of 1252 admissionsa)
First 1172 (93.6)
Second 67 (5.4)
Third 10 (0.8)
Fourth 3 (0.2)
a The ﬁgure ‘1252’ refers to admissions or patient admissions (and not unique patients) – there were 1172 patients,
of whom 67 were admitted/randomised at least twice.
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TABLE 2 Patient demographics at baseline
Covariate
Near patient
(n = 397)
Rapid molecular
(n = 387)
Traditional
(n = 388) p-valuea Missing, nb
Gender, n (%) 0.415 0
Male 203 (51.1) 197 (50.9) 182 (46.9)
Female 194 (48.9) 190 (49.1) 206 (53.1)
Age (years), n (%) 0.971 0
18–29 23 (5.8) 21 (5.4) 23 (5.9)
30–49 69 (17.4) 72 (18.6) 76 (19.6)
50–64 96 (24.2) 83 (21.5) 81 (20.9)
65–74 89 (22.4) 84 (21.7) 83 (21.4)
≥ 75 120 (30.3) 127 (32.8) 125 (32.2)
BMI (kg/m2) (mean, SD)
26.6 (6.96) 26.6 (7.49) 25.5 (6.22) 0.091 231b
Ethnicity, n (%) 0.940 0
White 361 (90.9) 347 (89.7) 354 (91.2)
Indian 25 (6.3) 29 (7.5) 25 (6.4)
Other 11 (2.8) 11 (2.8) 9 (2.3)
Smoking status, n (%) 0.123 0
Current 93 (23.4) 90 (23.3) 118 (30.4)
Previous 184 (46.4) 187 (48.3) 169 (43.6)
Never 120 (30.2) 110 (28.4) 101 (26.0)
Flu vaccination this season, n (%) 0.831 0
Yes 235 (59.2) 221 (57.1) 224 (57.7)
No 162 (40.8) 166 (42.9) 164 (42.3)
Flu vaccination last season, n (%) 0.435 0
Yes 240 (60.5) 218 (56.3) 233 (60.1)
No 157 (39.6) 169 (43.7) 155 (40.0)
Flu vaccination two seasons ago, n (%) 0.856 0
Yes 220 (55.4) 209 (54.0) 217 (55.9)
No 177 (44.6) 178 (46.0) 171 (44.1)
Flu vaccination ever, n (%) 0.866 0
Yes 297 (74.8) 283 (73.1) 287 (74.0)
No (never) 100 (25.2) 104 (26.9) 101 (26.0)
Hospital admissions in previous year IRRc (95% CI; p-value)
1 1.017 (0.744 to
1.391; 0.915)
1.037 (0.762 to
1.412; 0.816)
132b
BMI, body mass index; IRR, incidence rate ratio.
a The p-values are based on Pearson’s chi-squared test, except for BMI, which is based on ANOVA F-statistic.
b Missing values were equally distributed across groups: BMI, ‘near patient’ 21.6%, ‘rapid molecular’ 18.6%, traditional
21.9%; hospital admission in previous year, ‘near patient’ 11.8%, ‘rapid molecular’ 12.9%, traditional 9.0%.
c Incidence rate ratio based on negative binomial regression.
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STUDY POPULATION
26ComorbidityPre-existing medical conditions for the 1172 patients at ﬁrst admission are set out in Table 3. As can be seen
from Table 3, there is no evidence of any association between trial arm and comorbidity for any disease.
Time to convalescent blood samples
Convalescent blood samples were taken from patients following their admission. Median times to
collection of the samples are set out in Table 4, for ﬁrst admissions only, and are similar across trial arms.TABLE 3 Pre-existing medical conditions for ﬁrst admissions
Medical
condition
Near patient
(n = 397)
Rapid molecular
(n = 387)
Traditional
(n = 388) p-valuea Missing, nb
Myocardial infarction, n (%) 0.627 37b
Yes 48 (12.5) 56 (14.9) 51 (13.5)
No 335 (87.5) 319 (85.1) 326 (86.5)
Heart failure, n (%) 0.860 37b
Yes 21 (5.5) 21 (5.6) 18 (4.8)
No 362 (94.5) 354 (94.4) 359 (95.2)
Angina, n (%) 0.768 37b
Yes 44 (11.5) 37 (9.9) 41 (10.9)
No 339 (88.5) 338 (90.1) 336 (89.1)
Stroke, n (%) 0.369 37b
Yes 21 (5.5) 21 (5.6) 29 (7.7)
No 362 (94.5) 354 (94.4) 348 (92.3)
Chronic bronchitis, n (%) 0.533 37b
Yes 42 (11.0) 51 (13.6) 45 (11.9)
No 341 (89.0) 324 (86.4) 332 (88.1)
Asthma, n (%) 0.999 37b
Yes 162 (42.3) 159 (42.4) 160 (42.4)
No 221 (57.7) 216 (57.6) 217 (57.6)
a The p-values are based on Pearson’s chi-squared test.
b Missing values were equally distributed across groups: ‘near patient’ 3.5%, ‘rapid molecular’ 3.1%, traditional 2.8%.
TABLE 4 Time to convalescent samples
Investigation
Near patient
(n = 174)
Rapid molecular
(n = 185)
Traditional
(n = 183)
Total
(n = 542)
Median days from admission
to collection of convalescent
samples (IQR)
28.25
(14.58–59.45)
27.46
(17.95–55.97)
27.72
(19.09–61.59)
28.00
(17.07–59.49)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Chapter 4 Patient outcomesIntroductionIn this section, we report the ﬁndings relating to the patient outcomes. The main results reported are
based on the ﬁrst admission for 1172 patients. The following diagnostic tests contributed to the
diagnoses made:
1. rapid molecular tests (PCR): inﬂuenza and RSV
2. Quidel (NPT for inﬂuenza)
3. viral cultures (inﬂuenza, RSV)
4. BinaxNOW test (S. pneumoniae)
5. sputum cultures (S. pneumoniae), and
6. blood cultures (S. pneumoniae).
A patient was diagnosed as having any of the three infectious conditions (inﬂuenza, RSV or
S. pneumoniae) if any of the diagnostic tests (not necessarily a test to which the patient had been
randomised) showed a positive result, regardless of the results of the other tests. The Gram stain test was
not used in determining diagnosis as none of the outcomes were positive for S. pneumoniae. In Chapter 5,
sensitivity to diagnostic test results is further explored using serology data for inﬂuenza.Diagnostic test results for ﬁrst admissionsThe results of the diagnostic tests for 1172 ﬁrst admissions are set out in Table 5. Note that an outcome of
‘Not diagnosed’ does not indicate a deﬁnite negative diagnosis, as for the inﬂuenza tests, a diagnostic
result was not available for two patients (e.g. due to lack of a suitable sample). From the ﬁrst admissions,
four patients were diagnosed with both RSV and S. pneumoniae; also four patients were diagnosed with
both inﬂuenza and S. pneumoniae. No patients were diagnosed with both RSV and inﬂuenza.
Overall, the diagnoses appeared to be relatively evenly spread across the three trial arms, with no evidence
of an association between trial arm and diagnoses. No attempt is made in these analyses to distinguish
patients with multiple diagnoses (e.g. if a patient has a diagnosis of both RSV and S. pneumoniae, this
patient will be counted in both groups).Prescribing outcomes
Time from admission to first narrow-spectrum antibiotic
One of the outcomes of interest in this trial is the potential impact of the investigation on the time
from admission to the time of prescription of the ﬁrst narrow-spectrum antibiotic. Of the 1252 admissions,
a narrow-spectrum antibiotic was prescribed during 555 admissions. For 161 of these admissions,
the duration of time until the prescription was ≤ 0 hours, indicating that the time of prescription of the
narrow-spectrum antibiotic was prior to the recorded time of hospital admission, for example in the
accident and emergency (A&E) department. For these patients, duration of 0.01 hours was substituted to
facilitate the analysis. Of the 1172 ﬁrst admissions, a narrow-spectrum antibiotic was prescribed during
527 admissions.27
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TABLE 5 Diagnostic results for ﬁrst admissions
Diagnosis
Near patient
(n = 397)
Rapid molecular
(n = 387)
Traditional
(n = 388) p-valuea n missing
Inﬂuenza, n (%) 0.590 0
Diagnosed 27 (6.8) 30 (7.8) 34 (8.8)
Not diagnosed 370 (93.2) 357 (92.3) 354 (91.2)
RSV, n (%) 0.160 0
Diagnosed 11 (2.8) 13 (3.4) 5 (1.3)
Not diagnosed 386 (97.2) 374 (96.6) 383 (98.7)
S. pneumoniae, n (%) 0.099 0
Diagnosed 24 (6.1) 36 (9.3) 39 (10.1)
Not diagnosed 373 (94.0) 351 (90.7) 349 (90.0)
a The p-values are based on Pearson’s chi-squared test.
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28For ﬁrst admissions only, the time to prescription of the ﬁrst narrow-spectrum antibiotic is shown in
Table 6, which includes the HR with 95% CI based on a Cox proportional hazards model (with the
‘traditional’ group as the reference group) and median survival times for all three diagnostic groups.
Based on Table 6, there is weak evidence (p-value 0.082 for the Cox HR model) for an association between
diagnostic group and time to ﬁrst narrow-spectrum antibiotic comparing the ‘rapid molecular’ group to
the ‘traditional’ group. However, in the light of the width of the 95% CI for the HR (0.976 to 1.487) and
wide IQRs for both groups, the association does not appear to be strong. There is no evidence for an
association between diagnostic groups comparing the ‘near-patient’ group with the ‘traditional’ group.Time from admission to first oral antibiotic
All patients who received antibiotics were analysed for time until ﬁrst oral antibiotic (if prescribed oral
antibiotics at all), regardless of whether the patient received antibiotics by another route (e.g. i.v.) prior to
receiving oral antibiotics. In total, of the 1252 admissions, 851 received at least one oral antibiotic during
the hospital inpatient episode. Of these, 216 admissions had a time to ﬁrst oral antibiotic that was zero or
negative, and duration of 0.01 hours was substituted to facilitate the analysis. Of the 1172 patients with a
ﬁrst admission, 800 received at least one oral antibiotic. The analysis of time to ﬁrst oral antibiotic, for ﬁrst
admissions only, by diagnostic group, is set out in Table 7. Table 7 shows no evidence for any association
between diagnostic group and time to ﬁrst oral antibiotic.TABLE 6 Time to prescription of ﬁrst narrow-spectrum antibiotic: median hours until prescription of ﬁrst
narrow-spectrum antibiotics to 527 patients (among 1172 ﬁrst admissions), and Cox proportional hazards model by
diagnostic group
Investigation
Traditional
(n = 199)
Near patient
(n = 170)
Rapid molecular
(n = 158)
Total
(n = 527)
Median hours to ﬁrst
narrow-spectrum
antibiotic (IQR)
3 (0.01–8.17) 3.5 (0.01–9.83) 2.67 (0.01–6.75) 3 (0.01–8.08)
Cox HR (95% CI; p-value) 1 1.023 (0.833 to
1.257; 0.829)
1.205 (0.976 to
1.487; 0.082)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 7 Time to prescription of ﬁrst oral antibiotic: median hours until prescription of ﬁrst oral antibiotic to
800 patients and Cox proportional hazards model by diagnostic group, for all 1172 ﬁrst admissions
Investigation
Traditional
(n = 283)
Near patient
(n = 265)
Rapid molecular
(n = 252)
Total
(n = 800)
Median hours to ﬁrst oral
antibiotic (IQR)
4 (0.1–10.5) 3.75 (0.25–11.33) 4 (0.01–11.5) 4 (0.1–11)
Cox HR (95% CI; p-value) 1 0.957 (0.809 to
1.132; 0.605)
0.905 (0.763 to
1.074; 0.253)
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Time from admission to cessation of antibiotics
For patients with RSV or inﬂuenza only, the time to cessation of antibiotics (by all routes of administration)
was analysed. For patients with RSV or inﬂuenza, 96 received at least one antibiotic during the hospital
admission (across all 1252 admissions). Among the 1172 ﬁrst admissions, 93 of the 120 patients
diagnosed with inﬂuenza or RSV received at least one antibiotic during their admission. Six of these
patients had a time to cessation of antibiotics that was negative, and was replaced by a duration of
0.01 hours. The results of the Cox proportional hazards model, comparing diagnostic groups, and median
times to cessation of antibiotics, are shown in Table 8.
Table 8 shows no evidence for an association between time from initial hospital admission to ﬁnal dose of
antibiotics among patients with inﬂuenza or RSV. However, the numbers of eligible patients in each
diagnostics group are relatively small, leading to wide 95% CIs and IQRs.
A corresponding analysis was also performed for all patients with a ﬁrst admission (regardless of diagnostic
outcomes). Across all 1252 admissions, 911 patient episodes were associated with administration of at
least one antibiotic (in 44 cases the duration to cessation of antibiotics was negative and replaced by
0.01 hours). Of the 1172 patients admitted for the ﬁrst time within the study, 857 received at least one
antibiotic (42 of whom had a negative duration to cessation of antibiotics, which was replaced by
0.01 hours). The results are shown in Table 8. Again, there is no evidence to support an association
between diagnostic group and time to cessation of antibiotics.Neuraminidase prescriptions in patients with influenza
One patient was treated with a NI. This patient was a ﬁrst admission, in the traditional diagnostic group,
and was not diagnosed with S. pneumoniae, inﬂuenza or RSV.TABLE 8 Time to cessation of antibiotics: median hours cessation of antibiotics and Cox proportional hazards model
by diagnostic group, for ﬁrst admissions with RSV or inﬂuenza, and all ﬁrst admissions
Investigation Traditional Near patient Rapid molecular Total
All first admissions with RSV or influenza (n = 120)
Median hours to cessation of
antibiotics (IQR; n)
79.5
(34–116.75; 32)
56.42
(22.5–118; 24)
58.17
(18.98–152.75; 37)
77
(25.83–131.83; 93)
Cox HR (95% CI; p-value) 1 0.887 (0.512 to
1.537; 0.669)
1.014 (0.628 to
1.637; 0.955)
All first admissions (n = 1172)
Median hours to cessation of
antibiotics (IQR; n)
78.5
(27–116.75; 296)
60.75
(20.25–151; 286)
77.5
(17–152.75; 275)
77
(20.33–146.62; 857)
Cox HR (95% CI; p-value) 1 1.066 (0.906 to
1.255; 0.440)
1.030 (0.873 to
1.214; 0.726)
29
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30Clinical outcomes
Length of hospital stay
Length of hospital stay among survivors was calculated as the time between admission to hospital
and discharge for patients who were discharged only (excluding patients who died while in hospital).
For the ﬁrst admissions, only 46 patients died in hospital (39 within 28 days), with the remaining
1126 being discharged.
Using a Cox proportional hazards model to investigate any associations between the duration of hospital
stay and diagnostic group, the results are set out in Table 9, which shows the Cox HR and median hospital
stay (days). Two further analyses were performed on the full cohort of all discharged patients (1205),
including discharges resulting from admissions subsequent to the ﬁrst. These analyses used a Cox
proportional hazards model, one of which included a frailty (random effect on individual patient across
multiple admissions for those patients who had more than one admission, effectively treating patient as a
cluster variable).TABLE 9 Duration of hospital stay among survivors: median hospital stay (days) until discharge and Cox
proportional hazards model (for both survivors and those who died in hospital) by diagnostic group, for all ﬁrst
admissions, and ﬁrst admissions with RSV, inﬂuenza and S. pneumoniae only
Investigation Traditional Near patient Rapid molecular Total
All first admissions discharged (n = 1126)
Median days hospital stay (IQR; n) 3.23
(1.21–7.86; 374)
2.44
(0.90–7.56; 388)
2.81
(0.76–7.58; 364)
2.98
(0.95–7.75; 1126)
Cox HR (95% CI; p-value) 1 1.041 (0.903 to
1.201; 0.577)
1.109 (0.960 to
1.282; 0.160)
All first admissions discharged who were diagnosed with influenza (n = 90)
Median days hospital stay (IQR; n) 3.59
(1.40–7.28; 34)
2.08
(0.37–4.43; 26)
1.96
(0.74–6.82; 30)
2.52
(0.90–6.56; 90)
Cox HR (95% CI; p-value) 1 1.274 (0.758 to
2.143; 0.361)
1.248 (0.762 to
2.043; 0.380)
All first admissions discharged who were diagnosed with RSV (n = 27)
Median days hospital stay (IQR; n) 2.99
(2.98–3.16; 5)
2.56
(2.05–8.60; 11)
6.18
(1.27–11.75; 11)
3.10
(1.32–8.84; 27)
Cox HR (95% CI; p-value) 1 0.625 (0.203 to
1.920; 0.412)
0.559 (0.183 to
1.709; 0.308)
All first admissions discharged who were diagnosed with S. pneumoniae (n = 90)
Median days hospital stay (IQR; n) 4.21
(2.78–8.75; 37)
3.10
(1.60–6.19; 22)
4.02
(1.10–8.30; 31)
4.13
(1.82–8.50; 90)
Cox HR (95% CI; p-value) 1 1.131 (0.665 to
1.924; 0.651)
1.033 (0.637 to
1.676; 0.896)
All patients discharged (all admissions, 1205 discharges; no adjustment for multiple admissions)
Median days hospital stay (IQR; n) 3.23
(1.17–7.63; 404)
2.43
(0.90–7.48; 409)
2.81
(0.79–7.58; 392)
2.99
(0.97–7.52; 1205)
Cox HR (95% CI; p-value) 1 1.035 (0.902 to
1.188; 0.622)
1.098 (0.955 to
1.262; 0.190)
All patients who died or who were discharged (all admissions, 1205 discharges; frailtya on individual patient to
adjust for multiple admissions in same patient)
Cox HR (95% CI; p-value) 1 1.055 (0.904 to
1.230; 0.499)
1.118 (0.957 to
1.306; 0.159)
a Frailty (random effect) on individual patient (theta): 0.129, p-value for theta = 0 0.166.
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DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36As shown in Table 9, there was little difference in the HR whether including ﬁrst admissions only or
all admissions. Also, there was little difference in the HR when including frailty in the Cox proportional
hazards model. Frailty itself did not appear to be signiﬁcant (p-value = 0.166), indicating no evidence of an
effect on hospital stay, independent of diagnostic group.
Comparing the three diagnostic groups, there did not appear to be any evidence to support any
association between duration of hospital stay and diagnostic group. Figure 6 shows a Kaplan–Meier
estimated cumulative probability plot of time to discharge or death by randomised group. It shows the
overall similarity in length of stay by randomisation group.
Fever duration
Patients were considered to have been pyrexial from admission if any of the following were indicated:
1. temperature on admission (> 37.2 °C),
2. pyrexial (> 37.2 °C) within 48 hours of admission, and
3. end date of pyrexia present.
The time/date of the end of fever (or total duration of fever) was derived as follows (in order of precedence):
1. stated end time/date of fever if present (460 admissions out of 1252), or
2. discharge/death date if patient discharged/died within 10 days of admission (note: there were 148 patient
admissions who were pyrexial on admission but with no stated end time/date of fever out of 1252*).
[*1252 refers to admissions or patient admissions (and not unique patients) – there were 1172 patients, of
whom 67 were admitted/randomised at least twice.]
Also, there were two admissions with an unknown date of end of pyrexia (and hence substituted with
date of discharge or death) who were recorded as being pyrexial within 10 days, but who had a fever
duration of more than 10 days when using the substituted date of end of pyrexia. For these patients,
a fever duration of 240 hours was used. There were 26 patients with duration of fever calculated as
≤ 0 hours, and for these patients fever duration of 0.01 hours was substituted to facilitate the analysis.
Only patients who became apyrexial within ≤ 240 hours of admission to hospital were included in the
analyses (583 admissions out of 1252, and 549 patients out of 1172 ﬁrst admissions).
The results of a Cox proportional hazards model for median fever duration (hours) comparing the
‘near-patient’ and ‘rapid molecular’ diagnostic groups against the ‘traditional’ group are shown in Table 10.0.00
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n = 1126) by randomised group.
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TABLE 10 Fever duration: median duration, in hours, of fever, and Cox proportional hazards model by diagnostic
group, for all ﬁrst admissions, and ﬁrst admissions with S. pneumoniae only
Investigation Traditional Near patient Rapid molecular Total
All first admissions (n = 1172)
Median fever duration,
hours (IQR; n)
22.75
(11.25–51.33; 190)
22.5
(8.92–60; 185)
21.75
(8.17–46; 174)
22.5
(9.17–51.33; 549)
Cox HR (95% CI; p-value) 1 1.003 (0.819 to
1.230; 0.974)
1.158 (0.941 to
1.424; 0.165)
All first admissions diagnosed with S. pneumoniae (n = 99)
Median fever duration,
hours (IQR; n)
28.17
(8.92–71.5; 23)
28.5
(8.42–70.33; 19)
24
(11–46; 13)
28.17
(8.92–66.75; 55)
Cox HR (95% CI; p-value) 1 1.136 (0.608 to
2.122; 0.689)
1.223 (0.610 to
2.450; 0.570)
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the results in Table 10, there is no evidence to support an association between fever duration and diagnostic
group in all patients (regardless of any diagnosis), or for patients diagnosed with S. pneumoniae only,
although the small numbers of patients with S. pneumoniae should be noted.
Supplemental oxygen dependence
Of all 1252 admissions, 546 were associated with prescription of oxygen during the admission. Of these
546, 28 had no conﬁrmed end date for cessation of oxygen therapy. For these patients, the cessation date
for oxygen therapy was considered to be the date of discharge (n = 25) or death (n = 3). For patients
whose duration of oxygen therapy in hours (from admission to cessation of oxygen) was zero or negative
(i.e. their time of cessation of oxygen was recorded as being prior to the recorded time of admission to
hospital), their duration was replaced by 0.01 hours (41 patients). Patients with duration of oxygen therapy
of more than 240 hours (10 days) were excluded from the analyses.
Regarding the 1172 ﬁrst admissions only, 436 patients received oxygen therapy that ceased within
240 hours. The results of the time-to-event analysis by diagnostic group for the 436 patients, and for
40 out of 99 patients who were with diagnosed S. pneumoniae only, are shown in Table 11.ABLE 11 Time to cessation of oxygen therapy: median duration, in hours, of oxygen therapy and Cox proportional
azards model by diagnostic group for all ﬁrst admissions, and ﬁrst admissions with S. pneumoniae only
Investigation Traditional Near patient Rapid molecular Total
All first admissions (n = 1172)
Median hours from
admission to cessation of
oxygen therapy (IQR; n)
32.33
(11–75; 146)
23.92
(9.33–74; 146)
26
(9.25–70.08; 144)
26
(10–72.5; 436)
Cox HR (95% CI; p-value) 1 1.004 (0.798 to
1.265; 0.970)
1.043 (0.828 to
1.314; 0.718)
All first admissions diagnosed with S. pneumoniae (n = 99)
Median hours from
admission to cessation of
oxygen therapy (IQR; n)
45.33
(25.75–130; 18)
40
(17.25–74.5; 9)
30.17
(5.5–59.5; 13)
44.17
(12–80.5; 40)
Cox HR (95% CI; p-value) 1 1.401 (0.618 to
3.176; 0.420)
1.791 (0.847 to
3.790; 0.127)T
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to cessation of oxygen, in all patients, or in those diagnosed with S. pneumoniae.Continuous positive airway pressure dependence
Of all 1252 admissions, 17 were associated with the use of continuous positive airway pressure (CPAP)
during the admission, with 14 patients receiving CPAP during a ﬁrst admission. There were three patients
with no date of cessation of CPAP; for two of these, the date of CPAP cessation was taken as the date of
discharge, and for the third patient the time of death was used. There were three patients with a negative
duration of CPAP (from admission to cessation of CPAP, indicating that time of commencement of CPAP was
recorded as being before the recorded time of admission to hospital), replaced by a duration of 0.01 hours.
All 14 patients who received CPAP during a ﬁrst admission had duration of CPAP of ≤ 240 hours.
The results of the time-to-event analysis by diagnostic group, for all patients with a ﬁrst admission, are
shown in Table 12. Owing to the small numbers of patients who received CPAP, the results should be
viewed with caution; however, there is no evidence to support any association between diagnostic group
and time to cessation of CPAP. Only two patients diagnosed with S. pneumoniae received CPAP during a
ﬁrst admission, one in the ‘near-patient’ diagnostic group and one in the ‘traditional’ group. Owing to the
very small numbers of patients, analysis of the data is not feasible.
Admissions requiring intensive care and ventilator support
Across the 1252 admissions, six patients were admitted to intensive treatment unit (ITU), of whom ﬁve
were admitted on a ﬁrst admission. Of the total of six admissions, three were in the ‘near-patient’ group,
one was in the ‘rapid molecular’ group and two were in the ‘traditional’ group. One patient admitted to
ITU was diagnosed with S. pneumoniae (in the ‘near-patient’ group and a ﬁrst admission). None of the
patients who were diagnosed with inﬂuenza or RSV were admitted to ITU.
All patients who were admitted to ITU required ventilator support (no other patients were ventilated while
admitted). Owing to the small numbers of patients requiring ITU admission and ventilation, it is not
feasible to make any comparisons across the diagnostic groups for this outcome.Deaths
A total of 58 deaths were conﬁrmed among the 1252 admissions (57 in ﬁrst admissions), of which 50 (all
in ﬁrst admissions) occurred within 28 days of admission. Deaths that occurred more than 28 days after
admission were not comprehensively recorded, so only deaths that occurred within 28 days are considered
in this analysis. All 50 patients who died within 28 days of admission were patients who had been
admitted for the ﬁrst time (of the 1172 patients with ﬁrst admissions, 50 died within 28 days, 4.3%). Of
the 50 deaths, 39 died in hospital and 11 died after discharge. Deaths occurred within 28 days in three
(3.3%) admissions with inﬂuenza, two (6.9%) with RSV, and ten (10.1%) with S. pneumoniae. Table 13
shows the distribution of deaths within 28 days of admission in each diagnostic group, overall and by
diagnosis, for ﬁrst admissions only. Despite the small number of deaths in the study, we found noTABLE 12 Time to cessation of CPAP therapy: median duration, in hours, of CPAP therapy and Cox proportional
hazards model by diagnostic group, for 14 of all 1172 ﬁrst admissions
Investigation Traditional Near patient Rapid molecular Total
All first admissions (n = 1172)
Median hours from admission to
cessation of CPAP (IQR; n)
19.75
(8.5–26; 5)
15.5
(6.42–22.5; 4)
43.92
(0.01–48.83; 5)
19.75
(6.42–3.4; 14)
Cox HR (95% CI; p-value) 1 0.849 (0.220 to
3.276; 0.812)
0.254 (0.045 to
1.440; 0.122)
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TABLE 13 Deaths within 28 days of admission, for ﬁrst admissions only
Death within
28 days
Near patient
(n = 397)
Rapid molecular
(n = 387)
Traditional
(n = 388) p-valuea
Total cohort (N = 1172), n (%) 0.115
Yes 12 (3.0) 23 (5.9) 15 (3.9)
No 385 (97.0) 364 (94.1) 373 (96.1)
Inﬂuenza (N = 91), n (%) 0.635b
Yes 1 (3.7) 0 (0) 2 (5.9)
No 26 (96.3) 30 (100) 32 (94.1)
RSV (N = 29), n (%) 0.648b
Yes 0 (0) 2 (15.4) 0 (0)
No 11 (100) 11 (84.6) 5 (100)
S. pneumoniae (N = 99), n (%) 0.241b
Yes 2 (8.3) 6 (16.7) 2 (5.1)
No 22 (91.7) 30 (83.3) 37 (94.9)
a The p-values based on Pearson’s chi-squared test, unless marked with ‘b’ (see footnote ‘b’, below).
b Indicates Fisher’s exact test.
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34evidence to associate any diagnostic group with increased mortality for all patients, or for patients with
any speciﬁc diagnosis.
Use of isolation facilities
Across the 1252 admissions, 112 patients were admitted to isolation, and, of the 1172 ﬁrst admissions,
102 patients were admitted to isolation. Of the 1172 patients at a ﬁrst admission, 120 were diagnosed
with inﬂuenza or RSV of whom 14 were admitted to isolation at some time during their admission. In ﬁve
cases, their time from admission to hospital to admission to isolation was zero or negative, and was
replaced by duration of 0.01 hours. Owing to the small numbers of patients with RSV or inﬂuenza who
were admitted to isolation, a time-to-event analysis is difﬁcult, but the results are set out in Table 14.
The numbers of patients with inﬂuenza or RSV who were admitted to isolation within 120 hours
of admission in each group are shown in Table 15. Owing to the small number of admissions to
isolation within 120 hours of the admission, comparisons between the diagnostic groups are
considered inappropriate.TABLE 14 Time of isolation: median time, in hours, from admission to hospital to admission to isolation and Cox
proportional hazards model by diagnostic group, for 14 of all 1172 ﬁrst admissions with inﬂuenza or RSV
Investigation Traditional Near patient Rapid molecular
All first admissions (n = 1172), of whom 14 with influenza or RSV were isolated
Median hours from admission
to ‘isolation’ (IQR; n)
0.01 (0.01–27.37; 2) 0.01 (0.01–0.01; 4) 23.33 (5.50–55.08; 8)
Cox HR (95% CI; p-value) 1 0.65 (0.10 to 4.20; 0.655) 0.69 (0.14 to 3.39; 0.650)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 15 Admissions within 120 hours to single-room accommodation by patients with RSV or inﬂuenza
(ﬁrst admissions)
Patients
Near patient
(n = 397)
Rapid molecular
(n = 387)
Traditional
(n = 388)
All patients with inﬂuenza or RSV, n (%) 38 (9.6) 43 (11.1) 39 (10.1)
No. ‘isolated’ with inﬂuenza or RSV, n (%) 3 (7.9) 7 (16.3) 2 (5.1)
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Eight patients who experienced a ﬁrst admission and were diagnosed with S. pneumoniae (but not
concomitant inﬂuenza or RSV) were admitted to single-room accommodation. Seven were isolated for
> 12 hours, including two of 22 (who were diagnosed with streptococcal infection by any means but did
not have concomitant inﬂuenza or RSV) in the ‘near-patient’ group (9.1%), four of 34 in the ‘rapid
molecular’ group (11.8%) and one of 35 in the ‘traditional’ group (2.9%). Overall, taking data relating to
RSV, inﬂuenza and S. pneumoniae infections into consideration, we found no evidence to indicate that
diagnostic group has any association with use of isolation facilities, or that patients with RSV and
inﬂuenza, who pose a higher threat of nosocomial transmission than S. pneumoniae, are isolated
more often.Quality of lifeData regarding QoL (EuroQoL EQ-5D scores) are available at three time points in the trial: admission,
7 days and 28 days following admission, and was self-completed by participants. At ﬁrst admission, all
1172 patients were available for EQ-5D assessment, whereas at day 7, 16 patients (with a ﬁrst admission)
were deceased, and at day 28, 50 patients (with a ﬁrst admission) were deceased. The numbers of
patients alive, by diagnostic group, and with EQ-5D data available at different times, is shown in Table 16.
Numbers of patients across the diagnostic groups (ﬁrst admissions only) with full EQ-5D data available at
different times during the study period are shown in Table 17, which also provides descriptive analyses of
EQ-5D scores as combined into one overall score.66,67TABLE 16 Numbers of patients alive, by diagnostic group, with EQ-5D data available at different times
Days
Near patient
(n = 397)
Rapid molecular
(n = 387)
Traditional
(n = 388)
Total
(n = 1172)
Availability of all five EQ-5D scores n (%)
Admission only 57 (14.4) 64 (16.5) 78 (20.1) 199 (17.0)
Day 7 only 1 (0.3) 3 (0.8) 1 (0.3) 5 (0.4)
Day 28 only 1 (0.3) 0 (0) 0 (0) 1 (0.1)
Admission and day 7 72 (18.1) 91 (23.5) 90 (23.2) 253 (21.6)
Admission and day 28 29 (7.3) 22 (5.7) 26 (6.7) 77 (6.6)
Days 7 and 28 5 (1.3) 4 (1.0) 4 (1.0) 13 (1.1)
Admission, days 7 and 28 228 (57.4) 202 (52.2) 188 (48.5) 618 (52.7)
No EQ-5D at any time 4 (1.0) 1 (0.3) 1 (0.3) 6 (0.5)
For consistency, percentages have as denominator the total number of patients in each group, despite the fact that not all
patients remained alive at days 7 and 28.
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TABLE 17 Quality of life analyses, at admission to hospital, days 7 and 28 following admission, for patients alive
and with a ﬁrst admission only
Analysis
Near patient
(n = 397)
Rapid molecular
(n = 387)
Traditional
(n = 388)
Quality-of-life data on admission
All ﬁve EQ-5D scores, no. (%) 386 (97.2) 379 (97.9) 382 (98.5)
EuroQoL score:
Mean (SD) 0.463 (0.330) 0.459 (0.352) 0.469 (0.330)
Median (IQR) 0.487 (0.201–0.743) 0.487 (0.189–0.760) 0.516 (0.260–0714)
Quality-of-life data on day 7
All ﬁve EQ-5D scores, no. (%) 306/394 (77.7) 300/378 (79.4) 283/384 (73.7)
EuroQoL score:
Mean (SD) 0.563 (0.332) 0.593 (0.322) 0.591 (0.287)
Median (IQR) 0.639 (0.378–0.796) 0.689 (0.325–0.840) 0.620 (0.433–0.796)
Quality-of-life data on day 28
All ﬁve EQ-5D scores, no. (%) 263/385 (68.3) 228/364 (62.6) 218/373 (58.4)
EuroQoL score:
Mean (SD) 0.634 (0.308) 0.636 (0.288) 0.588 (0.310)
Median (IQR) 0.691 (0.516–0.814) 0.691 (0.516–0.814) 0.656 (0.516–0.796)
PATIENT OUTCOMES
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median EQ-5D score at admission (p = 0.931), 7 days (p = 0.466) or 28 days (p = 0.117).
Repeated measures analyses, with the aim of investigating an interaction between diagnostic group and
time of EQ-5D measurement on EQ-5D scores, using a linear mixed-effects model with a random effect for
individual patient, are reported in Table 18, for ﬁrst admissions only. These analyses were performed
initially on all data available at each time point, and subsequently on data from patients with EQ-5D scores
available at admission, days 7 and 28.
The analysis of all available data indicated that there was a signiﬁcant interaction between ‘near-patient’
diagnostic group and time of measurement at day 28 (p-value 0.033) and a borderline signiﬁcant
interaction between ‘rapid molecular’ diagnostic group and time of measurement at day 28 (p-value
0.074). In both cases the coefﬁcient of the interaction was positive, indicating that the EQ-5D scores for
day 28 were greater for the ‘near-patient’ and ‘rapid molecular’ groups compared with the traditional
group. Under both sets of analyses, the effect of changing EQ-5D levels over time was also highly
statistically signiﬁcant (p < 0.001), with increases in EQ-5D at both day 7 (0.123; 95% CI 0.076 to 0.169),
and day 28 (0.096; 95% CI 0.050 to 0.143) compared with admission.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 18 Repeated measures/linear mixed-effects model for EQ-5D score at admission, days 7 and 28, with random
effect on individual patient (ﬁrst admissions only)
Covariate Coefﬁcient (95% CI) p-value
All patients included with data available at each individual time (no. observations = 2745; no. patients = 1166)
Diagnostic group
Near patient –0.007 (–0.052 to 0.038) 0.763
Rapid molecular –0.008 (–0.054 to 0.037) 0.723
Time
Day 7 0.124 (0.086 to 0.162) < 0.001
Day 28 0.106 (0.064 to 0.148) < 0.001
Interactions
Day 7 × near patient –0.012 (–0.065 to 0.041) 0.665
Day 7 × rapid molecular 0.011 (–0.043 to 0.064) 0.696
Day 28 × near patient 0.062 (0.005 to 0.120) 0.033
Day 28 × rapid molecular 0.054 (–0.005 to 0.112) 0.074
Only patients with data at all three time points included (no. observations = 1854; no. patients = 618)
Diagnostic group
Near patient –0.038 (–0.099 to 0.022) 0.211
Rapid molecular –0.015 (–0.077 to 0.047) 0.639
Time
Day 7 0.123 (0.076 to 0.169) < 0.001
Day 28 0.096 (0.050 to 0.143) < 0.001
Interactions
Day 7 × near patient –0.007 (–0.069 to 0.056) 0.837
Day 7 × rapid molecular 0.004 (–0.060 to 0.069) 0.897
Day 28 × near patient 0.078 (0.015 to 0.141) 0.015
Day 28 × rapid molecular 0.057 (–0.008 to 0.122) 0.084
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Case reviewsAltogether eight patients in the ‘near-patient’ study group had a positive Quidel QuickVue Inﬂuenza A + B
result. We examined the CRFs of these eight patients to examine at a patient level whether their medical
management could have been inﬂuenced by the result of diagnostic testing. We also reviewed the CRFs of
the 21 patients in the ‘near-patient’ study group whose urine on admission was positive for pneumococcal
antigen using the BinaxNOW test to see if there was a temporal association between the test result and
changes to case management and isolation.QuickVUE influenza A + B test
The following results should be treated with caution given the small number of admissions in the
‘near-patient’ study group that tested positive in the QuickVUE Inﬂuenza A + B test.
A summary of the ﬁndings is shown in Table 19. None of the patients was admitted within 48 hours of
onset of symptoms and none was given NI. All seven patients with data on comorbidity had comorbidities
that made them eligible for treatment if their symptoms were of ≤ 48 hours’ duration. Two patients were
already ‘isolated’ when tested. Of the remaining six, one was discharged after the test and none of the37
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TABLE 19 Basic characteristics and NI and antibiotic treatment of eight patients in the ‘near-patient’ group with a
positive POCT for inﬂuenza
Observation
Patient
1 2 3 4 5 6 7 8
Temperature
on admission, °C
37.3 37.2 36.3 36.8 36.7 38.0 37.5 37.6
Age, years 22 30 39 71 74 75 83 86
Eligible for NIs, based on
Symptom
duration
No No No No No No No No
Comorbidity Yes Yes Yes Yes Yes Yes Yes Unknowna
NI prescribed No No No No No No No No
Isolated
At time of
diagnostic test
No Yes Yes No No No No No
Within 24 hours
of test
Discharged Discharged Discharged No No No No No
Antibiotics during
the admission:
Unknowna No Yes Yes No Yes No Yes
Oral, narrow
spectrum
Unknowna – Yes – – – – –
Oral, broad
spectrum
Unknowna – – Yes – Yes – –
Intravenous,
broad
spectrum
Unknowna – – Yes – Yes – Yes
Changed
within
24 hours
of testing
Unknowna – Yes,
stopped
Yes,
stepped
up from
oral to i.v.
– Yes,
from
i.v. to
oral
– No
Discharged within
24 hours of test
Yes Yes Yes No No No No Nob
Provisional
diagnosis at
admission
Exacerbation
of asthma,
chest
infection
Inﬂuenza/
ILI
Exacerbation
of asthma
Exacerbation
of airways
disease,
heart failure
Heart
failure
LRTI Exacerbation
of airways
disease
LRTI
a Notes missing.
b Patient died.
PATIENT OUTCOMES
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DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36remainder was isolated subsequently. Three of the eight patients were discharged within 24 hours of the
test without antibiotics – two had a provisional diagnosis of asthma, one had inﬂuenza/ILI; they were
the youngest of all of the eight patients.
There was no consistent pattern of treatment after diagnostic testing for the four patients who are
known to have received antimicrobials. One patient (No. 3), who had an exacerbation of asthma and was
apyrexial on admission, had treatment with a narrow-spectrum oral antibiotic stopped and was discharged
within 24 hours of testing. A 71-year-old patient (No. 4), who was pyrexial (38.8 °C) and was diagnosed
with heart failure and an exacerbation of chronic airways disease on admission, had broad-spectrum oral
antibiotics switched to the i.v. route for a presumed bacterial co-infection. Conversely, a 75-year-old
patient (No. 6) with LRTI had broad-spectrum oral antibiotics switched from the i.v. to the oral route.
Finally, an 86-year-old patient (No. 8) with LRTI was kept on broad-spectrum i.v. antibiotics but died from
methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia about 48 hours after admission.BinaxNOW Streptococcus pneumoniae test
Twenty-one admissions that were randomised to the ‘near-patient’ group had a positive BinaxNOW
S. pneumoniae test result. Characteristics of these patients are shown in Box 3. Details of the spectrum
and route of delivery of the antibiotics they received in hospital before and after the urinary antigen test
are shown in Table 20.
Table 20 shows the spectrum and route of delivery of antibiotics before and after the results of urinary
antigen tests for 20 patients in the ‘near-patient’ group. Antibiotics were given to everyone except four
patients before the test and one person afterwards. All but ﬁve patients received broad-spectrum
antibiotics before or after the test. Table 20 shows that four patients had a ‘step-up’ in treatment within
24 hours of the test result. Although it is unclear from the CRFs whether these changes in treatment
occurred in response to the test or slow clinical recovery, Table 20 shows that none of the patients had aBOX 3 Characteristics of 21 admissions in the ‘near-patient’ group that tested positive in the BinaxNOW
S. pneumoniae test
Median age (IQR), years: 59 (43–76.5).
Febrile on admission (≥ 37.3 °C), numerator/denominator (%), median (IQR) °C: 8/20a (40%), 37.1 °C
(36.5–37.65 °C).
Symptom duration on admission, median (IQR) hours: 120 (48–168).
Received pre-admission antibiotics from GP, numerator/denominator (%, 95% CI): 3/20a (15%,
95% CI 3.2% to 37.9%).
Provisional diagnoses on admission:
l CAP (n = 7).
l AE airways disease: COPD (n = 3), asthma (n = 2).
l ARI (n = 4).
l Cardiac: heart failure (n = 3), arrhythmia (n = 1).
l None entered (n = 1).
a Case notes missing for one patient.
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TABLE 20 Spectrum and route of delivery of antibiotics used from admission to hospital to the availability of the
BinaxNOW S. pneumoniae test, and during the ﬁrst 24 hours afterwardsa,b
Subject None
Narrow spectrum Broad spectrum
Oral i.v. Oral i.v.
Summary of changes
after result
1c ✓ None
2 ✓ [✓]d Step-up
3 ✓ None
4 ✓ None
5 ✓ [✓] Step-up
6 ✓ [✓] Step-up
7e ✓ None
8 ✓ None
9 ✓ None
10 ✓ None
11 ✓ None
12 ✓ None
13 ✓ None
14 ✓ None
15 ✓ None
16 ✓ None
17
18 ✓ None
19f ✓ None
20 ✓ [✓] Step-up
21 ✓ None
a Patients receiving broad-spectrum i.v. therapy may also have received broad-spectrum oral antibiotics or i.v. and
oral narrow-spectrum antibiotics. Similarly, those receiving broad-spectrum oral antibiotics may also have received i.v. or
oral narrow-spectrum antibiotics, and those receiving narrow-spectrum i.v. antibiotics may also have received oral
narrow-spectrum antibiotics.
b A ‘step-down’ of antibiotic treatment may have occurred between admission and when the urinary antigen test was
reported. This chart shows whether a step-down of antibiotic treatment occurred from the treatment given immediately
before the test and 24 hours later.
c Patient died despite broad-spectrum i.v. antibiotics and admission to the ITU. Certiﬁed cause of death: pneumonia,
COPD, and pulmonary ﬁbrosis.
d ‘[✓]’ refers to the spectrum and route of delivery of antibiotics that were given to patients within 24 hours of results of
the BinaxNOW S. pneumoniae test.
e The sample was analysed in error in the laboratory, not at the point of care.
f Patient died. Certiﬁed cause of death: colonic carcinoma and intra-abdominal sepsis.
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of patients that the test led to a ‘step-down’ in treatment.
All but two of the 21 patients had comorbidities placing them at risks from the consequences of inﬂuenza
and could reasonably be expected to be considered for treatment with NIs on admission, assuming that
their symptoms were of < 48 hours’ duration. We examined the data of all 21 patients to see whether any
were eligible for treatment, and whether it had been administered and stopped within 24 hours of the
urinary antigen test result. Only 4 of the 21 patients had symptoms of < 48 hours’ duration when admitted
(all four had symptoms of 24 hours’ duration) – two were pyrexial (temperature ≥ 37.3 °C). All four
patients had symptoms compatible with inﬂuenza, three had underlying respiratory comorbidity, and all
four had oxygen saturations of 89–95% on admission, the latter on treatment with 5 l of oxygen. None of
the 21 patients received treatment with a NI.
We examined data on ‘isolation’ for all 21 patients before and within 24 hours of the urinary antigen
test result. One of the 21 patients was nursed in single-room accommodation between admission and the
urinary pneumococcal antigen test result. This patient had a fever of 40.3 °C on admission and remained
in single-room accommodation after the test result. One other patient was isolated within 24 hours
of the urinary antigen test result – for diarrhoea. Overall, there was no evidence that the BinaxNOW
S. pneumoniae test inﬂuenced decisions on ‘isolation’.
We examined data regarding the time of discharge in relation to the urinary pneumococcal antigen test
result. Four patients were discharged within 24 hours of the urinary antigen test result. It is unknown
whether any of these discharges occurred as a consequence of the test.DiscussionIn this chapter we explored the relationship between the diagnostic group and clinical measures, notably
antiviral and antibacterial prescribing, the duration of fever and hospitalisation, treatment with oxygen and
CPAP, intensive care support and death. We also examined the use of single-room accommodation to see
whether the location of care was inﬂuenced by different diagnostic tests. Finally, we explored whether the
randomisation resulted in any differences in the QoL of survivors across groups. By each measure, we
failed to demonstrate any clinical beneﬁt to ﬁrst admission patients from POCTs for inﬂuenza A and B and
S. pneumoniae, or molecular diagnostic tests for inﬂuenza A and B, or RSV A and B. We also found no
evidence that the microbiological diagnosis, whether obtained by POCTs or by RT-PCR, had any effect
on containment.
This study was carried out in a busy teaching hospital environment that caters for a local population of
approximately one million people. The patients who were recruited to our study had a broad range of
acute cardiopulmonary conditions that are typically seen in acute care facilities around the country. Our
cohort included substantial numbers of patients who were diagnosed with acute exacerbations of asthma,
bronchitis, acute exacerbations of COPD, CAP – conditions that are associated with inﬂuenza A and B,
RSV and S. pneumoniae. In our study, inﬂuenza A or B occurred in 91 of 1172 ﬁrst admissions (7.8%,
6.3–9.4%), RSV in 29 (2.5%, 1.7–3.5%), and S. pneumoniae in 99 (8.4%, 6.9–10.2), i.e. infection with
these pathogens occurred in more than one in six patients.
Two recent studies68,69 suggest that rapid inﬂuenza testing may inﬂuence the management of adults with
inﬂuenza. Falsey et al.68 retrospectively evaluated the clinical management of patients with positive rapid
antigen tests for inﬂuenza upon admission, during a period when the hospital infection control policy
mandated such testing. Viral culture tests and/or RT-PCR, or serological testing were performed if the test
was negative using the Directigen POCT for inﬂuenza. Antibiotic use was cut modestly from 98.7%
(79 out of 80) in patients whose antigen test was negative or unknown to 86.0% (74 out of 86) (relative
risk reduction 12.8%: 95% CI 5.7 to 21.9%) in those in whom it was positive. This reduction was not41
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42associated with signiﬁcant differences in either antibiotic days, length of hospital stay among survivors
or antibiotic complications; rather, the mean length of stay was 41 hours longer (p = 0.16) in those found
positive using rapid inﬂuenza testing. Although antiviral use was high in the antigen-positive test group
(63 out of 86, 73%) compared with patients whose test was negative, or in whom the test was not
performed (6 out of 80, 6%), 39% of patients treated in the study presented outside the 48-hour
therapeutic window recommended for prescribing antiviral therapy. Regarding infection control, the
antigen test was falsely negative in 41.5% out of 147 patients tested; it is unclear whether any of these
patients were isolated. It is also uncertain how many antigen-positive cases had false-positive results and
were isolated and given antiviral therapy treatment inappropriately.
D’Heilly et al.69 evaluated the inﬂuence on clinical care of different diagnostic tests (an immunoassay
and two cell culture assays) that were used to detect inﬂuenza in adults with a mean age of 57.4 years
who presented to an urgent care or outpatient medical clinic at a Veterans Affairs medical centre in
Minneapolis, USA. The rapid antigen test had a sensitivity of 65% (84 patients tested positive overall);
20 of the 55 cases of inﬂuenza that were detected by rapid antigen testing had symptoms of < 48 hours
and received antiviral medication. Thus, in this study, rapid testing led to treatment of 23.8% of the
84 patients with inﬂuenza. Altogether, 91% of patients with a positive rapid antigen test who described
symptoms of ≤ 48 hours’ duration received antiviral therapy compared with only 8% of patients with
a positive rapid cell culture test but a negative rapid antigen test. Individuals with a positive rapid antigen
test were signiﬁcantly less likely to be treated with antibiotics.
Both of the above studies focused on older adults tested under clinical rather than controlled study
conditions and illustrate the potential for near-patient inﬂuenza tests to inﬂuence prescribing practices,
with certain provisos.
l First, to meet NICE criteria for treatment of seasonal inﬂuenza, it is essential that results are available
to clinicians within a period of 48 hours after the onset of symptoms.70 Our cohort presented with a
median duration of symptoms before admission of 120 hours (IQR 72–168 hours) (see Chapter 7), and
only 12% of all patients who were studied could potentially beneﬁt from treatment with inﬂuenza
antiviral drugs (on the basis of symptom duration, the turnaround time of the diagnostic tests and
NICE guidance), even if they all had inﬂuenza. However, as shown in Chapter 4, inﬂuenza occurred in
91 out of 1172 (7.7%) ﬁrst admissions. Thus, with current referral and admission practice, it seems
unlikely that detection and treatment of inﬂuenza in the small numbers of patients who are eligible
(because of underlying ill health and illness duration of < 48 hours) would impact on the outcomes in
our study. However, we did not stratify illness severity as part of the study or take into consideration
the possibility that late treatment may beneﬁt severely ill patients who are hospitalised with inﬂuenza,
as such treatment falls outside NICE guidance. Evidence indicates that oseltamivir (Tamiﬂu®, Roche)
treatment of patients hospitalised with seasonal71–73 and pandemic 2009 H1N1 inﬂuenza74–80 is
associated with reductions in radiological pneumonia, illness severity and death. Even when
administered > 48 hours after symptom onset, oseltamivir showed considerable potential for reducing
pneumonia due to 2009 pandemic H1N1 virus.79 Survival beneﬁts for H5N1 inﬂuenza have also been
observed when treatment with oseltamivir was delayed up to 6 days after symptom onset.81
l Second, the ability to diagnose inﬂuenza is dependent on the sensitivity of the test. Many of the
studies that have compared rapid tests with RT-PCR and/or cell culture have been carried out in young
healthy adults or in children. Children generally present earlier to medical practitioners with ILI and
they shed higher titres of virus than older people, who also present later.82 In our study, the sensitivity
of the POCT in comparison with RT-PCR was low at 24.4% (see Chapter 5), indicating that
opportunities to identify and treat patients like ours could be reduced considerably. The low sensitivity
in our study may reﬂect the length of illness and age of the patients prior to sample collection.
Nilsson et al.83 found the sensitivity of the BinaxNOW inﬂuenza A/B test against PCR to drop from
71% to 63% and 14% when specimens were collected from adults presenting to the emergency
department of Malmö University Hospital on days 1–3, 1–5 and > 5 days, respectively, following onset
of symptoms. Similarly, Stripeli et al.84 observed a fall in sensitivity from 76% to 65% for The QuickVueNIHR Journals Library www.journalslibrary.nihr.ac.uk
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< 48 hours compared with children with disease duration of longer than 48 hours.
l Third, the sensitivity of near-patient immunoassay tests can also be inﬂuenced by virus type, and
pandemic 2009 H1N1 virus compared with seasonal inﬂuenza.85 Heinonen et al.86 observed a
sensitivity of 90% for inﬂuenza A viruses but only 25% for inﬂuenza B viruses when specimens were
collected from young children aged 1–3 years who presented within 24 hours of onset of fever, and
tested using the Actim Inﬂuenza A&B POCT. Reduced sensitivity for inﬂuenza B virus has also been
noted by other investigators using other rapid tests.87–89 In our study more than one-third of the
specimens positive for inﬂuenza by RT-PCR were identiﬁed as inﬂuenza B virus, which may, in part,
account for the low sensitivity of the near-patient QuickVue Inﬂuenza A + B test in our study
(see Chapter 5), and the lack of clinical beneﬁt from the POCT in comparison with molecular or
conventional diagnostic tests in our study. Our study was carried out before the 2009 H1N1 pandemic.
l Fourth, the quality of the specimen and method of collection can also impact upon test sensitivity.
Scansen et al.90 compared the performance of the Quidel QuickVue Inﬂuenza A + B test on secretions
from the anterior nares when a polyurethane foam swab was used for collection to that of a nylon
ﬂocked swab. The QuickVue test was positive for 40 foam and 30 ﬂocked swabs, for sensitivities of
71% and 54%, respectively, a difference that achieved statistical signiﬁcance. Agoritsas et al.91 showed
that the sensitivity of the QuickVue test was 85% with nasopharyngeal swabs, 78% with nasal swabs
and 69% with nasopharyngeal washes, when specimens were collected from children with a mean age
of 5 years. Anterior nasal swab collection was performed ﬁrst with an absorbent foam swab, posterior
nasopharyngeal swab collection was performed second with a Dacron swab, and nasopharyngeal
washing was performed last with sterile saline. The difference in sensitivity between nasopharyngeal
swabs and nasopharyngeal washes was signiﬁcant. There was no difference in sensitivity between
anterior nasal swab collection and the two nasopharyngeal collection methods. Walsh et al.92 compared
nylon ﬂocked swab/universal transport medium collection method (sampling at the mid-turbinate level)
with nasal aspirates collected from infants and toddlers in a PCR test – the swab collection method
signiﬁcantly outperformed the use of nasal aspirates. Schmid et al.93 evaluated traditional and rapid
culture methods for inﬂuenza using nasopharyngeal aspirates and throat swabs from adults with
symptoms and signs consistent with inﬂuenza. Nasopharyngeal aspirates were twice as sensitive as
throat swabs. Similarly, Smit et al.94 tested upper respiratory tract samples in parallel with the
BinaxNOW Inﬂuenza A&B combination assay, BinaxNOW Flu A and BinaxNOW Flu B assays, the Becton
Dickinson Directigen Flu A + B assay and IF, and the results were compared with viral culture. Altogether
521 samples – including 338 nasopharyngeal swabs, 162 throat swabs, 19 nasal washes and two swabs
from unspeciﬁed sites – were collected from 448 adults and children. There were no signiﬁcant
differences in the performances of all rapid antigen tests, with sensitivities of 53–59% compared
with culture and IF but the sensitivities of all the rapid antigen tests were signiﬁcantly higher for
nasopharyngeal samples than for throat swabs. In our study, nasopharyngeal specimen collection
was undertaken by trained research staff, and specimens were handled as per the manufacturer’s
instructions. It is therefore unlikely that specimen quality was responsible for the observed outcomes.
Most antibiotics prescribed in general practice are for respiratory tract infections that represent about 70%
of all infections treated in primary care.95,96 In the USA, antibiotic prescribing for acute respiratory illness
accounts for over 50% of all antibiotics used in primary care.97 Antibiotic prescribing has decreased in UK
general practices in recent years mainly because there are fewer consultations for common respiratory
infections, and partly because GPs are prescribing antibiotics less frequently for conditions that are
primarily viral in aetiology.98 There is a paucity of evidence showing beneﬁt from antibiotic use in many
acute respiratory conditions including acute bronchitis,99 acute asthma exacerbations,100–102 and in
many cases of acute exacerbation of chronic obstructive airways disease.103–105 Although overprescription
of antibiotics has led to the emergence and proliferation of antibiotic-resistant bacteria,106–109 a
meta-analysis of 122 reports of CAP showed that approximately 6000 (18%) of 33,148 cases had a
bacterial pathogen, with S. pneumoniae accounting for 73% of all cases and 66% of fatal cases.16,110
Thus, clinicians face the problem of unnecessary use of antibiotics for some respiratory conditions – and
the requirement for prompt (empiric) antimicrobial treatment for others.43
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44National and international bodies including the British Thoracic Society (BTS) provide guidance for empiric
treatment of CAP due to the risks from delayed treatment and limitations of diagnostic tests.17 Isolation of
S. pneumoniae from the blood is speciﬁc but lacks sensitivity.111–113 Culturing blood before antibiotic
therapy is recommended by the BTS (and similar bodies) for all hospitalised patients with moderate and
high-severity CAP, but studies have suggested that blood cultures rarely alter antibiotic therapy for patients
presenting with pneumonia because of the low overall positive rate of blood cultures.112,114–118 Moreover,
clinicians did not follow protocols for narrowing an antibiotic spectrum even when appropriate. Sputum
culture is often used to help identify aetiological agents and is recommended by BTS to investigate
moderate severity CAP and severe CAP that fails to improve.17 The test lacks speciﬁcity, and isolation of
S. pneumoniae from sputum may represent colonisation.119 In our study, sputum culture had a sensitivity
of 100% (2.5–100%) (see Chapter 5) when compared with blood culture as the reference standard but
the CIs were extremely wide due to the infrequency of a productive cough in our cohort. Musher et al.120
analysed 105 patients with pneumococcal pneumonia proven by blood culture – sputum culture was
positive in only 44% of all cases. These investigators reviewed earlier articles and noted that sensitivity of
Gram staining in proven cases of pneumococcal pneumonia ranged from 20% to 69% and that the
sensitivity of culture ranged from 29% to 94% (see Chapter 6).
Given the limitations of conventional diagnostic tests for S. pneumoniae infection, the development of a
S. pneumoniae urinary antigen test offered several advantages – ease in getting a diagnostic specimen,
ability to detect pneumococcal infection after antibiotic treatment has been commenced, its diagnostic
yield, and a rapid turnaround time. Among adult patients with CAP, this test has shown sensitivities of
64–87% compared with blood culture,111,121 but dropped to 54% when cultures of respiratory tract
secretions were included in the reference standard.122 In our study, the sensitivity of the urinary antigen test
in comparison with blood culture was 57.1% (18.4% to 90.1%) (see Chapter 5), which is comparable with
previous reports. In our study, the POCT for pneumococcal infection was positive in 92 (7.8%; 6.4 to 9.5) of
all 1172 admissions and, together with POCT for inﬂuenza, it had no evident effect on clinical outcome.
Only one patient in this study was prescribed a NI. Reasons for the low use these drugs might include the
length of illness pre-admission together with unfamiliarity with NIs and the diagnostic test. The number of
patients in the ‘near-patient’ group with a positive QuickVue Inﬂuenza A+B test was too small to draw
deﬁnitive conclusions – none of eight patients with a positive result was eligible for treatment based on
their duration of symptoms pre-admission and NICE guidance.
Regarding ‘containment’, two of the eight patients in the ‘near-patient’ group with a positive QuickVue
Inﬂuenza A+B test were already in single-room accommodation when the test was carried out. One
patient was discharged shortly afterwards. None of the remaining ﬁve patients was isolated, but four had
fever and respiratory symptoms and were probably still shedding inﬂuenza virus.123–125 We may reason that
single-room accommodation was either unavailable, or that the nursing and medical carers were unaware
of the possible risk of nosocomial transmission. Altogether, 120 of the 1172 patients with a ﬁrst admission
had positive tests for inﬂuenza or RSV, of whom only 14 were given single-room accommodation during
the admission.
The US Healthcare Infection Control Practices Advisory Committee recommends that patients with
inﬂuenza are given single-room accommodation, when available, for a period of 5 days, and masked
when transported out of the room.126 The problem for clinicians is recognising patients with inﬂuenza, as
exacerbations of asthma,127 cystic ﬁbrosis,128 COPD,129 heart failure,130 bouts of pneumonia,17 acute
bronchitis131 and other acute respiratory conditions are all associated with inﬂuenza, and such complications
may dominate the features of inﬂuenza. Nosocomial inﬂuenza is a well-recognised problem in acute care
hospital settings.132–135 Evidence indicates that nosocomial infection of health-care workers with inﬂuenza in
acute hospitals is not uncommon136 and that inﬂuenza acquired within hospitals can be fatal.137 In our
study, the rate of isolation for patients with inﬂuenza or RSV (14/120; 11%, 95% CI 7.1% to 18.6%) was
no different to the overall rate of isolation (112/1172; 9.5%, 95% CI 7.9% to 11.4%), suggesting that
hospitals like ours have inadequate resources to contain infection.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36The extremely low prescription rate for NIs in this study indicates that near-patient testing for
S. pneumoniae could not reduce NI use, even if considered appropriate. Bacterial pneumonia is a
well-recognised complication of inﬂuenza and occurred in 29% of ≈1200 patients hospitalised during
the 2009 H1N1 pandemic. The pneumococcus was by far the most common pathogen,138–145 suggesting
that withdrawal of NIs from some patients with a positive urinary pneumococcal antigen test may
be inappropriate.45
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DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Chapter 5 Diagnostic outcomesStatistical methodsData on diagnostic performance of the various tests (blood culture, viral culture, sputum culture, PCR,
Quidel and Binax POCTs) for the diagnosis of (1) inﬂuenza and (2) S. pneumoniae infection, are
summarised as:
l percentage diagnostic agreement (the percentage of test results, either positive or negative, that are in
agreement) (and associated 95% CI), or
l sensitivity (percentage of true-positives correctly identiﬁed)
l speciﬁcity (percentage of true-negatives correctly identiﬁed) (and associated 95% CI)
l positive predictive values (PPVs) (percentage of positive test results that are truly positive) and negative
predictive values (NPVs) (percentage of negative test results that are truly negative) (and associated
95% CI), and
l area under receiver operating characteristic (ROC) curve (area under the curve, AUC) (the probability
that two patients – one diseased and one not diseased – would be both correctly classiﬁed by the test)
(and associated 95% CI).
In the case of inﬂuenza, uncertainty remains as to what is currently considered to be the reference
standard to which all tests should be compared (i.e. ‘gold standard’). When the 3WS was designed,
standard laboratory testing procedures were anticipated to be the then current ‘gold standard’. However,
during the course of the 3WS, PCR techniques have been developed and now may be considered to be
the ‘gold standard’ – for example in the meta-analysis reported in Chapter 6 of inﬂuenza diagnoses,
13 out of 64 (20%) studies used PCR as the ‘gold standard’ and only 24 of 64 (37%) studies considered
laboratory culture alone to be the ‘gold standard’. Hence a number of analyses using different ‘gold
standards’ have been undertaken to enable comparison between the results from 3WS and those found in
the literature.
In the case of inﬂuenza, test performance could also be assessed by serology. The primary analysis uses
only deﬁnite positive serology results and does not allow for month and time between blood samples.
However, due to the nature of the 3WS, patients could be discharged from hospital and subsequently
have had an inﬂuenza vaccination prior to a second (convalescent) blood sample being taken. In order to
allow for this, and the fact that positive serology results were graded as deﬁnite, probable and possible,
two sensitivity analyses were undertaken: (1) excluding those who had their first blood taken between
September and December and had > 30 days between samples and (2) including both deﬁnite and
probable positive serology results.
All analyses were undertaken in Stata version 11.Results
Influenza
Comparison between tests themselves
Table 21 summarises the diagnostic performance of the tests in terms of inﬂuenza using either PCR or viral
culture as the ‘gold standard’. Although there is a relatively high level of overall agreement between the
tests, the Quidel POCT has relatively low sensitivity compared with either PCR (24.4%, 95% CI 16% to47
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TABLE 21 Comparison of test performance for the diagnosis of inﬂuenza
‘Gold standard’ Comparator Measure Estimate 95% CI
PCR Quidel POCT Agreement 94.3% 92.8% to 95.5%
Sensitivity 24.4% 16% to 34.6%
Speciﬁcity 99.7% 99.2% to 99.9%
PPV 88.0% 68.8% to 97.5%
NPV 94.4% 93.0% to 95.7%
ROC AUC 0.62 0.58 to 0.67
Viral culture Agreement 94.1% 92.6% to 95.4%
Sensitivity 21.6% 13.5% to 31.6%
Speciﬁcity 99.8% 99.4% to 100%
PPV 90.5% 69.6% to 98.8%
NPV 94.2% 92.7% to 95.4%
ROC AUC 0.61 0.56 to 0.65
Viral culture Quidel POCT Agreement 97.4% 96.4% to 98.2%
Sensitivity 33.3% 14.6% to 57.0%
Speciﬁcity 98.6% 97.7% to 99.2%
PPV 29.2% 12.6% to 51.1%
NPV 98.8% 98.0% to 99.3%
ROC AUC 0.66 0.56 to 0.76
PCR Agreement 94.1% 92.6% to 95.4%
Sensitivity 90.5% 69.6% to 98.8%
Speciﬁcity 94.2% 92.7% to 95.4%
PPV 21.6% 13.5% to 31.6%
NPV 99.8% 99.4% to 100.0%
ROC AUC 0.92 0.86 to 0.99
DIAGNOSTIC OUTCOMES
4834.6%) or viral culture (33.3%, 95% CI 14.6% to 57.0%), although the corresponding speciﬁcity is
always over 90%. Thus, although the Quidel POCT appears to perform acceptably at classifying truly
negative patients, in terms of inﬂuenza, less than one-third of those with inﬂuenza appear to be detected
with the test. In terms of sensitivity, this is considerably lower than values reported in the literature.
Overall, in the meta-analysis reported in Chapter 6, the 64 studies included yielded a pooled sensitivity of
74%, although those using PCR and viral culture as ‘gold standards’ produced sensitivities of 51% and
86%, respectively. However, subgroup and sensitivity analyses suggest that comparable estimates to 3WS
based on the meta-analysis are lower than these overall headline ﬁgures (see Chapter 6 for further details).
Comparison with serology
Table 22 summarises the diagnostic performance of the tests in terms of inﬂuenza using serology as the
‘gold standard’. Of the three approaches to testing for inﬂuenza, all have relatively high speciﬁcities,
although PCR has the highest sensitivity (42.6%, 95% CI 28.3% to 57.8%), those of viral culture andNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 22 Comparison of test performance with serology in the diagnosis of inﬂuenza
Comparator Measure Estimate 95% CI
PCR
Primary analysis
Agreement 92.3% 90.6% to 93.7%
Sensitivity 42.6% 28.3% to 57.8%
Speciﬁcity 94.2% 92.7% to 95.4%
PPV 22.2% 14.1% to 32.2%
NPV 97.7% 96.6% to 98.5%
ROC AUC 0.68 0.61 to 0.76
Sensitivity analysesa
(i) Agreement 91.8% 90.0% to 93.3%
Sensitivity 48.8% 32.9% to 64.9%
Speciﬁcity 93.3% 91.5% to 94.7%
PPV 22.7% 14.5% to 32.9%
NPV 97.7% 96.6% to 98.5%
ROC AUC 0.71 0.63 to 0.79
(ii) Agreement 92.3% 90.7% to 93.7%
Sensitivity 43.8% 29.5% to 58.8%
Speciﬁcity 94.3% 92.8% to 95.5%
PPV 23.3% 15.1% to 33.4%
NPV 97.7% 96.6% to 98.5%
ROC AUC 0.69 0.62 to 0.76
Viral culture
Primary analysis
Agreement 95.4% 94.1% to 96.5%
Sensitivity 13.3% 5.05% to 26.8%
Speciﬁcity 98.7% 97.9% to 99.3%
PPV 28.6% 11.3% to 52.2%
NPV 96.7% 95.5% to 97.7%
ROC AUC 0.56 0.51 to 0.61
Sensitivity analysesa
(i) Agreement 95.1% 93.7% to 96.4%
Sensitivity 15.4% 5.8% to 30.5%
Speciﬁcity 98.5% 97.5% to 99.1%
PPV 28.6% 11.3% to 52.2%
NPV 96.6% 95.3% to 97.6%
ROC AUC 0.57 0.51 to 0.63
continued
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TABLE 22 Comparison of test performance with serology in the diagnosis of inﬂuenza (continued )
Comparator Measure Estimate 95% CI
(ii) Agreement 95.1% 94.1% to 96.5%
Sensitivity 13.0% 4.9% to 26.3%
Speciﬁcity 98.7% 97.9% to 99.3%
PPV 28.6% 11.3% to 52.2%
NPV 96.6% 95.4% to 97.6%
ROC AUC 0.56 0.51 to 0.61
Quidel POCT
Primary analysis
Agreement 95.3% 93.9% to 96.4%
Sensitivity 14.9% 6.2% to 28.3%
Speciﬁcity 98.5% 97.6% to 99.1%
PPV 28.0% 12.1% to 49.4%
NPV 96.7% 95.6% to 97.7%
ROC AUC 0.57 0.52 to 0.62
Sensitivity analysesa
(i) Agreement 95.1% 93.6% to 96.3%
Sensitivity 17.1% 7.15% to 32.1%
Speciﬁcity 98.3% 97.3% to 99.0%
PPV 29.2% 12.6% to 51.1%
NPV 96.6% 95.4% to 97.6%
ROC AUC 0.58 0.52 to 0.64
(ii) Agreement 95.3% 93.9% to 96.4%
Sensitivity 14.6% 6.1% to 27.8%
Speciﬁcity 98.5% 97.6% to 99.1%
PPV 28.0% 12.1% to 49.4%
NPV 96.7% 95.5% to 97.6%
ROC AUC 0.57 0.52 to 0.62
a Sensitivity analyses: (i) excluding those who had their first blood taken between September and December and had
> 30 days between samples; (ii) including both deﬁnite and probable positive serology results.
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50Quidel POCT are relatively low, at 13.3% and 14.9%, respectively. Both sensitivity analyses indicate that
these estimates of sensitivity could increase, although only very slightly.
Streptococcus pneumoniae infection
Table 23 summarises the diagnostic performance of the tests in terms of identifying S. pneumoniae
infection using either blood culture or sputum culture as the ‘Gold standard’. In all cases speciﬁcity is
> 90%, whereas the Binax POCT produces a sensitivity of 57.1% (95% CI 18.4% to 90.1%) compared
with blood culture and 30.0% (95% CI 6.7% to 65.2%) compared with sputum culture.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 23 Comparison of test performance for the diagnosis of S. pneumoniae infection
‘Gold Standard’ Comparator Measure Estimate 95% CI
Blood culture Binax Agreement 92.3% 90.3% to 93.9%
Sensitivity 57.1% 18.4% to 90.1%
Speciﬁcity 92.5% 90.6% to 94.1%
PPV 5.5% 1.5% to 13.4%
NPV 99.6% 99.0% to 99.9%
ROC AUC 0.75 0.55 to 0.95
Sputum culture Agreement 97.2% 94.4% to 98.9%
Sensitivity 100% 2.5% to 100.0%
Speciﬁcity 97.2% 94.3% to 98.9%
PPV 12.5% 0.3% to 52.7%
NPV 100% 98.5% to 100%
ROC AUC 0.99 0.48 to 1.00
Sputum culture Binax Agreement 90.0% 85.6% to 93.1%
Sensitivity 30.0% 6.7% to 65.2%
Speciﬁcity 92.0% 88.1% to 95.0%
PPV 12.5% 2.7% to 32.4%
NPV 97.2% 94.3% to 98.9%
ROC AUC 0.61 0.46 to 0.76
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We compared the diagnostic performances of viral culture, Quidel QuickVue Inﬂuenza A + B test and
RT-PCR, using either PCR or viral culture as the ‘gold standard’. With PCR as the gold standard, viral
culture carried out at the UHL NHS Trust laboratory had a sensitivity of just 21.6% (95% CI 13.5% to
31.6%), which, although similar to the sensitivity reported by the Portuguese national surveillance
network, during the 7-year period 1992–93 to 1998–99,146 is suboptimal in comparison with sensitivities
of 61–96% reported in nine studies90,91,147–153 (Table 24) that were identiﬁed for the systematic review and
meta-analysis of POCTs for inﬂuenza (see Chapter 6). However, the sensitivity of viral culture was similar to
that of the Quidel POCT (24.4%, 95% CI 16% to 34.6%). Although the performance of both the viral
culture and the Quidel POCT appears relatively low in terms of identifying truly positive cases, especially in
comparison with the headline estimates of the meta-analysis of POCTs for inﬂuenza (see Chapter 6), any
comparisons need to be approached with caution owing to the extremely heterogeneous nature of the
studies reported, and because subgroup and sensitivity analyses indicate that 3WS provides comparable
estimates of diagnostic performance to appropriate comparator studies (see Chapter 6).
Factors that may contribute to lower rates of inﬂuenza virus isolation, include the type of swab collection
device, the cell culture system, the passage history of the mammalian cells used, the stability of protease
supplement to the media and, possibly, alterations in receptor binding properties of isolates of inﬂuenza
A H3N2 and H1N1 since the late 1980s.146,154 Specimens were collected according to the methods
recommended by the HPA, and by the manufacturer of the Quidel POCT (see www.cliawaived.com/web/
items/pdf/QDL-20183-Quidel_Inﬂuenza_Tests_Insert∼619ﬁle1.pdf) by research nurses dedicated to the
project. Thus, it seems unlikely that the expertise of personnel who collected the specimens or the method51
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ABLE 24 Sensitivities and speciﬁcity of viral culture compared with PCR as the gold standard for the diagnosis
f inﬂuenza
Author Location Children Adults
No. in
study
Culture sensitivity,
% (no. positive by
culture/no.
positive by PCR)
Culture
speciﬁcity
Agoritsas, 200691 USA From 2 weeks
to 18 years
None 122 91.5 (54/59)
Chan, 2002147 Hong
Kong
From < 2 years To > 55 years 250 91.7 (54/57)
Cheng, 2010148 China From 5 months To 70 years 5740 95.7 (551/576)
Mehlmann, 2007149 USA From 3 months To 86 years 102 93.4 (57/61)
Poehling, 2002150 USA From 6 months
to 18 years
None 233 61.1 (11/18) 99.5
(214/215)
Rahman, 2008151 USA From 6 months To ≥ 65 years 932 94.9 (93/98) 100
Ruest, 2003152 Canada From 1 day To 98 years 200 83.5 (71/85)
Scansen, 201090 USA ≤ 17 None 100 87.5 (49/56)
Simmerman, 2007153 Thailand From 1 month To 86 years 1092 81.3 (205/252)
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oof specimen collection were important contributory factors to the low sensitivities of culture and the
Quidel POCT observed in our study. In our study specimens were received by the laboratory at a median of
3.6 hours after specimen collection, making delayed transportation and inappropriate specimen handling
unlikely as contributory factors. A more plausible explanation is the length of illness prior to sampling,
which in our study was a median of 120 hours. Lee et al.125 evaluated secular shedding of seasonal
inﬂuenza virus from 147 inpatients aged > 16 years (mean age 72 years, ± 16 years) in Hong Kong.
The results of virus isolation showed that among untreated (i.e. by NIs) patients, 38.5% and 21.2%
remained culture positive by symptom day ≥ 4 and ≥ 5, respectively, and in patients with comorbidities
the proportions were somewhat higher, at 41.7% and 33.3%, respectively. Leekha et al.155 examined
secular shedding of seasonal inﬂuenza virus by 50 hospitalised patients by culture. Results showed that by
symptom days 3, 4, 5 and ≥ 7, 91%, 75%, 52% and 20% of patients, respectively, remained culture
positive. Although these observations have implications for infection control, they show that by day 5 of
symptoms (i.e. the median duration of symptoms upon sampling in our study), approximately 50–80% of
patients with inﬂuenza were unlikely to be shedding infectious virus. Presence of viral nucleoproteins that
are detectable by the Quidel POCT is likely to fall at a similar rate.
Despite being the most common pathogen in CAP, S. pneumoniae is underdiagnosed because of the
limitations of conventional diagnostic tests. Although blood culture is used as the ‘gold standard’ for
diagnosis of pneumococcal CAP in many studies, it has low sensitivity and premedication with antibiotics
reduces it further. The observed sensitivity (57.1%, 95% CI 18.4% to 90.1%) and speciﬁcity (92.5%,
95% CI 90.6% to 94.1%) for the BinaxNOW urinary antigen detection test in our study are comparable to
sensitivities of 75% to 88%49,156–160 compared with blood culture (or culture of blood and pleural aspirate)
in previous studies. The BinaxNOW POCT has a high speciﬁcity, in excess of 90%, and contributed to
a reduction in the spectrum of antibiotic cover of 41 of 474 episodes of CAP in one recent study.161
In comparison with blood and sputum cultures, the pneumococcal urinary antigen test has advantages
of being a simple and rapid method with visually detectable results (see Chapter 7), providing speedy
diagnosis without any additional equipment or reagents in a clinic or triage setting; is non-invasive; positive
results persist over a period of days and occur despite treatment with antibiotics; and the test has high
sensitivity and speciﬁcity. However, a negative result cannot rule out pneumococcal infection.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36In our study, sputum culture had a sensitivity of 100% (2.5–100%) when blood culture was used as the
gold standard. The CIs are wide due to the small number of patients with a positive blood culture and
productive cough. Musher et al.120 analysed 105 patients with pneumococcal pneumonia proven by blood
culture. Sputum culture yielded a pneumococcus in 44% of cases. Sensitivity data for sputum culture from
that review and several recent studies are shown in Table 25.119,120,162–167 Random-effects meta-analysis of
the data in Table 25 reveals sensitivities of 43% (33–53.0%) when cases who received antibiotics are
included, and 59% (21–92%) when they are excluded. Speciﬁcity data are not available, but the speciﬁcity
of sputum culture is generally poor due to colonisation of the respiratory tract. The poor sensitivity and
speciﬁcity of sputum culture therefore question its value in the management of lower respiratory
infections. Sputum culture also has downsides of cost and ease and speed of use, but empiric antibiotic
recommendations are ultimately dependent upon the accumulated information available from such tests.TABLE 25 Sensitivities of sputum culture compared with blood culture as the gold standard for the diagnosis of
pneumococcal infection
Author Location No. in study
Sensitivity: % (95% CI)
(no. positive by sputum
culture/no. of positive by
blood culture)
Patients with prior
antibiotics excluded
Davidson, 1976119 USA 25 100 (15.8 to 100) (2/2) No
Kalin, 1982162 Sweden 89 44.1 (31.1 to 57.6) (26/59) No
Musher, 2004120 USA 105 43.8 (34.1 to 53.8) (46/105) No
Torres, 1998163 USA 71 48.8 (33.3 to 64.5) (21/43) No
Watanakunakorn, 2002164 USA 59 28.8 (33.3 to 64.5) (21/43) No
Drew, 1977165 USA 31 93.5 (78.6 to 99.2) (29/31) Yes
Fiala, 1969166 USA 25 56.0 (34.9 to 75.6) (14/25) Yes
Garcia-Vazquez, 2004167 Spain 133 17.3 (11.3 to 24.8) (23/133) Yes
Kalin, 1982162 Sweden 89 66.7 (49.8 to 80.9) (26/39) Yes
53
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DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Chapter 6 Systematic review and meta-analysis of
near-patient tests for inﬂuenza A and BIntroductionInﬂuenza resembles other acute viral respiratory infections with respect to its seasonality, clinical
presentation and complications, but it differs from other respiratory viral conditions by being preventable
by annual vaccination and ameliorated by antiviral drugs if given within 48 hours of symptom onset.
The gold standard for inﬂuenza diagnosis is viral culture, which, although speciﬁc, had low sensitivity
compared with real-time RT-PCR in our study and gave results long after hospital discharge or death (see
Chapters 5 and 7). In contrast, we were able to correlate the results of PCR and serology (see Chapter 5),
conﬁrming the accuracy of RT-PCR, and we showed that it gave a diagnosis in a busy clinical setting within
a median of 29 hours (IQR 13.5–31.6 hours) (see Chapter 7). This turnaround time might facilitate timely
antiviral therapy but concerns have been raised that the demands of the test, requiring transportation of
specimens to a laboratory with specialised expertise and equipment, and its turnaround time make it too
slow for therapeutic or infection control purposes.168–170
Commercial POCTs were used to manage patients with ILI during the 2009 H1N1 pandemic.168,169,171,172
However, there have been mixed reports of the diagnostic accuracy of such tests, perhaps reﬂecting the
test used, patient age, the method of sample collection and transport, the ‘gold standard’ used, and the
type and subtype of inﬂuenza (i.e. whether seasonal or pandemic inﬂuenza, or inﬂuenza B). According to
the manufacturer, the QuickVue Inﬂuenza A + B test detected all 24 inﬂuenza A viruses, subtypes H1–H15,
which were isolated from birds and mammals, although performance characteristics were not established
(see www.cliawaived.com/web/items/pdf/QDL-20183-Quidel_Inﬂuenza_Tests_Insert∼619ﬁle1.pdf).
We used the QuickVue (Quidel, USA) POCT in our study and found that it had a sensitivity of 33.3% and
a speciﬁcity of 98.6% when compared with culture and 24.4% and 99.7%, respectively, when compared
with RT-PCR (see Chapter 5). To compare our ﬁndings with other studies, we systematically reviewed
published articles on the diagnostic accuracies of commercially available inﬂuenza POCTs. To assess the
quality of the methodology and the completeness of the reporting of each manuscript, we ‘scored’ each
publication using the QUADAS (quality assessment tool for diagnostic accuracy studies) tool and the
Standards for Reporting of Diagnostic Accuracy (STARD) initiative.173–176Methods
Literature searches
On-line searches were made on MEDLINE/PubMed on 28 April 2011 and on the Bioscience Information
Service (BIOSIS) and The Cochrane library on 27 May 2011 for publications on inﬂuenza POCT diagnostic
accuracy studies between 1991 and 2011 (inclusive) that met the following ﬁve criteria:
1. Articles written in English.
2. Commercially available test kits.
3. Testing done in human seasonal and pandemic inﬂuenza.
4. Sensitivity results with speciﬁc numerators and denominators.
5. We had authorised journal access.55
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56Medical subject heading (MeSH) search phrases included:
1. “QuickVue test inﬂuenza”.
2. “Rapid inﬂuenza test”.
3. “Rapid antigen test inﬂuenza”.
4. “POCT inﬂuenza”.
5. “Immunochromatographic test inﬂuenza”.
6. “Bedside test inﬂuenza”.
Figure 7 shows a ﬂow diagram of the manuscript screening process, taken from the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline on systematic reviews.177
Manuscript scoring
The QUADAS tool is an evidence-based scheme for the determination of the quality of both the
methodology and the reporting of ﬁndings when doing systematic reviews. It consists of 14 questions
called ‘items’ about the study patients, selection criteria, testing standards, results and clinical data that
were answered with a ‘yes,’ ‘no’ or ‘unclear.’Publications identified through
database searching
(n = 2289)
Additional publications identified
through other sources
(n = 0)
Publications screened
(n = 490)
Publications screened after
duplicates removed
(n = 449)
Publications assessed for
eligibility
(n = 118)
Publications excluded,
with reasons
(n = 48)
Publications included in
qualitative synthesis
(n = 70)
No. of studies in articles
(n = 143)
Articles included in
quantitative synthesis
(meta-analysis; n = 28)
No. of studies in articles
(n = 64)
Publications excluded
(n = 42)a
No. of studies in
articles excluded
(n = 79)
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ti
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n
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FIGURE 7 The manuscript screening process. a. Partial data from three publications.
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DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36The STARD initiative was another evidence-based tool used to assess the accuracy, completeness, and risk
of bias in the systematic review of diagnostic accuracy studies. The STARD checklist consists of 25 questions
pertaining to a study’s title, introduction, methodology, results and discussion sections; the more of the
25 items that are identiﬁed or described in the report, the more favourable the outcome.Data analysis
For those studies that reported a full 2 × 2 table, i.e. numbers of true-positives, false-positives,
false-negatives and true-negatives, or for which these could be calculated, pooled sensitivity and
speciﬁcities were estimated using a bivariate mixed-effects meta-analysis model.178 As well as summarising
the overall diagnostic measures a hierarchical summary ROC curve was also estimated using the derived
logit estimates of sensitivity, speciﬁcity and their respective variances.179 Heterogeneity was assessed using
the I2 measure and explored using subgroup analyses using study-level covariates.180 A number of studies
reported only estimates of sensitivity, and in order to explore whether there was a selection effect between
those studies that reported both sensitivity and speciﬁcity, and those that reported only sensitivity,
a sensitivity analysis was undertaken in which the sensitivities were pooled separately for the two groups
of studies using a standard random-effects meta-analysis model on the logit scale, and the pooled
estimates compared.ResultsMore than 2000 publications were found using the MeSH terms and 490 of these were relevant. In total,
70 out of the 490 publications met all ﬁve criteria and were selected for the systematic review. Some
of the 70 had more than one ﬁnding, which we called ‘studies’. There were 143 studies altogether.
Twenty-eight of the 70 publications reported full 2 × 2 data and were used for meta-analysis. There were
a total of 68 studies in the 28 publications but four studies from three publications were excluded.88,172,181
Thus 64 studies from 28 publications were included in the meta-analysis. Figure 7 shows a ﬂow diagram
of the manuscript screening process, taken from the PRISMA guidance on systematic reviews.178
Appendix 6 summarises the publications that were screened and Table 26 summarises the sensitivities and
speciﬁcities of the 64 POC studies that were included in the qualitative synthesis. Table 27 presents the
QUADAS results and Table 28 the STARD results. Figure 8 shows the percentage of studies satisfying each
of the QUADAS items and Figure 9 displays the distribution of the overall QUADAS score. As can be seen
from Figure 9, 40 of the 64 (62.5%) studies that were included in the meta-analysis scored > 10 indicating
that the studies were of a reasonably high quality overall.57
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TABLE 27 The QUADAS results for the 27 publications in the meta-analysis of POCTs for inﬂuenza
(PCR as gold standard)
Methodology
checklist
Agoritsas,
200691
Bellei,
2003189
Booth,
2006190
Cazacu,
2004201
Cazacu,
2004200
Chan,
2002147
Chen,
2010191
Chomel,
1992181
Covalciuc,
1993193
Diederen,
2010195
Hamilton,
2002192
Hara,
2008187
Hawkes,
2010184
Patients
representative
of who will
receive test
in practice?
N N Y U Y Y U U Y Y N N N
Selection
criteria clearly
described?
Y Y Y Y Y Y N Y Y Y Y N Y
Reference
standard likely
to correctly
classify target
condition?
Y N N N N Y N N N Y Y Y Y
Short time
period between
index and
standard tests?
U N N N N N N N N U N U U
Veriﬁcation
with reference
standard?
Y Y Y Y Y Y Y Y Y Y Y Y Y
Samples
received same
reference
standard?
Y Y Y Y Y Y Y N Y Y Y Y Y
Reference
standard
independent
of index test?
Y Y Y Y Y Y Y Y Y Y Y Y Y
Execution of
index test
described in
detail?
Y Y Y Y Y Y N Y Y N Y Y Y
Execution of
reference
standard
described in
detail?
Y Y Y Y Y Y Y Y Y Y Y Y Y
Index test
results
interpreted
without
knowledge of
reference test
result?
Y N N Y Y Y U N U U Y Y Y
Reference test
results
interpreted
without
knowledge of
index test
result?
U Y Y U U U U Y U U U U U
Routine clinical
data available?
Y Y Y Y Y Y Y Y Y Y Y Y Y
Uninterpretable/
intermediate
results
reported?
N Y Y N N Y N N N N Y N N
Study
withdrawals
explained?
Y Y Y Y Y Y U Y Y Y Y Y Y
N, no; U, unclear; Y, yes.
Hurt,
200788
Kim,
2010202
Lucas,
2011198
Nougairede,
2010183
Quach,
2002199
Rahman,
2007196
Rahman,
2008151
Rashid,
2007182
Rodriguez,
2002185
Ruest,
2003152
Sabetta,
2009186
Scansen,
201090
Shoji,
2009188
Waner,
1991194
Yoo,
2007197
Y Y Y Y N Y Y Y N Y N N U N Y
Y N Y Y Y Y Y Y Y Y Y Y Y Y Y
N Y Y Y N N Y Y N Y Y Y Y N N
U Y U Y U N U N Y N U Y U N U
Y Y N Y Y Y Y Y Y Y Y Y Y Y Y
Y Y N Y Y Y Y Y Y Y Y Y Y Y Y
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Y Y Y Y Y Y Y Y N Y Y Y U Y Y
Y Y Y Y Y Y Y Y N Y N Y U Y Y
Y Y U U Y Y Y Y U U N U U U Y
U U U U Y U U U U U N U U U U
Y Y Y Y Y Y Y Y Y N Y Y Y Y Y
N N N N Y N N N N Y N N U Y N
Y Y Y Y Y Y Y Y Y Y Y Y Y Y N
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TABLE 28 The STARD results for the 27 publications in the meta-analysis of POCTs for inﬂuenza
(PCR as the gold standard)
STARD
checklist
Agoritsas,
200691
Bellei,
2003189
Booth,
2006190
Cazacu,
2004201
Cazacu,
2004200
Chan,
2002147
Chen,
2010191
Chomel,
1992181
Covalciuc,
1993193
Diederen,
2010195
Hamilton,
2002192
Hara,
2008187
Hawkes,
2010184
Identify the
article as
diagnostic
accuracy
study
Y Y Y Y Y Y Y Y Y Y Y Y Y
Stated
study aims
Y Y Y Y Y Y Y Y Y Y Y Y Y
Speciﬁed
inclusion and
exclusion
criteria?
Y Y Y Y Y Y N Y Y Y Y N Y
What was
recruitment
based upon?
PS a PS PS PS PS PS PS PS PS PS PS PS
Consecutive
series of
participants?
Y Y Y Y Y Y N Y Y Y Y Y Y
If not, specify
further
selection
process?
U
Prospective or
Retrospective
study?
P R P P P P P P P P P P P
Rationale for
reference
standard?
Y Y Y N Y Y N Y Y Y Y Y Y
Technical
speciﬁcation
of materials
and methods?
N Y Y Y Y Y Y Y Y Y Y Y Y
Deﬁnition of,
and rationale
for, units,
cut-offs and/
or categories
of results?
Y Y Y Y Y Y Y Y Y Y Y Y Y
Number,
training and
expertise
of the
technicians?
Y N N Y N Y N N N N N N N
Blinding of
results?
N N Y N N Y N N N N N N N
Specify data
analysis
methods?
Y N Y Y Y Y N N Y N Y Y Y
Specify
methods for
calculating
reproducibility,
if done?
NA NA NA NA NA NA NA NA NA NA NA NA NA
Include
beginning
and end
dates of
recruitment?
Y Y Y Y Y Y N Y Y N Y Y Y
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Hurt,
200788
Kim,
2010202
Lucas,
2011198
Nougairede,
2010183
Quach,
2002199
Rahman,
2007196
Rahman,
2008151
Rashid,
2007182
Rodriguez,
2002185
Ruest,
2003152
Sabetta,
2009186
Scansen,
201090
Shoji,
2009188
Waner,
1991194
Yoo,
2007197
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Y N Y Y Y Y Y Y Y Y Y Y Y Y Y
PS PS PS PS PS PS PS PS PS PS PS PS PS PS PS
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
P P P P P P P P P P P P P P P
Y Y Y N Y Y Y N N Y Y Y NA Y Y
Y Y Y Y Y Y Y Y Y Y Y Y NA Y Y
Y Y Y Y Y Y Y Y Y Y Y Y NA Y Y
N N N Y N Y Y N Y N Y N NA N Y
N N N N Y N N N Y Y N N NA N N
N Y Y N N Y Y N N Y N Y NA N Y
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
Y Y Y Y Y Y Y Y Y Y Y Y Y N Y
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TABLE 28 The STARD results for the 27 publications in the meta-analysis of POCTs for inﬂuenza
(PCR as the gold standard) (continued )
STARD
checklist
Agoritsas,
200691
Bellei,
2003189
Booth,
2006190
Cazacu,
2004201
Cazacu,
2004200
Chan,
2002147
Chen,
2010191
Chomel,
1992181
Covalciuc,
1993193
Diederen,
2010195
Hamilton,
2002192
Hara,
2008187
Hawkes,
2010184
Include
participant
clinical and
demographic
data?
Y Y Y N Y Y N N Y Y Y Y Y
Include no. of
participants
satisfying the
inclusion
criteria?
Y Y Y Y Y Y N Y Y Y Y Y Y
Stated time
interval
between
index and
reference
test?
N N Y Y Y Y N Y N N Y N N
Included
distribution
of disease
severity?
NA NA NA NA NA NA NA NA NA NA NA NA NA
Cross-
tabulation of
index test
results with
reference
standard?
Y Y Y Y Y Y Y Y Y Y Y Y Y
Indicated any
adverse events
from the test
procedure?
NA NA NA NA NA NA NA NA NA NA NA NA NA
Provided
estimates of
diagnostic
accuracy and
statistical
uncertainty
(e.g. 95% CI)?
Y N N Y N N N N N Y N N Y
Specify how
indeterminate
results and
outliers were
handled?
N Y Y N N Y N Y N N Y N N
Provided
estimates of
variability of
diagnostic
accuracy
among
subgroups,
readers or
centres?
Y NA Y N Y NA Y Y Y Y Y Y Y
Provided
estimates
of test
reproducibility,
if done?
NA NA NA NA NA NA NA NA NA NA NA NA NA
Discuss clinical
applicability of
ﬁndings?
Y Y Y Y Y Y Y Y Y Y Y Y Y
N, no; NA, not applicable; P, prospective; PS, presenting symptoms; R, retrospective; U, unclear; Y, yes.
a Recruitment based upon having received a reference standard test.
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Hurt,
200788
Kim,
2010202
Lucas,
2011198
Nougairede,
2010183
Quach,
2002199
Rahman,
2007196
Rahman,
2008151
Rashid,
2007182
Rodriguez,
2002185
Ruest,
2003152
Sabetta,
2009186
Scansen,
201090
Shoji,
2009188
Waner,
1991194
Yoo,
2007197
Y Y Y Y N Y Y Y Y Y Y N NA Y Y
Y Y Y Y Y Y Y Y Y Y Y N Y Y Y
N Y N Y N Y N N Y Y N N NA Y N
NA NA NA NA NA NA NA NA NA NA N N NA NA NA
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
N Y Y N Y Y Y N N Y N Y NA N N
N N N N Y N N N N Y N N NA Y N
Y Y Y Y Y Y Y Y Y Y Y Y NA Y Y
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
Y Y Y Y Y Y N Y Y Y Y Y Y Y Y
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72Of the 143 studies in Appendix 6 for which data could be extracted, 64 (45%) reported the full 2 × 2 table,
and using a bivariate mixed-effects meta-analysis model produced an overall estimate of sensitivity of 0.73
(95% CI 0.66 to 0.80) and of speciﬁcity of 0.99 (95% CI 0.98 to 0.99). However, there was a high level of
heterogeneity between the studies for both outcomes (sensitivity: Q = 777.5, p < 0.01, I2 = 91.9%, 95% CI
90.5% to 93.3%; speciﬁcity: Q = 2128.9, p < 0.01, I2 = 97.0%, 95% CI 96.7% to 97.4%), as can be seen
from the Forest plots in Figure 10. Figure 11 displays the summary receiver operating characteristic (SROC)
curve derived using the estimated overall pooled sensitivity and speciﬁcity. Superimposed on the SROC
curve are the results from 3WS using (1) PCR (sensitivity 24.4%, speciﬁcity 99.7%) and (2) viral culture
(sensitivity 33.3%, speciﬁcity 98.6%) as the ‘Gold standard’ tests. As can be seen from Figure 11, the 3WS
results, although being within the associated prediction region, are nevertheless considerably lower, in
terms of sensitivity, than those estimates from other studies in the meta-analysis.
To explore the between-study heterogeneity observed, a number of subgroup-speciﬁc models were
estimated using study-level covariates (age of participants, ‘gold standard’ used, geographical region in
which study was conducted, type of inﬂuenza tested for, type of POCT, and study quality assessed using
the QUADAS tool). Owing to the relatively small numbers of studies in some speciﬁc subgroups (i.e. < 4) it
was not always possible to estimate the associated effects. It can seen from Table 29 that the pooledNIHR Journals Library www.journalslibrary.nihr.ac.uk
Sensitivity (95% CI)
Q = 777.48, df = 63.00, p = 0.00
I 2 = 91.9 (90.48 to 93.31)
0.73 (0.66 to 0.80)
0.79 (0.66 to 0.89)
0.15 (0.02 to 0.45)
0.31 (0.09 to 0.61)
0.20 (0.08 to 0.39)
0.47 (0.35 to 0.59)
0.62 (0.46 to 0.76)
0.55 (0.36 to 0.72)
0.42 (0.27 to 0.58)
0.61 (0.36 to 0.83)
0.47 (0.31 to 0.64)
1.00 (0.85 to 1.00)
1.00 (0.86 to 1.00)
0.80 (0.73 to 0.86)
1.00 (0.85 to 1.00)
0.88 (0.71 to 0.96)
0.75 (0.63 to 0.85)
0.88 (0.77 to 0.95)
0.86 (0.76 to 0.94)
0.80 (0.69 to 0.88)
0.91 (0.82 to 0.97)
0.86 (0.76 to 0.92)
0.94 (0.89 to 0.98)
0.44 (0.37 to 0.51)
0.85 (0.73 to 0.93)
0.59 (0.42 to 0.75)
0.42 (0.20 to 0.67)
0.65 (0.46 to 0.80)
0.53 (0.27 to 0.79)
0.69 (0.55 to 0.82)
0.30 (0.07 to 0.65)
0.71 (0.57 to 0.83)
0.30 (0.07 to 0.65)
0.67 (0.52 to 0.80)
0.30 (0.07 to 0.65)
0.10 (0.03 to 0.22)
0.73 (0.59 to 0.85)
0.30 (0.07 to 0.65)
0.70 (0.64 to 0.76)
0.80 (0.63 to 0.92)
0.47 (0.21 to 0.73)
0.80 (0.63 to 0.92)
0.47 (0.21 to 0.73)
0.88 (0.80 to 0.94)
0.88 (0.79 to 0.95)
0.74 (0.58 to 0.87)
0.88 (0.79 to 0.94)
1.00 (0.93 to 1.00)
0.76 (0.71 to 0.81)
1.00 (0.93 to 1.00)
0.86 (0.81 to 0.90)
1.00 (0.93 to 1.00)
0.78 (0.73 to 0.83)
0.47 (0.33 to 0.62)
0.93 (0.83 to 0.98)
0.95 (0.86 to 0.99)
0.95 (0.85 to 0.99)
0.72 (0.58 to 0.83)
0.62 (0.52 to 0.71)
0.69 (0.59 to 0.78)
0.68 (0.58 to 0.76)
0.72 (0.60 to 0.82)
0.68 (0.56 to 0.78)
0.58 (0.48 to 0.67)
0.22 (0.13 to 0.35)
Study ID
0.0 1.0
SENSITIVITY
COMBINED
Quach 2002199
Lucas 2011198
Lucas 2011198
Lucas 2011198
Yoo 2007197
Yoo 2007197
Yoo 2007197
Rahman 2007196
Rahman 2008151
Diederen 2010195
Waner 1991194
Waner 1991194
Covalciuc 1999193
Chan 2002147
Chan 2002147
Hamilton 2002192
Hamilton 2002192
Ruest 2003152
Ruest 2003152
Ruest 2003152
Ruest 2003152
Cazacu 2004201
Cazacu 2004200
Agoritsas 200691
Scansen 201090
Scansen 201090
Scansen 201090
Scansen 201090
Hurt 200788
Hurt 200788
Hurt 200788
Hurt 200788
Hurt 200788
Hurt 200788
Hurt 200788
Hurt 200788
Hurt 200788
Kim 2010202
Booth 2006190
Booth 2006190
Booth 2006190
Booth 2006190
Chomel 1992181
Chen 2010191
Bellei 2003189
Shoji 2009188
Hara 2008187
Hara 2008187
Hara 2008187
Hara 2008187
Hara 2008187
Hara 2008187
Sabetta 2009186
Rodriguez 2002185
Rodriguez 2002185
Rodriguez 2002185
Rodriguez 2002185
Hawkes 2010184
Hawkes 2010184
Hawkes 2010184
Hawkes 2010184
Hawkes 2010184
Nougairede 2010183
Rashid 2007182
(a)
FIGURE 10 Forest plot of sensitivity and specificity for 64 studies reporting full 2×2 data table. (continued)
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Specificity (95% CI)
Q = 2128.85, df = 63.00, p = 0.00
I 2 = 97.04 (96.66 to 97.42)
0.99 (0.98 to 0.99)
0.83 (0.77 to 0.87)
0.99 (0.98 to 0.99)
0.99 (0.98 to 1.00)
0.99 (0.98 to 0.99)
0.95 (0.91 to 0.97)
0.97 (0.94 to 0.99)
1.00 (0.99 to 1.00)
0.96 (0.89 to 0.99)
1.00 (0.94 to 1.00)
0.95 (0.88 to 0.98)
0.92 (0.86 to 0.95)
0.95 (0.90 to 0.98)
0.73 (0.67 to 0.78)
0.99 (0.96 to 1.00)
0.97 (0.93 to 0.99)
0.93 (0.89 to 0.96)
0.92 (0.88 to 0.95)
0.94 (0.89 to 0.98)
0.98 (0.94 to 1.00)
0.86 (0.79 to 0.92)
0.92 (0.86 to 0.96)
1.00 (0.99 to 1.00)
1.00 (1.00 to 1.00)
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FIGURE 11 Summary receiver operating characteristic estimated using bivariate mixed-effects meta-analysis model
with 3WS results using PCR (a) and viral culture (b) as ‘gold standard’ superimposed.
TABLE 29 Subgroup effects estimated using bivariate mixed-effects meta-analysis model
Covariate/level No. of studies Measure Estimate 95% CI
Age
Children and adolescents 21 Sensitivity 0.86 0.75 to 0.93
Speciﬁcity 0.99 0.97 to 0.99
Mixed 43 Sensitivity 0.67 0.58 to 0.75
Speciﬁcity 0.99 0.98 to 0.99
‘Gold standard’
PCR 13 Sensitivity 0.51 0.38 to 0.64
Speciﬁcity 0.99 0.97 to 0.99
Culture 24 Sensitivity 0.86 0.77 to 0.92
Speciﬁcity 0.98 0.95 to 0.99
Culture and IF 13 Sensitivity 0.78 0.66 to 0.87
Speciﬁcity 0.98 0.94 to 0.99
IF 11 Sensitivity 0.51 0.35 to 0.66
Speciﬁcity 1.00 0.97 to 1.00
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ABLE 29 Subgroup effects estimated using bivariate mixed-effects meta-analysis model (continued )
Covariate/level No. of studies Measure Estimate 95% CI
Region
North America 32 Sensitivity 0.76 0.66 to 0.83
Speciﬁcity 0.97 0.95 to 0.98
Australasia 13 Sensitivity 0.53 0.38 to 0.67
Speciﬁcity 1.00 0.99 to 1.00
Asia 14 Sensitivity 0.89 0.75 to 0.96
Speciﬁcity 0.99 0.97 to 0.99
Europe 4 Sensitivity 0.56 0.29 to 0.80
Speciﬁcity 0.99 0.93 to 1.00
Type of influenza
Inﬂuenza A 19 Sensitivity 0.81 0.64 to 0.91
Speciﬁcity 0.99 0.98 to 0.99
Inﬂuenza B 16 Sensitivity 0.59 0.47 to 0.70
Speciﬁcity 1.00 0.99 to 1.00
Seasonal 23 Sensitivity 0.84 0.74 to 0.90
Speciﬁcity 0.94 0.90 to 0.97
Pandemic (swine origin) 6 Sensitivity 0.52 0.39 to 0.65
Speciﬁcity 0.99 0.94 to 1.00
Testing kit
Directigen EZ 16 Sensitivity 0.85 0.71 to 0.93
Speciﬁcity 0.99 0.97 to 0.99
BinaxNOW 13 Sensitivity 0.69 0.58 to 0.79
Speciﬁcity 0.99 0.99 to 0.99
Quidel QuickVue 16 Sensitivity 0.66 0.48 to 0.80
Speciﬁcity 0.96 0.93 to 0.98
Study qualitya
‘Low’ (QUADAS ≤ 10) 24 Sensitivity 0.85 0.72 to 0.93
Speciﬁcity 0.97 0.94 to 0.98
‘High’ (QUADAS > 10) 40 Sensitivity 0.67 0.59 to 0.75
Speciﬁcity 0.99 0.99 to 1.00
a Assessed using the QUADAS tool and using a cut-point of 10.
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variation; however, for sensitivity there was variation in the pooled estimates across subgroups with
a mixed age distribution, use of PCR as a ‘gold standard’, and testing for inﬂuenza of swine origin all
yielding lower estimates of sensitivity. There was also some variation in sensitivity depending on the
geographical region in which the study was conducted, with Europe and Australasia yielding lower
estimates; this was also seen for study quality, with ‘higher’-quality studies producing a lower pooled
sensitivity than those of ‘lower’ quality.
In terms of the subgroup speciﬁc estimates of pooled sensitivity, even the lower estimates were still
higher than those found in 3WS – using PCR as the ‘gold standard’, a Quidel POCT produced a sensitivity
of 24.4%, whereas using viral culture as the ‘gold standard’ it was 33.3%. Although the distribution of
studies across the various study-level covariates (and their levels) makes it difﬁcult to obtain an estimate
of sensitivity that closely matches the characteristics of 3WS – it is possible to estimate a pooled effect
for those studies (n = 5), which (1) included both adults and children (as opposed to only children) and
(2) compared Quidel with PCR. These produced an overall pooled sensitivity of 34% (95% CI 14% to 62%)
and speciﬁcity of 99% (95% CI 97% to 100%), which are much more similar to those obtained in 3WS.
As only 64 out of 143 studies (45%) reported sufﬁcient data to permit a formal bivariate analysis to be
undertaken, a sensitivity analysis only pooling sensitivities for the 64 and 79 studies separately was
undertaken to assess whether there was in fact a selection effect. The 79 studies produced a pooled
sensitivity of 60.2% (59.0% to 61.0%), whereas the 64 studies produced an estimate of 69.1% (67.5%
to 70.6%) – the latter was slightly lower than that produced by the bivariate model (73%, 95% CI 66%
to 80%). A formal test of heterogeneity between the two sets of studies was highly signiﬁcant (p < 0.001)
indicating that had the 79 studies reported both sensitivity and speciﬁcity the corresponding bivariate
model would have produced an estimate of sensitivity lower than that observed.DiscussionThis systematic review concurs with other reviews of diagnostic studies in different disease areas in that
there was considerable heterogeneity – both in terms of reporting of data and clinical and methodological
characteristics, thus making formal synthesis of study results using appropriate bivariate meta-analysis
methods challenging.203
Overall, the bivariate meta-analysis produced estimates of sensitivity that were considerably higher than
that observed in 3WS. However, exploration of the considerable between-study heterogeneity using
subgroup analyses showed that for some subgroup combinations the pooled estimate of sensitivity was
considerably lower than that estimated for others. In fact, the subgroup combination most closely
resembling the characteristics of 3WS (comparing Quidel POCT with PCR in a mixed-age population)
produced an estimate of sensitivity in close agreement with 3WS.
Further sensitivity analysis comparing those studies that reported fully data for sensitivity and speciﬁcity
with those that only reported sensitivity indicated the possibility of a selection effect that would further
reduce the true estimate of sensitivity of POCT for testing for inﬂuenza.
Published evidence on the usefulness of diagnostic tests has been summarised in four systematic reviews
including this review. Uyeki204 reviewed published evidence on clinically useful diagnostic tests and antiviral
treatment for inﬂuenza virus infections in children, which were published in the English language from
1966 to September 2002. The topics covered were wide-ranging, including clinical diagnosis, IF and rapid
inﬂuenza diagnostic tests, as well as antiviral treatment. Altogether 28 studies of rapid inﬂuenza tests were
identiﬁed. This was a descriptive study with no formal assessment of study quality or meta-analysis of the
ﬁndings, rather the author presented median sensitivity values for the tests in comparison with cell culture
as the gold standard. Overall, the POCTs had sensitivities and speciﬁcities of 40.4% to 100% and77
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7865.2% to 100%, respectively. The median sensitivity of the Zstat Flu test (Zyme Tx, Oklahoma City, OK,
USA) was 68.8% (range 28.1–96%) and median speciﬁcity was 83% (range 62.7–92.4%). The median
sensitivity of the Directigen Flu A test was 87.2% (range 39–100%), and the median speciﬁcity was 98.1%
(range 84–100%).The median sensitivity of the FLU OIA test (Biostar, Boulder, CO, USA) was 71.8% (range
36.7–93%), and the median speciﬁcity was 82% (range 65.2–95.7%). In ﬁve studies of the QuickVue
Inﬂuenza Test the median sensitivity was 79.2% (range 74–95%) and the median speciﬁcity was 91.9%
(range 76–98%). The studies were evidently heterogeneous in terms of age and the author concluded that
rapid inﬂuenza diagnostic tests were ‘moderately to reasonably’ accurate for detecting inﬂuenza virus
infections, and that false-negative results appeared more common than false-positive results.
Petrozzino et al.205 were supported by the Quidel Corporation, the manufacturer of the QuickVue
Inﬂuenza A + B test, to undertake a systematic review and meta-analysis of studies reporting sensitivity,
speciﬁcity, and effects of ‘rapid ﬂu tests’ (RFTs) and clinical diagnosis on decision-making for patients with
ILI. Search results were limited to literature published in English between 1984 and 2009. Results from
included studies were stratiﬁed according to age categories with an approximate cut-off of 15 years of
age. It was not possible to stratify results for older people aged > 60 years. No RCTs were found directly
comparing RFTs against the clinical diagnostic skills of clinicians. All included studies used an independent
gold standard test for conﬁrmatory inﬂuenza diagnosis. Separately, these investigators evaluated the
clinical diagnosis of inﬂuenza.
Among older subjects aged ≥ 15 years, data on the QuickVue test from ﬁve studies showed that this
POCT had a sensitivity in a ﬁxed-effects model of 57% (52–62%) and speciﬁcity of 96% (95–97%). In a
random-effects model, the POCT had a sensitivity of 61% (36–81%) and speciﬁcity of 96% (94–98%).
Data from 11 studies showed the sensitivity of clinical diagnosis in a ﬁxed-effects model to be 64%
(51–75%) and much lower speciﬁcity of 65% (63–66%). In the random-effects model, clinical diagnosis
had a sensitivity of 64% (51–75%) and speciﬁcity of 68% (57–77%). Thus clinicians were as able to
diagnose inﬂuenza clinically as POC testing but wrongly identiﬁed other individuals as having inﬂuenza,
which could be problematic when isolation facilities for adults are scarce, although it is conceivable that
these patients also posed an infection risk to others.
Among younger subjects aged < 15 years, data on the QuickVue test from 14 studies showed that this
POCT had a sensitivity in a ﬁxed-effects model of 63% (60–67%) and speciﬁcity of 94% (92–95%). In
a random-effects model, the POCT had a sensitivity of 76% (65–85%) and speciﬁcity of 95% (92–98%).
Data from ﬁve studies showed the sensitivity of clinical diagnosis in a ﬁxed-effects model to be 70%
(66–74%), and the speciﬁcity of 61% (59–63%) was again lower than that of the POCT. In the
random-effects model, clinical diagnosis had a sensitivity of 69% (44–87%) and speciﬁcity of 63%
(31–87%). For all age groups combined, the sensitivities of the POCT and clinical diagnosis in both the
ﬁxed and random-effects models were similar, with sensitivities of 61% (59–64%) and 62% (60–63%)
respectively in the ﬁxed-effects model, and 72% (62–81%) and 65% (55–74%) in the random-effects
model. The respective sensitivities were 94% (93–95%) and 63% (62–64%) in the ﬁxed model, and 96%
(93–97%) and 67% (57–76%) in the random-effects model.
These authors examined 10 studies reporting outcomes relating to patient management associated with
the use of POCT for inﬂuenza. This overview led the authors to conclude that in various clinical settings
and across a wide age range, RFT use in patients presenting with ILI leads to reduced diagnostic testing,
antibiotic use and emergency department length of stay, although increases antiviral prescribing.
Babin et al.206 did a review and meta-analysis of published literature on the 2009 novel swine ﬂu outbreak
to assess the potential utility of POCTs for initiating infection treatment and control for this pathogen.
Although these POCTs were not developed for swine-origin virus, their speed and ease of use (EoU) made
them attractive for clinical and public health use. These authors identiﬁed 14 reports on sensitivity and/or
speciﬁcity of seven different POC inﬂuenza tests for diagnosis of 2009 pandemic H1N1 virus on clinical
specimens. The pooled sensitivity and speciﬁcity for all studies were 67.5% (95% CI 66.2% to 68.9%) andNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 3680.7% (95% CI 80.0% to 81.4%). Pooled data were provided for three POCTs from different
manufacturers: BinaxNOW Inﬂuenza A&B, with a pooled sensitivity of 31.4% (95% CI 26.3% to 36.7%)
(no speciﬁcity data); Directigen EZ Flu A + B, with a pooled sensitivity of 52.8% (95% CI 45.9% to
59.6%)%) (no speciﬁcity data); and QuickVue A + B, with a pooled sensitivity of 73.6% (95% CI 72.1% to
75.0%), and speciﬁcity of 76.6% (95% CI 75.5% to 77.5%). In conclusion, the authors considered that
the relatively poor performance of the POCTs afﬁrmed recommendations by the US Centers for Disease
Control and Prevention (CDCP) that caution should be applied in the interpretation of negative POCTs.
Our systematic review and meta-analysis conﬁrms and extends the observations in the above reports. In
our study, speciﬁcity across subgroups was consistently high but sensitivity was higher in studies involving
children and adolescents than in ‘mixed’ populations (i.e. mixed age groups). We may speculate that this
might reﬂect decreased virus shedding in adults than in young children (although virus shedding may be
high in very elderly hospitalised patients)125 and the effects of vaccination and past infection. We also
found that the test sensitivity was a function of the nature of the gold standard used, with PCR setting
a higher target than virus culture. The caution issued by the CDCP regarding the sensitivity of POCTs for
the detection of the 2009 pandemic ‘swine-origin’ H1N1 virus was afﬁrmed in our analyses, which also
showed better performance of POCTs in the detection of seasonal inﬂuenza type A virus than type B virus.79
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molecular and traditional test methods for the
diagnosis of respiratory infectionsBackgroundThe beneﬁts of rapid diagnosis are increasingly appreciated in diverse health-care settings. Besides direct
clinical beneﬁts, political and economic imperatives, including the UK NHS 4-hour patient assessment rule in
A&E departments, are likely to accelerate demand for rapid diagnostic tests.207–209 However, successful
adoption of new technology in the health-care sector, and especially in hospitals, depends on its acceptance
by end users.210,211 The latter is a function of the ease of the required associated procedures, extent of
demand on staff time, perceived efﬁciency, quality and added clinical value of speedy results and the actual
reduction in time to a result for the new rapid diagnostic test compared with the method in use. Although
there have been various studies comparing one or more of these features of diagnostics tests,212–214 to the
best of our knowledge only one formal rating system has been described to score the ease and speed of use
of diagnostic methods.215
In the USA, the Secretary of Health and Human Services has delegated to the Food and Drug
Administration (FDA) the authority to determine whether particular tests are ‘simple’ and have ‘an
insigniﬁcant risk of an erroneous result’. The US Clinical Laboratory Improvement Amendments (CLIA)
categorisation criteria grade speciﬁc laboratory test system, assay and examination for level of complexity
by assigning scores of 1, 2 or 3 for each of seven criteria: (1) knowledge; (2) training and experience;
(3) reagents and materials preparation; (4) characteristics of operational steps; (5) calibration, quality
control and proﬁciency testing materials; (6) test system troubleshooting and equipment maintenance; and
(7) interpretation and judgement.215 A score of ‘1’ indicates the lowest level of complexity, and the score
of ‘3’ indicates the highest level. These scores are totalled to derive a measure of complexity. Here we
evaluate the ease and speed of use of selected POCTs, PCR-based rapid molecular assays and traditional
culture for the aetiological diagnosis of respiratory infections. As outlined below, we modiﬁed the scoring
system proposed by CLIA and included additional criteria, speciﬁcally: (1) test site requirements;
(2) equipment; (3) storage and disposal of waste test materials and reagents; (4) health and safety
implications; and (5) time to reporting (TtR) of results.Specimen handling and diagnostic testsSpecimens were collected and transported as described in Chapter 2. We evaluated point of care,
molecular, and traditional test methods for the diagnosis of respiratory infections as described in
Chapter 2. These included the following.
POCTs:
l QuickVUE Inﬂuenza A&B (Quidel, USA).
l BinaxNOW S. pneumoniae test.81
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82Molecular diagnostic tests:
l Semi-nested multiplex conventional PCR for inﬂuenza A subtypes H1 and H3, inﬂuenza B, and RSV A
and B (as used during Year 1).
l HPA Cambridge, one-step, quadriplex, real-time RT-PCR for the detection of inﬂuenza (as used during
Year 2).
l HPA Colindale, one-step, multiplex, real-time RT-PCR for the detection of inﬂuenza (as used
during Year 3).
l RSV and hMPV, one-step (Year 2) and two-step (Year 3), multiplex real-time RT-PCR.
Conventional diagnostic tests:
l Virus isolation and culture on continuous cell lines.
l Blood culture.
l Sputum culture.
l Sputum Gram stain and microscopy.Ease-of-use scoresEach speciﬁc test procedure was graded by assigning EoU scores of ‘1’, ‘2’ or ‘3’ for each of the 11 criteria
listed below. Like the CLIA system, a low score reﬂects the lowest levels of complexity of test procedures
that can be carried out quickly by personnel with minimal training. A high score reﬂects high levels of
complexity. A score of ‘2’ was assigned to scoring criteria when the characteristics for a particular test are
intermediate between those listed for scores of ‘1’ and ‘3’.Scoring criteria1. Test site:
Score 1 Is a POCT.
Score 3 A facility with purpose-built accommodation, ventilation systems and dedicated space
is essential.
2. Equipment:
Score 1 (A) No special equipment is required and (B) the test is readily transferred between
hospital facilities.
Score 3 Specialised equipment is essential and non-portable.
3. Materials and reagents:
Score 1 (A) Materials and reagents are stable and (B) they are pre-packaged, and/or pre-measured,
and require no special handling steps, or storage conditions.
Score 3 Materials and reagents are labile requiring special storage conditions or require special
handling steps to ensure reliability and (B) materials and reagents preparation requires manual steps,
for example volumetric measurement.
4. Operational steps:
Score 1 (A) Operational steps are either automatically operated (e.g. pipetting, temperature control,
mixing of reagents or timing of steps) or (B) are easily controlled.
Score 3 Operational steps require close monitoring and control, and may require special preparation
(e.g. for manual nucleic acid extraction), precise temperature control or timing of procedural steps,
accurate pipetting or extensive calculations.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Score 1 (A) Minimal scientiﬁc and technical knowledge and experience are required to perform the
test and (B) knowledge to perform the test may be obtained through on-the-job instruction [i.e. in the
UK the test could be done readily by someone at Agenda for Change (AFC) Band 4 or less].
Score 3 Specialised scientiﬁc and technical knowledge is essential to perform the testing, and (B)
substantial experience is required (i.e. in the UK the test requires skills and knowledge commensurate
with someone at AFC Band 7 or higher).
6. Calibration and quality control:
Score 1 (A) Calibration is either automatic or not required or (B) quality control materials are stable
and are included in the test, or are readily available.
Score 3 (A) Calibration materials, if available, may be labile, or (B) quality control materials, if
available, may be labile, or not available, or (C) technical expertise is required for calibration.
7. Interpretation and judgement:
Score 1 (A) Minimal interpretation and judgement are required to perform the test; and (B) problems
require limited interpretation, judgement, and decision-making.
Score 3 (A) Extensive interpretation and judgement are required to perform the test; and (B)
resolution of problems requires extensive interpretation, judgement and decision-making.
8. Test system troubleshooting and equipment maintenance:
Score 1 (A) Test system troubleshooting is automatic or self-correcting, or clearly described or requires
minimal judgement and (B) equipment maintenance is seldom needed, or can be easily performed.
Score 3 (A) Test system troubleshooting is not automatic or self-correcting and requires decision-
making and intervention to resolve most problems and (B) equipment maintenance requires special
knowledge, skills, and abilities.
9. TtR of results (included as possible indicator of EoU):
Score 1 Results are reported within 4 hours of collection of almost all specimens.
Score 3 The median TtR of results exceeds the median duration of hospitalisation/time to death.
10. Health and safety:
Score 1 The test is completed using low levels of personal protection, i.e. gloves, and can be
conducted outside a laboratory setting.
Score 3 One or more operational steps in the testing process require Biosafety level (BSL) category 3
or higher.
11. Storage and disposal of waste test materials and reagents:
Score 1 Waste materials and reagents from the testing process are stored and disposed using medium
duty ‘Clinical Waste’ plastic bags and Sharps Containers (to BS 7320/UN 3291), or a sluice.
Score 3 Waste materials or reagents from the testing process include hazardous materials (including
highly infectious waste, chemical waste, waste with a high content of heavy metals, genotoxic waste
or radioactive waste) that require special attention.ResultsAs outlined in Chapter 3, 1252 admissions were enrolled into the study, of which 418 were randomised to
the ‘near-patient’ group, 415 to the ‘molecular’ diagnostic group, and 419 to the ‘conventional’ diagnostic
group. The median duration of symptoms before recruitment was 120 hours (IQR 72–168 hours), and the
median time to discharge or death was 72 hours (IQR 21–180 hours).83
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84Speed of use of test methods for the diagnosis of respiratory infections
Quidel QuickVUE Influenza A&B
The interval between specimen collection and the results of the near-patient Quidel QuickVue Inﬂuenza
A + B test was recorded for 327 of the 418 admissions who were randomised to ‘near-patient’ test group
(Group 1). The median interval from specimen collection to the provision of a positive or negative result for
the 327 admissions was 15 minutes (IQR 10–23 minutes) (Figure 12). Altogether, 278 results (85%,
95% CI 80.7% to 88.7%) were reported by 30 minutes.
BinaxNOW S. pneumoniae test
Urine samples from 412 out of 418 admissions in the ‘near-patient’ group (Group 1) were available on
recruitment for POC testing using the BinaxNOW S. pneumoniae test. The interval between specimen
collection and the results of the near patient BinaxNOW S. pneumoniae test was recorded for 324
admissions. The median interval from specimen collection to the provision of a positive or negative result
was 20 minutes (IQR 15–30 minutes) (Figure 13). Altogether, 270 results (83.3%, 95% CI 78.8%
to 87.2%) were reported by 30 minutes.0
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FIGURE 13 Time interval between specimen collection and report (BinaxNOW S. pneumoniae test).
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The median TtR of results obtained by ‘conventional’ semi-nested multiplex PCR (n = 57, Group 2) was
50.8 hours (IQR 44.3–92.6 hours). Figure 14 shows a plot of the time interval between specimen collection
and the report. Altogether 12 results (21.0%, 95% CI 11.4% to 33.9%) were reported by 36 hours; 18
(31.6%, 95% CI 19.9 to 45.2%) were reported by 48 hours; 36 (63.1%, 95% CI 49.3% to 75.6%) were
reported by 72 hours, and 45 (78.9%, 95% CI 66.1% to 88.6%) were reported by 96 hours.
One-step, quadriplex/multiplex, real-time reverse-transcriptase polymerase chain
reaction for influenza, and one-step and two-step respiratory syncytial virus
and human metapneumovirus multiplex real-time polymerase chain reaction
These real-time PCRs are considered together owing to their similarity. The median TtR
of results obtained by ‘real-time’ RT-PCR (n = 358, Group 2) was 29.2 hours (IQR 26–46.9 hours)
(Figure 15). The difference between the time taken to analyse specimens by the ‘conventional’ semi-nested
multiplex PCR and real-time PCR was 21.9 hours (p < 0.0001, Mann–Whitney U-test). Figure 16 shows the
percentage of specimens that are reported as positive or negative by real-time PCR in increments of
12 hours (and at 30 hours) after specimen collection. By 30 hours, results were available for 220 (61.3%,
56.0% to 66.3%) admissions.
Viral culture
Viral culture results were available for 1245 (99.4%, 95% CI 98.8% to 99.8%) of the 1252
nasopharyngeal specimens that were collected from all admissions in Groups 1, 2 and 3. The cumulative
percentage of specimens reported by 24-hour time periods for inﬂuenza A and B (n = 21), other viruses
(n = 49) and specimens that were culture negative (n = 1175) is shown in Figure 17. The median time
from specimen collection to reporting a positive culture result for admissions with inﬂuenza A and B was
629.6 hours (IQR 262.5–846.7), which is approximately nine times greater than the median time to
discharge or death (72.08 hours). The median turnaround time of 220.4 hours (IQR 172.1–314.5 hours)
for reports of viruses other than inﬂuenza was signiﬁcantly shorter than for the time for inﬂuenza
(p < 0.0001, Kruskal–Wallis test). The time to report the isolation of inﬂuenza A or B did not differ from
the time to report culture negative results (454.7 hours, IQR 406.0–621.5 hours). Less than 6% (70 of
1245, 5.6%, 95% CI 4.4% to 7.0%) of all virus culture results were reported within 14 days of specimen
collection. The results for 17 out of 21 (80%, 95% CI 56.3% to 94.3%) nasopharyngeal specimens that
grew inﬂuenza virus became available only a median of 459.1 hours (IQR, 290.1–768.2 hours) after death
or discharge. For 33 specimens that grew herpes simplex type 1 virus (another virus for which therapy is0
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FIGURE 16 Percentage (± 95% CIs) of specimens reported as positive or negative by real-time RT-PCR at 12-hour
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298.9 hours (IQR 135.95–552.35 hours) after death or discharge – which is outside the therapeutic
window for treatment.
Blood culture
Blood culture results were available for 973 (77.7%, 95% CI 75.3% to 80.0%) patients in Groups 1, 2
and 3. Eighty of the 973 blood cultures grew an organism (including contaminants), and 10 of the 80 grew
S. pneumoniae. The median TtR S. pneumoniae cultures was 84.4 hours (IQR 70.7–137.8 hours), but a
provisional report was issued a median of 36.8 hours (IQR 22.7–48.75 hours) after specimen collection.
The median TtR bacterial growth for the other 70 specimens was 53.8 hours (IQR 47.7–71.8 hours). The
median TtR negative culture results for the remaining 893 specimens was 136.2 hours (IQR 124.4–143.25).
Blood culture results for three specimens that grew S. pneumoniae were reported a median of 139.2 hours
(IQR 27.9–163.4 hours) after death or discharge. The remaining seven pneumococcal culture results were
reported a median of 53.2 hours (IQR 30.4–58.1 hours) before discharge. The median interval between
specimen collection and reporting all 973 blood culture ﬁndings was 130.8 hours (IQR 123.8–142.8 hours).
Altogether 619 of the 973 admissions were discharged or died before their blood culture results, i.e. fewer
subjects were discharged after the blood culture result was reported than before.
Antimicrobial sensitivity data became available a median of 84.4 hours after specimen collection for the
10 admissions with positive S. pneumoniae blood culture results.Sputum culture
As in previous studies, we found that a substantial number (941) (75.2%, 95% CI 72.7% to 77.5%) of
the 1252 admissions with acute cardiopulmonary conditions were unable to produce sputum for analysis.
Sputum was collected from 311 (24.8%) admissions. Test results were only available for 296 (23.6%,
95% CI 21.3% to 26.1%) sputa owing to rejection of 15 samples by the laboratory for reasons of poor
quality. Of the 296 specimens, sputum culture and Gram stain results were available for 274 specimens
and sputum culture results were available for only an additional 22.
A total of 76 of the 296 sputum cultures grew an organism (excluding Candida species in ﬁve additional
specimens); of the 76, 10 grew S. pneumoniae after a median interval from specimen collection of
71.4 hours (IQR 69.15–84.0%). The median turnaround time was 60.7 hours (IQR 50.15–71.6 hours)
for the remaining 66 culture-positive sputa (p = 0.0065, Kruskal–Wallis test) and 50.5 hours
(IQR 48.3–66.9 hours) for the 219 of 220 culture-negative sputa with relevant data (p < 0.0001).
The median interval between specimen collection and reporting sputum culture results for 295 out of
296 admissions was 51.4 hours (IQR 48.75–69.2 hours). Overall, 129 of 294 (43.9%) admissions with
relevant data were discharged before their sputum cultures were reported.
The median TtR antimicrobial sensitivity was 133 hours (IQR 123.1–148.1 hours) for 8 of the 10 isolates of
S. pneumoniae.Sputum Gram stain
Gram-staining of sputum samples is not routinely performed by the University Hospitals of Leicester
NHS Trust, and the median TtR of Gram stain results for 274 sputum samples was 60.7 hours
(IQR 50.0–89.4 hours). Figure 18 shows the cumulative percentage of sputa with Gram stain reports at
12-hour intervals after collection.87
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Table 30 shows summary EoU scores for the POCT, molecular and conventional diagnostic tests for the
diagnosis of respiratory infections. The component scores for each test are shown in Appendix 7. EoU
scores of 11 (i.e. component scores of ‘1’ for each of the 11 criteria for categorisation) identiﬁed test
procedures as being straightforward and undemanding to use, scores of 12–22 identiﬁed tests as being of
moderate complexity and requirements, and scores of ≥ 23 as being ‘complex’, requiring particular skills,
training and knowledge, specialised equipment and reagents, and/or accommodation, etc.
QuickVUE influenza A&B test
Samples from all 418 patients in the ‘near-patient’ group (Group 1) were tested using the QuickVUE
inﬂuenza A&B test at the POC. Unequivocal results were reported for all samples tested. The summary EoU
score for the QuickVUE inﬂuenza A&B test was 11, indicating that the test was straightforward to use,
with component scores of ‘1’ for each of the 11 criteria for categorisation (see Appendix 7, Table 38).TABLE 30 Summary EoU scores for POCTs, molecular and traditional diagnostic tests for the diagnosis of
respiratory infections
Test Summary EoU score
Point-of-care tests
QuickVUE Inﬂuenza A&B 11
BinaxNOW Streptococcus pneumoniae test 11
Molecular diagnostic tests
Semi-nested multiplex PCR for inﬂuenza A subtypes H1 and H3, inﬂuenza B, and RSV A and B 30
One-step, quadriplex/multiplex, real-time RT-PCR for the detection of inﬂuenza, RSV and hMPV 25
Two-step multiplex real-time RT-PCR for RSV and hMPV 26
Conventional tests
Virus culture 26
Blood culture 20
Sputum culture 25
Sputum Gram stain and microscopy 23
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Urine samples from 412 of the 418 patients in the ‘near-patient’ group (Group 1) were available on
recruitment for POC testing using the BinaxNOW Streptococcus pneumoniae test. Unequivocal results were
reported for all 412 samples tested. The summary EoU score for the BinaxNOW Streptococcus pneumoniae
test was ‘11’, indicating that the test was straightforward to use, having component scores of ‘1’ for each
of the 11 criteria for categorisation (see Appendix 7, Table 39).Polymerase chain reaction
Samples from 57 (13.7%) of the 415 patients randomised to the ‘molecular’ diagnostic group (Group 2)
were tested using conventional PCR, whereas real-time PCR methods were used to analyse samples from
a further 358 patients. All rapid molecular samples were received and tested and unequivocal results were
reported for samples from all 415 patients.Semi-nested multiplex reverse-transcriptase polymerase chain reaction for
influenza A subtypes H1 and H3, influenza B, and RSV A and B
The EoU score for the ‘conventional’ semi-nested multiplex RT-PCR was 30, indicating its complexity and
requirements. Inspection of the component scores for the 11 categorisation criteria (see Appendix 7,
Table 40) reveal scores of ‘3’ for eight categories: ‘equipment’; ‘operational steps’; ‘training, experience
and knowledge’; ‘calibration and quality control’; ‘interpretation and judgement’; ‘test system
troubleshooting and equipment maintenance’; ‘health and safety’ and ‘storage and disposal of waste
test materials and reagents’. Scores of ‘2’ were recorded for the remaining three categories: ‘test site’,
‘materials and reagents’ and ‘time to reporting (TtR) of results’. None of the categories scored ‘1’.One-step, quadriplex/multiplex, real-time reverse-transcriptase polymerase
chain reaction for influenza, and one-step and two-step respiratory syncytial
virus and human metapneumovirus multiplex real-time polymerase
chain reaction
These real-time PCRs are considered together owing to their similarity. The EoU score for real-time
PCR was 25 for one-step PCR and 26 for two-step PCR, indicating their complexity and requirements.
Component scores for the 11 categorisation criteria are shown in Appendix 7, Tables 41 and 42. In contrast
with ‘conventional’ semi-nested multiplex PCR, a score of ‘1’ was allocated to one category – ‘materials
and reagents’. Besides some minor additional mixing steps, we used real-time PCR kits (SuperscriptTM III
Platinum® One-Step qRT-PCR kit and Platinum® Quantitative PCR Supermix-UDG, Invitrogen, Paisley, UK)
that contained ready-to-use reagents, which were optimised and quality-controlled by the manufacturer
(Invitrogen). In addition, the test calibration was automatic and all reactions were performed in closed
tubes, which reduced the level of risk to the operator and environment. With the one-step method, a score
of ‘3’ was allocated to four categories: ‘equipment’, ‘calibration and quality control’, ‘health and safety’ and
‘storage and disposal of waste test materials and reagents’. With the two-step method, ‘operational steps’
also scored ‘3’ (a score of ‘2’ was given with the one-step method) because the reverse transcription step
involved precise temperature control and timing. All other steps were scored ‘2’.Viral culture
Although swabs in VTM were received from all 1252 patients, viral culture results were available for
1209 (96.6%); contamination of the PLC/PRF5 and MRC-5 tubes prevented the culture of specimens from
41 patients, and two were rejected by the laboratory due to improper storage of samples at room
temperature. A further 29 (2.4%) had only partial results due to contamination of PLC/PRF5 or MRC-5
tubes. The EoU score for virus culture was 26, reﬂecting the complexity and requirements of the method.
The component scores for the 11 categorisation criteria (see Appendix 7, Table 43) included scores of
‘3’ for ﬁve categories: ‘equipment’, ‘materials and reagents’, ‘operational steps’, ‘interpretation and
judgement’ and ‘time to reporting (TtR)’. Scores of ‘2’ were recorded for all other categories, except
‘Calibration and quality control’, which scored ‘1’.89
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Blood cultures from 967 patients were processed using the Bact/ALERT 3D system. The EoU score for
blood culture was ‘20’, reﬂecting moderate complexity and requirements. The component scores for the
11 categorisation criteria (see Appendix 7, Table 44) included scores of ‘3’ for one category – ‘equipment’.
Scores of ‘2’ were given to seven categories: ‘test site’; ‘training, experience and knowledge’; ‘calibration
and quality control’; ‘interpretation and judgement’; ‘time to reporting (TtR) of results’; ‘health and safety’
and ‘storage and disposal of waste test materials and reagents’. The categories ‘materials and reagents’,
‘operational steps’ and ‘test system troubleshooting and equipment maintenance’ all scored ‘1’.Sputum culture and Gram stain and microscopy
Sputum culture received an EoU score of 25 (see Appendix 7, Table 45), indicating its complexity or
requirements. It scored ‘3’ in ﬁve categories: ‘test site’; interpretation and judgement’; test system
troubleshooting and equipment maintenance’; ‘health and safety’ and ‘storage and waste disposal.’ It
scored ‘2’ in four categories: ‘equipment’; ‘materials and reagents’; ‘training, experience and knowledge’;
and ‘time to reporting (TtR) of results’. It scored ‘1’ on ‘operational steps’ and ‘calibration and
quality control’.
Sputum Gram staining and microscopy received an EoU score of 23 (see Appendix 7, Table 46), primarily
reﬂecting its requirements rather than complexity. It scored ‘3’ in three categories: ‘test site’; ‘training,
experience and knowledge’; and ‘health and safety’. It scored ‘2’ in six categories: ‘equipment’; ‘materials
and reagents’; ‘operational steps’; ‘interpretation and judgement’; ‘test system troubleshooting and
equipment maintenance’; and ‘time to reporting (TtR) of results’. It scored ‘1’ in ‘calibration and quality
control’ and ‘storage and disposal of waste test materials and reagents’.Sensitivity analysis
The EoU score incorporated a score for the time to reporting (TtR) of results as a possible indicator of EoU
– the rationale being that tests that provide timely results are easier to use or are less demanding than
tests that provide results more slowly. We undertook a sensitivity analysis to examine whether our scoring
and ranking of test was unduly inﬂuenced by the (TtR) of results or its combination with another measure
of EoU and test requirements/complexity. Table 31 shows total EoU scores and their ranking when (1) all
11 criteria are considered; (2) the total EoU score excluding the component score for the ‘time to reporting
(TtR) of results’; and (3) the total EoU score excluding the component score for the ‘time to reporting (TtR)
of results’ and each remaining component score in addition. The score relating to the (TtR), when
considered alone or with other component scores, has no appreciable effect on ranking of tests in terms
of their EoU and/or test requirements (see Table 31).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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92Discussion
A prime purpose of POCTs and molecular diagnostic tests is to provide information that enables medical
and nursing staff to treat patients with optimal medication as soon as possible, and to inform the use of
isolation facilities and infection control procedures and equipment. Such measures can potentially cut
illness duration, prevent or ameliorate complications, shorten the duration and costs of hospitalisation,
improve the cost-effectiveness of health delivery, and also reduce cross-infection. To be of clinical value,
such diagnostic tests must have high sensitivity and speciﬁcity across all age ranges, be inexpensive and
provide test results sufﬁciently early for a measurable effect. Here we consider the speed and ease of tests
rather than their costs, sensitivity and speciﬁcity, clinical impact or cost-effectiveness.
The EoU scores used in this study provide a measure of the complexity and requirements of the test
procedures that we assessed. We included TtR of results in the scoring system as a possible indicator of
EoU. We did a sensitivity analysis and found that exclusion of TtR of results in the scoring system – either
alone or with each other component scores – had no appreciable effect on the overall ranking of tests in
terms of EoU and/or test requirements.
The patients in our study had a median duration of illness of 120 hours before admission with a lower
quartile of 72 hours. Recent systematic reviews and meta-analyses of the therapeutic use of NIs,70,216,217
show that a clinically beneﬁcial effect of oseltamivir and zanamivir (Relenza®, GSK) depends on treatment
starting within 48 hours of ﬁrst symptoms when seasonal (inter-pandemic) inﬂuenza is circulating. In our
study, only the Quidel QuickVUE Inﬂuenza A&B test provided results soon enough to inﬂuence treatment
decisions that might beneﬁt patients – and then only to a small percentage (150/1240, 12.1%) of
admissions. In our study, the Quidel QuickVUE Inﬂuenza A&B test had a median turnaround time of
< 30 minutes, and 85% of results were reported within half an hour of specimen collection. The PCR
tests were much slower in comparison – the median TtR of results using molecular tests was
50.8 hours for conventional PCR, and 29.2 hours for real-time RT-PCR. For patient cohorts as in our study,
these turnaround times preclude RT-PCR from guiding decisions to start antiviral treatment but could
inﬂuence infection control procedures in hospitals with limited single-room accommodation, as inﬂuenza
virus can still be detected in nasopharyngeal aspirates by real-time RT-PCR up to 1 week or more among
patients who do not receive antiviral therapy.125,155 In contrast, conventional virus culture provided results
of no clinical or public health relevance to the patient or hospital. In our study, the median TtR of results
obtained by virus culture was 452.6 hours (IQR 403.6–620.8 hours) and fewer than 5% of results were
available within 14 days of specimen collection – too late to initiate antiviral therapy for inﬂuenza or
recurrent orolabial herpes simplex virus (HSV) infection. The virus culture results usually became available
when the patient had either been discharged or died; this occurred for 80% of the specimens that grew
inﬂuenza A or B, and 57% of those that grew HSV.
In the EoU evaluation of the diagnostic tests for inﬂuenza, the Quidel QuickVUE Inﬂuenza A&B POCT was
allocated a score of ‘11’ (i.e. component scores of ‘1’ for each of the 11 criteria for categorisation),
indicating that it was straightforward and undemanding to use, and can be used with minimum levels of
training, knowledge and technical skills. The tests kits can be stored at room temperature and have a
24-month shelf life from date of manufacture, are readily transferable and convenient to use. In contrast,
the ‘conventional’ RT-PCR test for inﬂuenza A and B and RSV A and B had the highest of all EoU scores in
the analysis (‘30’), reﬂecting its complexity and requirements. In comparison with ‘real-time’ PCR tests, the
‘conventional’ RT-PCR test took 20 hours longer when median turnaround times were compared. The EoU
scores for the ‘real-time PCRs’ were ‘25’ and ‘26’, indicating PCRs to be ‘complex’ in terms of EoU and
requirements. Our observations of turnaround times and EoU scores indicate that the ‘real-time’ RT-PCR
method should be used in preference to the ‘conventional’ RT-PCR test, assuming that both methods are
otherwise comparable in terms of sensitivity, speciﬁcity and cost. However, it is acknowledged that the
technology is evolving rapidly, so what is complex now, with multiple steps, is gradually being automated
so as to reduce the skill requirements, and improve turnaround times. The EoU score for the conventional
cell culture diagnostic test was ‘26’, which reﬂects its general complexity and requirements in performanceNIHR Journals Library www.journalslibrary.nihr.ac.uk
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replacement of conventional virus culture with an alternative test. However, virus culture remains of value
in providing specimens for antigenic analysis and antiviral susceptibility, and guiding strain selection for
vaccine production.
In the UK, treatment of ILI with NIs is inﬂuenced by illness duration and virus activity established through
surveillance, rather than POCTs. Similarly, initial therapy of CAP with antibiotics is guided by severity
scores – such as CURB-65 – and cannot await ‘early’ microbiology results, although ‘early’ results might
subsequently inﬂuence the spectrum of antibiotics that are used.
For pneumococcal infection, only the BinaxNOW S. pneumoniae test provided results rapidly – the test
had a median turnaround time of < 30 minutes, and 85% of results were reported within half-an-hour of
specimen collection. The BinaxNOW S. pneumoniae POCT had an EoU score of 11 (i.e. component scores
of ‘1’ for each of the 11 criteria for categorisation), indicating that it was as equally straightforward and
undemanding to use as the Quidel QuickVUE Inﬂuenza A&B POCT. Like the QuickVUE Inﬂuenza A&B test,
the BinaxNOW test can be used with minimum levels of training, knowledge and technical skills, can be
stored at room temperature, and is readily transferable and convenient to use. The blood and sputum
culture results were much slower in comparison. The median TtR growth of S. pneumoniae was
84.4 hours, although a provisional report of the growth of an organism was reported after a median of
36.8 hours. Antimicrobial sensitivity data did not become available for a median of 84.4 hours after
specimen collection. Similarly, growth of S. pneumoniae from sputum was reported a median of
71.4 hours after collection, and the median TtR antimicrobial sensitivity was 133 hours.
As noted in the review of cases that tested positive in the pneumococcal POCT (see Chapter 4), the much
shorter turnaround time of the urinary antigen test for pneumococcal antigen compared with blood and
sputum culture, did not lead to any step-down in antimicrobial treatment within 24 hours of the test
result, nor did a positive test result lead to the release any single-room accommodation. Similarly, the
substantially faster turnaround time of the POCT for inﬂuenza compared with virus culture had no impact
on the use of NIs, antibiotics or single-room accommodation but the number of patients with positive
results was very small, and the data should therefore be interpreted with caution.93
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DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Chapter 8 Process outcomes and cost-effectivenessIntroductionThis chapter reports the results of a trial-based cost-effectiveness analysis. Resource-use data were
collected prospectively during the time patients were in hospital via the CRFs, and retrospectively from
discharge until day 28 via the 28-day follow-up. UK unit costs obtained from a variety of sources were
then applied to the resource use data to estimate total cost per patient. As well as describing the
distribution of total costs for the three diagnostic strategy groups, an incremental cost-effectiveness
analysis was undertaken with cost per quality-adjusted life-year (QALY) (estimated using the EQ-5D and
mortality data reported in Chapter 4 via an AUC approach218) being estimated when appropriate, together
with cost per (correct) case detected (using the diagnostic data reported in Chapter 5). To simultaneously
allow for the potential for correlation between cost and outcome, as well as their inherent uncertainty,
together with the fact that some data were missing for both resource use (and therefore cost) and EQ-5D
(see Chapter 4 for details), a Bayesian approach was adopted219–221 using Markov chain Monte Carlo
(MCMC) methods, implemented in WinBUGS version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) to
estimate the uncertainty surrounding the outcome measures.222 A series of sensitivity analyses were
undertaken, both to assess the sensitivity to the MCMC methods used, and to the prices of the index tests
(PCR and POCT), and also the model structure used to estimate cost-effectiveness. The perspective
adopted was that of the NHS.Methods
Resource use data and unit costs
Table 32 displays the unit costs, derived from a variety of sources,223–226 for the various major resource use
components identiﬁed in 3WS. As well as the unit costs in Table 32, all drugs prescribed in the index
admission, and subsequently associated with the index admission, were costed using the British National
Formulary (BNF).227 The price year adopted was 2007–8, i.e. the ﬁnal year of the study,228 and those unit
prices that were not in this year were adjusted accordingly using the Hospital and Community Health
Services (HCHS) Pay and Price Index.229 No discounting of either costs or QALYs was applied to the
cost-effectiveness analyses, as the time horizon over which patients were followed was 28 days. As well as
the average total cost per patient for each of the diagnostic strategies, the main cost components, namely
hospital stay (both non-ITU and ITU), index test costs (including stafﬁng and materials), complications
[myocardial infarction, stroke, urinary tract infection, wound infection, MRSA/Clostridium difficile),
post-discharge visits (GP/nurse visits) and A&E attendance], additional investigations (electrocardiography,
full blood count, blood gases, blood biochemistry, oxygen levels, ward-based urine analysis and chest
radiography) and antibiotic prescribing (both for the index admission and post discharge) were also
reported in terms of means and SDs. Owing to the relatively large sample size, both cost components
and mean resource were formally compared between the diagnostic strategies using parametric
methods – one-way ANOVA or Fisher’s exact test as appropriate.23095
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Nicholson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ABLE 32 Unit costs for the various resources collected
Cost component/resource Unit cost (£) Source
Hospital cost per day
Ward 276.21 HRG code and DH Reference Costs223
ITU 1410.54 HRG code and DH Reference Costs223
Oxygen therapy 212.00 HRG code and DH Reference Costs223
Ward-based CPAP 219.75 HRG code and DH Reference Costs223
Tests (including staffing and materials)
Quidel 15.83 UHL NHS Trust
Binax 25.56 UHL NHS Trust
Blood culture 46.00 UHL NHS Trust
Viral culture 48.00 UHL NHS Trust
Sputum culture 38.00 UHL NHS Trust
PCR 48.00 UHL NHS Trust
Complications (average costs for acute phase)
Myocardial infarction 1138.64 Bravo-Vergel et al.224
Stroke 790.03 Bravo-Vergel et al.224
Urinary tract infection 32.08 Turner et al.225
Wound infection 148.00 DH NHS Reference Costs223
MRSA/C. difficile 688.00 DH NHS Reference Costs223
Post-discharge visits
GP: surgery 36.00 PSSRU226
GP: home 58.00 PSSRU226
Practice nurse 11.00 PSSRU226
District nurse 26.00 PSSRU226
Home-care worker 39.00 PSSRU226
A&E attendance 111.00 PSSRU226
Additional investigations
Electrocardiography 33.45 DH NHS Reference Costs223
Full blood count 2.99 DH NHS Reference Costs223
Blood gases 2.99 DH NHS Reference Costs223
Oxygen levels 2.99 DH NHS Reference Costs223
Blood biochemistry 1.34 DH NHS Reference Costs223
Ward urine analysis 9.15 DH NHS Reference Costs223
Chest radiography 16.00 DH NHS Reference Costs223
DH, Department of Health; HRG, Healthcare Resource Group; PSSRU, Personal Social Services Research Unit; UHL, University
Hospitals of Leicester.
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In order to simultaneously allow for the potential for correlation between cost and outcome a bivariate
model was assumed for the two outcomes.220,231 Thus, if y1ij and y2ij represented the total costs and QALYs
for the ith patient in the jth group, respectively, these were then assumed to come from a bivariate normal
distribution (model A), such that:
 y1ij
y2ij

∼N
 μ1j
μ2j

, Σj

ð1Þ
where μ1j and μ2j are the mean total costs and mean QALYs for the jth randomisation group respectively,
and Σj is the associated covariance matrix. Adopting a Bayesian approach to estimating the unknown
parameters of model (1), i.e. μ1j, μ2j and Σj, prior distributions, representing a priori beliefs, are required for
these parameters. To represent vague or non-informative prior beliefs regarding μ1j and μ2j appropriately
diffuse normal distributions centred at zero were used, i.e. N(0,108) and N(0,10–2), respectively. For the
covariance matrix, a Wishart prior distribution is placed on the precision matrix, i.e. the inverse of the
covariance matrix. Thus:
Σ−1 ¼

σ21 σ
2
12
σ212 σ
2
2
−1
∼ WishartðA, kÞ ð2Þ
where A in (2) represents a priori beliefs regarding the corresponding covariance matrix, and by setting k to
be the rank of A, in this case k = 2, a non-informative prior distribution is obtained. Initially, A is set such that:
A ¼

10,000 0
0 0.01

ð3Þ
Having speciﬁed the prior distributions for model A as above, the marginal posterior distributions for μ1j
and μ2j are required to assess cost-effectiveness. Owing to the number of unknown parameters in model A
(1), MCMC methods are used in which random samples from the conditional posterior distributions are
obtained, but which under ergodic theory will converge to the required marginal posterior distributions
providing that a sufﬁcient number of samples (iterations) are obtained and that the sampling algorithm has
converged to an equilibrium distribution.232Estimation of model parameters and software
The results were reported as posterior means and 95% CrIs, which are analogous to CIs. Primary results
are based on a ‘burn-in’ of 20,000 iterations followed by a further sample of 50,000 iterations. Further
sensitivity analyses were conducted to assess both convergence/mixing of the sampling algorithm and
inﬂuence of prior distributions, which were all chosen to be non-informative. Appendix 8 displays a sample
of the WinBUGS code used for model A. The model parameters were estimated in WinBUGS 1.4.3,222 and
further post-estimation processing of the samples was undertaken in R.233Missing data
There were missing values for both total costs and QALYs for a number of patients (costs – traditional
8.4%, POCT 8.6% and PCR 8.4%; QALYs – traditional 51.1%, POCT 44.0% and PCR 48.1%) and these
were treated as unknown parameters in the estimation of model A, and hence at each iteration values
were sampled from their corresponding posterior predictive distribution, i.e. conditional upon both the
data and the model parameters, in a manner similar to multiple imputation.234 Thus, appropriate allowance
for all uncertainty in the MCMC estimated mean total costs and QALYs has been made.23597
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Having estimated the mean effects, i.e. QALYs and total costs per patient, and after allowing for the
imputation of missing data, the posterior probability of each diagnostic strategy being the least costly and
also having the highest gain in QALYs was estimated from the MCMC samples, i.e. at each iteration the
strategies were ranked and the probability of each strategy being ranked ﬁrst (for QALYs) and third (for
costs) was calculated as the proportion of iterations for which this was the case. An incremental
cost-effectiveness analysis was then undertaken in which the three diagnostic strategies were ﬁrst ranked in
terms of ascending cost, and then any strategies which were dominated, i.e. for which there was another
strategy which produced a greater QALY gain at lower cost, or extendedly dominated, i.e. for which there
was another combination of strategies which produced the same QALY gain at lower cost, were excluded
from the incremental analysis. For the two or three strategies that remain, cost-effectiveness was then
assessed by calculating the appropriate incremental cost-effectiveness ratios (ICERs) to obtain an estimate of
cost per additional QALY. Thus, for two strategies, j and k, the ICER is obtained by:
ICER ¼ μ1j − μ1k
μ2j − μ2k
ð4Þ
where μ¯1j and μ¯2j are obtained by averaging over the MCMC samples in R outside WinBUGS.221
The probability of cost-effectiveness at willingness-to-pay thresholds, λ, of £20,000 per QALY and £30,000
per QALY, the currently accepted thresholds for NICE,236 were estimated as the proportion of MCMC
samples for which the corresponding monetary net-beneﬁt (NB) function was positive.220
Thus, for strategy j the NB function is given by
NB ¼ μ2jλ − μ1j ð5Þ
In addition, the probability of error for any strategy deemed to be cost-effective was also estimated,
i.e. the probability that by adopting that strategy an incorrect adoption decision had been made. For the
incremental cost per conﬁrmed case of inﬂuenza analysis, the strategies were again ranked in terms of
ascending average total cost per patient, and the mean total cost per case, conﬁrmed using serology
(see Chapter 5), estimated.237Sensitivity analyses
A series of one-way sensitivity analyses were undertaken to examine whether the MCMC methods
(i.e. initial settings of burn-in, sample length and starting values), prior distributions, statistical model or
price of PCR or POCT had an impact on the mean costs and QALYs, i.e. μ1j and μ2j, and therefore on the
incremental cost-effectiveness analysis.Markov chain Monte Carlo methods
To assess evidence of non-convergence, the history trace plots, i.e. the sampled values at each iteration
plotted against iteration number, were examined for systematic movement in the chain and therefore
evidence of non-convergence. In addition, the auto-correlation functions/plots were examined to identify
poor mixing of the MCMC sampler, i.e. that successive sampled values were not entirely random, and
therefore a longer sample length would be required.
To assess the sensitivity of the cost-effectiveness results to the length of burn-in, length of sample, initial
starting values and prior distributions in using MCMC methods to estimate mean costs and QALYs, a
number of one-way sensitivity analyses were undertaken. Speciﬁcally, two additional sets of length of
burn-in/sample were used: 10,000/20,000 and 50,000/100,000 compared with the base-case analysis,NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36which used 20,000/50,000. Alternative prior distributions for μ1j and μ2j were also used, i.e. N(0,105) and N
(0,1), respectively, compared with N(0,108) and N(0,10–2) in the base case, and A was set such that:
A ¼

1000 0.5
0.5 0.1

ð6Þ
Finally, two additional chains, i.e. runs of the MCMC sampler, were used with qualitatively very different
initial starting values to those used in the base case, and Brooks–Gelman–Rubin plots were explored,238 as
well as the separate summary statistics for μ1j and μ2j, to identify evidence that the chains did not produce
qualitatively similar results. The Brooks–Gelman–Rubin plots compare the width of 80% CrIs of the pooled
chains with the average width of 80% CrIs across chains – the two should be the same unless there is
evidence of non-convergence. This also gives an informal way in which to check whether a longer period
of burn-in is required.Model B
Model A (1) assumes that y1ij and y2ij, representing the total costs and QALYs for the ith patient in the jth
group, respectively, are assumed to come from a bivariate normal distribution. This theoretically means
that both totals costs and QALYs could become negative. To assess the sensitivity of the base-case results
to this modelling assumption an alternative statistical model (model B)221 was developed in which y1ij
is assumed to follow a gamma distribution, i.e. so that costs can only be positive, and logit of y2ij,
i.e. log(y2ij/(1 – y2ij)) is assumed to follow a normal distribution but that these two distributions are
interlinked so that correlation between costs and QALYs is allowed. Thus:
y1ij∼Gammaðηj,λiÞ λi ¼
ηj
ϕi
ð7Þ
logitðy2ijÞ∼Nðμ2j,σ2j Þ where ϕi ¼ μ1j þ βjðy2ij−μ2jÞ ð8Þ
The unknown parameters in (7) and (8) are then given plausible yet vague or non-informative prior
distributions. The means of the costs and logit QALYs, i.e. μ1j and μ2j, are given uniform(1,50000) and
normal(0,1000) distributions, respectively, whereas the shape parameters of the gamma distribution in
(5), ηj are given uniform(1,100) prior distributions, and σj, the SD of logit QALYs in each randomisation
group, is given a half-normal prior distribution with a mean of zero and a SD of 1 truncated at zero,
i.e. σj ∼ N(0,1)I(0,). Finally, βj, the regression parameters that represent the degree of correlation between
costs and (logit) QALYs, through λi – the scale parameter of the gamma distribution in (7) – are given
vague normal prior distributions, i.e. βj ∼ N(0,1000). Although the mean costs can be estimated directly
from the MCMC samples, because the logit transformation is not linear it cannot be directly back
transformed to provide estimates of mean QALY gain. However, it is possible to estimate mean QALYs on
their natural scale using Monte Carlo integration within R (see Appendix 8, section C, for R code used).221Price reductions for polymerase chain reaction and point-of-care test
To assess the impact of price of the index test in the different diagnostic strategies, further
cost-effectiveness analyses were undertaken in which either the price of PCR or POCT, as these are
evolving technologies, was reduced by either 20% or 50%.ResultsTable 33 displays the mean/frequency of resource use for the main constituents of the cost components
for patients with no missing data, i.e. complete case analysis. As can be seen, the only statistically
signiﬁcant difference between the three strategies was in terms of use of a practice nurse (p = 0.03).99
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TABLE 33 Mean resource use for the elements of the different cost components for each of the
diagnostic strategies
Cost component
Traditional
(n = 419)
Near patient
(n = 418)
Rapid molecular
(n = 415) p-valuea
Hospital stay Mean (SD)b [n]c Mean (SD)b [n]c Mean (SD)b [n]c
Non-ITU (days) 7.11 (11.30) [419] 6.70 (10.96) [418] 6.35 (9.56) [415] 0.6
ITU (days) 0.07 (0.84) [3] 0.15 (2.06) [3] 0.03 (0.45) [2] 0.4
Oxygen therapy (hours) 38.75 (108.47) [160] 48.64 (214.14) [177] 51.25 (257.75) [169] 0.6
Ward-based CPAP (hours) 0.59 (11.74) [5] 0.38 (5.63) [5] 0.06 (0.87) [2] 0.6
Complications n (%) n (%) n (%)
Myocardial infarction 3 (0.72) 1 (0.24) 4 (0.96) 0.4
Stroke 1 (0.24) 0 (0.00) 0 (0.00) 0.9
Urinary tract infection 5 (1.19) 3 (0.72) 6 (1.45) 0.6
Wound infection 1 (0.24) 1 (0.24) 2 (0.48) 0.7
C. difficile 6 (1.43) 2 (0.48) 1 (0.24) 0.1
MRSA 1 (0.24) 3 (0.72) 2 (0.48) 0.6
Additional investigations Mean (SD)b [n]c Mean (SD)b [n]c Mean (SD)b [n]c
Electrocardiography 1.51 (1.52) [344] 1.47 (1.64) [336] 1.44 (1.74) [322] 0.8
Full blood count 2.71 (3.19) [399] 2.69 (3.35) [397] 2.51 (3.14) [385] 0.6
Blood gases 1.86 (8.13) [249] 2.11 (12.55) [245] 1.39 (4.11) [245] 0.5
Oxygen levels 15.88 (20.16) [397] 16.24 (31.85) [387] 15.57 (21.41) [395] 0.9
Blood biochemistry 3.23 (5.17) [403] 2.99 (3.84) [397] 2.81 (3.68) [387] 0.4
Ward urine analysis 0.40 (0.64) [141] 0.38 (0.61) [140] 0.37 (0.61) [130] 0.7
Chest radiography 1.22 (1.04) [397] 1.22 (1.07) [392] 1.20 (0.98) [385] 0.9
Post-discharge visits Mean (SD)b [n]c Mean (SD)b [n]c Mean (SD)b [n]c
GP: surgery 0.36 (0.77) [100] 0.40 (0.98) [91] 0.35 (0.84) [91] 0.7
GP: home 0.14 (0.53) [37] 0.11 (0.42) [34] 0.10 (0.38) [33] 0.4
Practice nurse 0.01 (0.15) [1] 0.04 (0.29) [9] 0.06 (0.41) [12] 0.03
District nurse 0.17 (1.54) [22] 0.09 (0.69) [25] 0.09 (0.69) 0.5
Home-care worker 0.28 (2.60) [17] 0.15 (1.12) [18] 0.24 (2.03) [18] 0.6
A&E attendance 0.02 (0.15) [6] 0.03 (0.23) [8] 0.01 (0.11) [2] 0.3
a Calculated using either one-way ANOVA or Fisher’s exact test.
b Calculated using all index admissions for each diagnostic strategy regardless whether resource was used.
c Number of admissions in which resource was used.
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Table 34 displays the mean (and SD) cost per patient for the cost components that make up the overall
total cost, as well as the mean overall total cost itself, for each of the three diagnostic strategies. It can
be seen that the means for each cost component, as well as for the total, are similar across the three
strategies, although there is considerable uncertainty surrounding some of these. Formal comparison of
the three strategies using one-way ANOVA did not identify any statistically signiﬁcant differences between
them (p = 0.3). For the observed QALYs, i.e. based on patients who did not have any missing data,
POCT produced a mean QALY gain of 0.008137 (SD 0.007191), PCR 0.007724 (SD 0.005977) and
traditional laboratory culture 0.007631 (SD 0.006244), which were not statistically signiﬁcant from one
another (p = 0.7).
Figure 19 displays the distribution of observed total costs for the three diagnostic strategy groups. As can
be seen, the distributions are skew, but are very similar to one another.
Table 35 displays the MCMC posterior mean estimates for the total costs and QALYs (gained during the
28 day follow-up period of the trial) associated with each of the three strategies, together with associated
95% CrIs, which can also be seen to very similar to one another. More formally, the posterior probabilities
that each strategy has the highest QALY gain are all less than 50%, ranging from 21.1% for traditional
laboratory culture to 48.9% for POCT, whilst the posterior probability that PCR is the least costly is only
78.6%. Figure 20 displays 50,000 samples for the mean total costs and QALYs gained for each of the
three diagnostic strategies, and again demonstrates both the level of uncertainty in both costs and QALYs,
and broad similarity between the strategies. Table 35 also shows a formal incremental analysis which
indicates that traditional laboratory culture testing is dominated by POCT, in that it has the highest mean
total costs but the smallest QALY gain, and is therefore excluded further from the incremental analysis.
Although PCR has lower mean total cost than POCT (cost difference: +£181, 95% CrI: –£219 to +£587),
POCT also has a larger QALY gain (QALY difference: +0.000256, 95% CrI: –0.001474 to +0.001978), and
the associated ICER of POCT compared with PCR is £734,717.
TABLE 34 Mean costs for different resource use components for each of the diagnostic strategies
Cost component
Traditional mean
(SD), £
Near-patient mean
(SD), £
Rapid molecular mean
(SD), £ p-valuea
Hospital stay: 2004 (3174) 1972 (3753) 1782 (2698) 0.5
Non-ITU 1977 (3121) 1855 (3030) 1759 (2652) 0.6
ITUa 27 (485) 117 (1662) 24 (482) 0.3
Index testsb 94 41 112
Complicationsa 22 (139) 11 (94) 16 (120) 0.5
Post-discharge visitsa 56 (143) 52 (126) 50 (156) 0.8
Additional investigations 137 (116) 138 (151) 130 (118) 0.6
Antibiotics 26 (56) 23 (58) 23 (61) 0.7
Total costs 2326 (3370) [172c] 2158 (3254) [167c] 1980 (2355) [121c] 0.3
a Calculated using one-way ANOVA.
b Index tests were standard within each arm and, therefore, there was no uncertainty around them.
c Standard error.
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IGURE 19 Distribution of total costs for each of the diagnostic strategies. (a) POCT; (b) PCR; (c) laboratory culture.
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102FFigure 21 displays the cost-effectiveness plane, i.e. incremental costs plotted against incremental QALYs for
POCT compared with PCR, together with a £20,000-per-QALY willingness-to-pay threshold. In fact, the
probability of POCT being cost-effective at £20,000 threshold is 18.3%, and at £30,000 is 18.6%,
reﬂecting the considerable uncertainty, whereas the probability of PCR being cost-effective at a £20,000
threshold is 78.3% and at £30,000 is 78.1%. The probability of error for adopting PCR, i.e. the probability
of making an incorrect adoption decision, is 21.7% at a £20,000 threshold and 21.9% at £30,000. The
corresponding cost-effectiveness acceptability curves (CEACs) for all three diagnostic strategies are
displayed in Figure 22.
To assess the impact of price on the overall cost-effectiveness results, Table 36 displays the results of a series
of one-way sensitivity analyses exploring the impact of 20% and 50% price reductions for POCT and PCR.
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IGURE 20 Mean costs and QALYs for ‘traditional’, ‘near-patient’ and ‘molecular’ diagnostic tests for 50,000
CMC samples.
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IGURE 21 Cost-effectiveness plane, i.e. incremental costs plotted against incremental QALYs for POCT compared
ith PCR, using 50,000 MCMC samples together with a £20,000 per QALY willingness-to-pay threshold. Sampled
alues below the threshold line indicate that POCT should be adopted as the most cost-effective strategy at a
illingness to pay of £20,000 per QALY.
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FIGURE 22 Cost-effectiveness acceptability curve for the three diagnostic strategies, based on 50,000 MCMC samples
together with a willingness-to-pay threshold of £20,000 per QALY.
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estimated mean total costs and QALY gains for the three diagnostic strategies, for example even with a
50% price reduction for PCR the mean total costs for PCR are £1953 (95% CrI £1719 to £2189) compared
with £1978 (95% CrI £1743 to £2165) in the base case, and similarly a 50% reduction in the price of POCT
results in estimated mean total costs of £2139 (95% CrI £1813 to £2468) compared with £2159 (95% CrI
£1828 to £2485) in the base case. In all cases not only are the estimated mean costs and QALYs very similar
to the base case, but also the ranking of the treatments in terms of both costs and QALYs remains the same
as in the base case.
Table 36 also presents the results obtained using an alternative statistical model (model B) in which costs
are assumed to follow a gamma distribution and logit transformed QALYs a linked normal distribution. As
anticipated, given the skewness of the original cost data presented in Figure 19, the estimated mean costs
for each of three diagnostic strategies are higher than in the base case, although for each diagnostic
strategy the 95% CrIs for both mean costs and QALYs overlap, and the ranking of the treatments remains
the same, with traditional laboratory culture being dominated by POCT, and the associated ICER for POCT
compared with PCR, which still has the lowest estimated mean cost, being £342,750 per QALY, still
considerably higher than the normal upper limit of £30,000 adopted by NICE in England and Wales.
Sensitivity analyses to the MCMC methods used are displayed in Appendix 8, section B. Here, Table 47
displays the results of using different combinations of length of burn-in/sample, initial starting values and
prior distributions. It can be seen that there appears to be little evidence of non-convergence of the
MCMC estimation of model A, with the resulting estimated mean costs and QALYs being very similar
across the different sensitivity analyses. This is further supported by Figures 23–25, which display the
history trace plots, the Brooks–Gelman–Rubin plots, and the autocorrelation function plots, respectively,
for the estimated mean costs and QALYs for each diagnostic strategy, i.e. μ1j and μ2j. Figure 23 shows that
the mean of the MCMC samples remains approximately constant over the 50,000 iterations with only
random variation present, whereas Figure 24 shows that the two methods of calculating 80% CrIs (either
by pooling the three chains, deﬁned by the different sets of initial starting values, or by averaging over
them) give very similar results in terms of the estimated mean costs and QALYs. Finally, Figure 25 indicates
that the MCMC algorithm is efﬁciently sampling for the joint posterior distribution with relatively little
autocorrelation present, i.e. successive samples appear to be virtually random, thus providing further105
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TABLE 36 One-way sensitivity analyses exploring impact of 20% and 50% price reductions for POCT and PCR and
an alternative statistical model
Models Traditional Rapid molecular Near patient
Base case (model A)
Costs, average total
cost (95% CrI)
2327 (1989 to 2664) 1978 (1743 to 2165) 2159 (1828 to 2485)
QALYs 0.007588
(0.006334 to 0.008854)
0.007779
(0.006555 to 0.008983)
0.008035
(0.006772 to 0.009280)
PCR, cost reduction of 20%
Costs, average total cost,
£ (95% CrI)
2327 (1989 to 2667) 1967 (1733 to 2204) 2160 (1834 to 2488)
QALYs 0.007601
(0.006331 to 0.00889)
0.007779
(0.006575 to 0.008985)
0.008029
(0.006776 to 0.009286)
PCR, cost reduction of 50%
Costs, average total cost,
£ (95% CrI)
2327 (1989 to 2667) 1953 (1719 to 2189) 2160 (1834 to 2488)
QALYs 0.007601
(0.006331 to 0.00889)
0.007779
(0.006575 to 0.008985)
0.008029
(0.006776 to 0.009286)
POCT, cost reduction of 20%
Costs, average total cost,
£ (95% CrI)
2327 (1989 to 2667) 1977 (1743 to 2213) 2152 (1825 to 2480)
QALYs 0.007601
(0.006331 to 0.00889)
0.007779
(0.006575 to 0.008985)
0.008029
(0.006776 to 0.009286)
POCT, cost reduction of 50%
Costs, average total cost,
£ (95% CrI)
2327 (1989 to 2667) 1977 (1743 to 2213) 2139 (1813 to 2468)
QALYs 0.007601
(0.006331 to 0.00889)
0.007779
(0.006575 to 0.008985)
0.008029
(0.006776 to 0.009286)
Alternative model (model B)
Costs, average total cost,
£ (95% CrI)
2349 (2131 to 2589) 2007 (1819 to 2210) 2189 (1976 to 2424)
QALYs 0.008392
(0.007033 to 0.009750)
0.008896
(0.007452 to 0.010341)
0.009427
(0.007734 to 0.011120)
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106evidence that the 20,000/50,000 burn-in/sample length combination used in the base case is
sufﬁciently large.
Finally, Table 37 presents the results of an incremental cost per conﬁrmed case of inﬂuenza analysis. In this
analysis, potential cases of inﬂuenza identiﬁed by the three diagnostic strategies were conﬁrmed by serology
(see Chapter 5). It can be seen that on the basis of the diagnostic strategies the prevalence of inﬂuenza was
low but conﬁrmation with serology reduced this even further, with, in fact, no correctly identiﬁed cases being
identiﬁed under the POCT strategy, thus hampering the calculation of a cost-per-case estimate. It should be
noted that in Chapter 5, as the aim was to estimate diagnostic performance, all 1252 admissions were used
as each received all three diagnostic strategies but only those randomised to each strategy had their clinical
management based on the strategy to which they randomised, and hence the absolute prevalence was
considerably greater. Consequently, the cost per case for PCR was estimated as £164,570 (based on ﬁve
cases) and for traditional laboratory culture £315,696 (based on three cases), with traditional laboratory
culture being dominated by PCR.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 23 Markov chain Monte Carlo history plots for mean costs and QALYs.
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TABLE 37 Incremental cost per conﬁrmed (using serology) case of inﬂuenza analysis
Mean total
cost
(£)/patient
(95% CrI)
No. of
patients
with
eligible
serology
No. (%) of
patients testing
positive for
inﬂuenza with
index test
No. (%) of
serology
conﬁrmed
cases of
inﬂuenza
Cost per
conﬁrmed
case of inﬂuenza
Incremental cost
per additional
conﬁrmed case of
inﬂuenza detected
PCR
1978 (1743 to 2216) 416 30 (7.2) 5 (1.2) 164,570 –a
POCT
2159 (1828 to 2485) 416 8 (1.9) 0 (0) –b –a
Traditional
2327 (1989 to 2664) 407 9 (2.2) 3 (0.7) 315,696 Dominated
a Not estimated as traditional was dominated and POCT had zero conﬁrmed cases of inﬂuenza.
b Cannot be estimated as there are zero conﬁrmed cases of inﬂuenza in this group.
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There is relatively little difference in the cost distributions or QALYs gained by each of the three diagnostic
strategies. A strategy of using traditional laboratory culture led to an overall cost proﬁle that is the most
expensive but is also associated with the lowest gain in terms of QALYs, and is therefore dominated.
Although POCT has the highest gain in terms of QALYs, this gain over PCR is not offset by its higher cost
at current thresholds of willingness to pay.
The cost-per-case analysis is hampered by the relatively low prevalence (within each diagnostic strategy
group) of inﬂuenza as diagnosed by serology. Indeed, as discussed in Chapter 5 and Chapter 6, there are
issues with the manner in which serology was undertaken in 3WS, although sensitivity analyses in
Chapter 5 imply that as far possible this had little impact on the results, and in Chapter 6 the majority of
other studies identiﬁed in fact used PCR as the ‘gold standard’. Thus, if the 30 cases of inﬂuenza identiﬁed
in the PCR strategy group were in fact ‘true’ cases of inﬂuenza the cost per case detected would fall to
£26,042 for that strategy compared with £164,570 when serology was used as a ‘gold standard’. If PCR
was adopted as a ‘gold standard’ for the other two strategies, then ﬁve of the eight cases identiﬁed under
the POCT strategy would be conﬁrmed, rather than zero using serology, leading to a cost per case of
£179,628, and all 9 cases identiﬁed by traditional laboratory culture would be conﬁrmed leading to a cost
per case of £105,232. Both POCT and traditional laboratory culture would however be dominated by PCR.
From a purely cost-effectiveness point of view, PCR would appear to be the most cost-effective diagnostic
strategy, and, in fact, when viewed in light of the comparison with serology for inﬂuenza its superior
diagnostic ability would reinforce that. However, set against this is the fact that there are no statistically
signiﬁcant differences between the three groups in terms of the main clinical and process outcomes. The
fact that in the systematic review and meta-analysis, reported in Chapter 6, the majority of studies identiﬁed
used PCR as the ‘gold standard’ perhaps also underlines the fact PCR should be adopted as the de facto
standard, but that POCT would appear to offer no clear beneﬁt either in terms of cost or effectiveness.
As described in Chapter 2, the 3WS was designed/powered to be able to estimate the diagnostic accuracy
of the three strategies to within prespeciﬁed limits. In fact if the 3WS was designed with respect to clinical
end points, for example length of stay, then the study would have been considerably smaller. However,
with respect to cost-effectiveness or rather the differences in cost and effect, in terms of QALYs, a
retrospective power analysis was undertaken. Assuming that cost-effectiveness was established using a
willingness-to-pay threshold of £20,000 per QALY, the difference in mean costs and the difference in
mean QALYs required to achieve such a threshold, providing the other outcome was held constant as109
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110estimated in Table 35, the power of the study assuming a sample size of 1252 admissions was calculated.
In terms of QALYs, the actual sample size of 3WS ensured over 90% power to detect a QALY difference
that would ensure cost-effectiveness of one strategy over another. However, owing to the large variability
in costs, as can be seen from Tables 34 and 35 for both the observed and estimated cost components and
total costs, the 3WS as it was designed had < 50% power to be able to detect a minimum cost difference
between any two strategies, assuming the QALY difference was as estimated in Table 35. Whether 3WS
could have ever been undertaken to ensure an appropriate level of power typically required, given the level
of variability, is debatable, especially as its already relatively large sample size was driven by diagnostic
accuracy rather than clinical effectiveness.
A possible major limitation of the cost-effectiveness analysis reported here is the fact that it is a purely
trial-based analysis, with follow-up limited to 28 days post admission/randomisation, and that therefore
further readmissions, for example, are not captured and costed appropriately. It could be argued that if
any differences between the diagnostic strategies did exist then these would be expected to be seen
within 28 days, and, in fact, within the index admission, and that if such a scenario did exist the key
question would be whether any short-term beneﬁt, for example if reduced length of stay was offset by a
higher probability of readmission in the near future. However, as there are few differences, if any,
between any of clinical outcomes, and in fact the clinical management of patients overall, then this would
appear to be an unlikely scenario. A further limitation of the analyses presented is the level of missing
data, approximately 50% for QALYs and 8.5% for costs, necessitating the use of MCMC predictive-based
methods to impute missing values, conditional on the model and observed data. Although this approach is
recommended for cost-effectiveness analyses,234 under the assumption that data were missing at random,
a further sensitivity analysis using only complete cases was undertaken. The mean costs and QALYs for the
three diagnostic strategies were broadly similar to those obtained using MCMC methods, and resulted in
traditional laboratory culture remaining dominated, and POCT still having higher mean total cost than PCR,
but with a smaller associated gain in QALYs, resulting in an ICER of £4,080,242 per QALY, and the
probability of PCR being cost-effective rising to 93%. Finally, the perspective considered was that of the
NHS, and it could be argued that there could be wider societal costs borne by patients or their informal
carers, for example family members, which are not considered as part of the analyses presented here.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Prescribing outcomesl Antibiotic use was high in our cohort of patients. Altogether, 857 (73.1%) of all 1172 first admissions
received at least one antibiotic for a median of 77 hours.
l Overall, 77.5% (96/120) of all first admissions with RSV or influenza received at least one antibiotic for
a median of 77 hours – indicating that antibiotics are often prescribed for prolonged periods to patients
with viral infections, many of whom are unlikely to derive clinical benefit. We found no evidence for
an association between diagnostic group and time to final dose of antibiotics in patients infected
with RSV or influenza.
l Regardless of the high level of antibiotic use, we found no evidence for any association between
diagnostic group and three prescribing outcomes, specifically (1) time from admission to first
narrow-spectrum antibiotic; (2) time from admission to first oral antibiotic; and (3) time from admission
to cessation of antibiotics.Clinical outcomesl Altogether, 48.5% (608/1252) of admissions had a raised temperature (≥ 37.3 °C) on admission.
There was no evidence for any association between fever duration and diagnostic group for (1) all ﬁrst
admissions (regardless of any diagnosis) and (2) patients diagnosed with S. pneumoniae infection.
l Overall, 43.6% (546/1252) of all admissions and 37.2% (436/1172) of ﬁrst admissions received oxygen
therapy during the admission. Time-to-event analysis for the 436 ﬁrst admissions and for 40 out of
99 ﬁrst admissions who were diagnosed with S. pneumoniae and were prescribed oxygen found no
evidence of an association between diagnostic group and time to cessation of oxygen, in all patients,
and in those diagnosed with S. pneumoniae.
l CPAP dependence was infrequent in our patient cohort (1.2%, 14 out of 1172 ﬁrst admissions).
Time-to-event analysis by diagnostic group for all patients with a ﬁrst admission found no evidence of
an association between diagnostic group and time to cessation of CPAP.
l Admissions to ITU were infrequent in this cohort (0.4%, 5 of 1172 ﬁrst admissions). All ﬁve patients
who were admitted to the ITU were ventilated. The small numbers of patients requiring ITU admission
and ventilator support precluded comparison across the diagnostic groups for either end point.
l We found no evidence for any association between duration of hospital stay and diagnostic group.
Using a Cox proportional hazards model, we found that length of stay was comparable across the
following groups (1) all ﬁrst admissions who were discharged; (2) all ﬁrst admissions discharged who
were diagnosed with inﬂuenza; (3) all ﬁrst admissions discharged who were diagnosed with RSV; and
(4) all ﬁrst admissions discharged who were diagnosed with S. pneumoniae infection.
l Fifty deaths occurred within 28 days of admission. All 50 deaths occurred in ﬁrst time admissions. We
found no evidence to associate any diagnostic group with any increase or decrease in mortality for
(1) ‘all’ patients, or for ﬁrst admissions with a speciﬁc diagnosis of (2) inﬂuenza (n = 91); (3) RSV
(n = 29); and (4) S. pneumoniae infection (n = 99).
l Only 8.7% of ﬁrst admissions (102/1172) were given single-room accommodation at some time
during their admission. Hardly any (11.7%, 14/120) admissions with inﬂuenza or RSV received care in
single-room accommodation. Owing to the small number of patients with RSV or inﬂuenza who
were isolated, comparison across diagnostic groups was considered inappropriate. The majority of
admissions with inﬂuenza and RSV were nursed in open areas of the hospital where they posed some
degree of risk of nosocomial infection to vulnerable patients and staff. We found no evidence of any
association with ‘containment’ across groups for infections with RSV, inﬂuenza, and S. pneumoniae.111
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112l We found no statistically signiﬁcant differences between the three intervention groups in terms of
EQ-5D scores on admission and subsequently. However, repeated measures analyses using a linear
mixed-effects model revealed greater improvements in scores at both days 7 and 28 for the
‘near-patient’ and ‘rapid molecular’ groups compared with the ‘traditional’ group.
l A review of data for eight patients in the ‘near-patient’ group with a positive test for inﬂuenza showed
that none was eligible for treatment with a NI because they had illness duration of > 48 hours. None of
the patients who remained in hospital after the result became available were isolated. There was no
consistency in their subsequent treatment with antibiotics but the number of patients was too small to
draw meaningful conclusions.
l A review of data for 21 patients in the ‘near-patient’ group with a positive pneumococcal antigen test
showed that none of the patients had a step-down in antibiotics within 24 hours of the result. The
number eligible for treatment with a NI was small (4 out of 21), as assessed by duration of symptoms
at presentation. There was no change in use of single-room accommodation following the diagnosis.
l The median duration of symptoms before admission was 120 hours overall; few admissions were
eligible for treatment with an NI as assessed by duration of symptoms.Diagnostic accuracyl In comparison with PCR as the ‘gold standard’, the Quidel POCT had a sensitivity of 24.4% (95% CI
16% to 34.6%), a speciﬁcity of 99.7% (95% CI 99.2% to 99.9%), and PPVs and NPVs of 88.0%
(95% CI 68.8% to 97.5%) and 94.4% (95% CI 93.0% to 95.7%), respectively.
l In comparison with viral culture as the ‘gold standard’, the Quidel POCT had a sensitivity of 33.3%
(95% CI 14.6% to 57.0%), a speciﬁcity of 98.6% (95% CI 97.7% to 99.2%), and PPVs and NPVs of
29.2% (95% CI 12.6% to 51.1%) and 98.8% (95% CI 98.0% to 99.3%), respectively.
l In comparison with PCR as the ‘gold standard’, viral culture test had a sensitivity of 21.6%, (95% CI
13.5% to 31.6%), a speciﬁcity of 99.8% (95% CI 99.4% to 100%), and PPVs and NPVs of 90.5%
(95% CI 69.6% to 98.8%) and 94.2% (95% CI 92.7% to 95.4%), respectively.
l In comparison with viral culture as the ‘gold standard’, PCR had a sensitivity of 90.5%, (95% CI 69.6%
to 98.8%), a speciﬁcity of 94.2% (95% CI 92.7% to 95.4%), and PPVs and NPVs of 21.6% (95% CI
13.5% to 31.6%) and 99.8% (95% CI 99.4% to 100.0%), respectively.
l In comparison with serology as ‘gold standard’, PCR had the highest sensitivity (42.6%, 95% CI
28.3% to 57.8%). The sensitivity of viral culture and the Quidel POCT were low in comparison
(culture: 13.3%, 95% CI 5.05% to 26.8%; POCT: 14.9%, 95% CI 6.2% to 28.3%).
l In comparison with blood culture as the ‘gold standard’, the BinaxNOW pneumococcal POCT had
a sensitivity of 57.1%, (95% CI 18.4% to 90.1%), a speciﬁcity of 92.5% (95% CI 90.6% to
94.1%), and PPVs and NPVs of 5.5% (95% CI 1.5% to 13.4%) and 99.6% (95% CI 99.0% to
99.9%), respectively.
l In comparison with sputum culture as the ‘gold standard’, the BinaxNOW POCT had a sensitivity of
30.0% (95% CI 6.7% to 65.2%), a speciﬁcity of 92.0% (95% CI 88.1% to 95.0%), and PPVs and
NPVs of 12.5% (95% CI 2.7% to 32.4%) and 97.2% (95% CI 94.3% to 98.9%), respectively.
l In comparison with blood culture as the ‘gold standard’, sputum culture had a sensitivity of 100%
(95% CI 2.5% to 100%), a speciﬁcity of 97.2% (95% CI 94.3% to 98.9%), and PPVs and NPVs of
12.5% (95% CI 0.3% to 52.7%) and 100% (95% CI 98.5% to 100%), respectively.Systematic review and meta-analysis of point-of-care tests for
influenza A and Bl A bivariate mixed-effects meta-analysis model produced an overall estimate of sensitivity of 74%
(95% CI 67% to 80%) and speciﬁcity of 99% (95% CI 98% to 99%). There was a high level of
heterogeneity between the studies for both outcomes.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36l Exploration of between-study heterogeneity using bivariate mixed-effects meta-analysis showed that
for some subgroup combinations the pooled estimate of sensitivity was considerably lower than
that estimated for others:
¢ Age Sensitivity of POCTs in children and adolescents was 86% (95% CI 75% to 93%) but 67%
(95% CI 58% to 75%) in populations of ‘mixed’ age.
¢ ‘Gold standard’ Use of PCR as ‘gold standard’ produced an estimate of sensitivity of 51% (95% CI
38% to 64%), but the estimate of sensitivity was 86% (95% CI 77% to 92%) when virus culture
was used as ‘gold standard’.
¢ Target virus Sensitivity of POCTs for diagnosis of seasonal inﬂuenza was 84% (95% CI 74%
to 90%) but 52% (95% CI 39% to 65%) for diagnosis of infection caused by 2009 pandemic
H1N1 virus.
l Comparison of estimates of sensitivity of POCTs produced by different manufacturers indicated that they
were broadly similar – Directigen EZ: 85% (95% CI 71% to 93%); BinaxNOW: 69% (95% CI 58% to
79%); Quidel QuickVue: 66% (48–80%).
l Comparison of estimates of sensitivity of POCTs for the detection of influenza A and B suggested that kits
may detect influenza A more readily than influenza B – Influenza A: 81% (95% CI 64% to 91%);
Influenza B: 59% (95% CI 47% to 70%).
l Analyses of five studies152,182,198 that included both adults and children and compared the Quidel POCT
with PCR produced an overall pooled sensitivity of 34% (95% CI 14% to 62%) and specificity of 99%
(95% CI 97% to 100%), which are much more similar to those obtained in 3WS.Speed of usel Quidel QuickVUE Influenza A&B POCT The median interval from specimen collection to the provision
of a positive or negative result was 15 minutes (IQR 10–23 minutes).
l BinaxNOW S. pneumoniae test: The median interval from specimen collection to the provision of a
positive or negative result was 20 minutes (IQR 15–30 minutes).
l Semi-nested multiplex PCR for influenza A subtypes H1 and H3, influenza B, and RSV A and B
The median interval from specimen collection to the provision of a positive or negative result was
50.8 hours (IQR 44.3–92.6 hours).
l One-step, quadriplex/multiplex, real-time RT-PCR for influenza, and one-step and two-step RSV and
hMPV multiplex real-time PCR The median interval from specimen collection to the provision of a
positive or negative result was 29.2 hours (IQR 26–46.9 hours). By 30 hours, results were available for
61.3% of 220 specimens that were tested.
l Viral culture The median interval from specimen collection to the provision of a positive result for
patients with inﬂuenza A or B was 629.6 hours (IQR 262.5–846.7 hours), which is approximately nine
times greater than the median time to discharge or death (72.08 hours).
l Blood culture: Eighty of the 973 blood cultures grew an organism (including contaminants), and 10 of
the 80 grew S. pneumoniae with median time of 84.4 hours (IQR 70.7–137.8 hours); a provisional
report was issued a median of 36.8 hours (IQR 22.7–48.75 hours) after specimen collection. Seven
pneumococcal culture results were reported a median of 53.2 hours (IQR 30.4–58.1 hours) before the
patients’ discharge. Three others were reported a median of 139.2 hours (IQR 27.9–163.4 hours) after
death or discharge. Altogether 619 of 973 (63.6%) admissions were discharged or died before their
blood culture results were reported.
l Sputum culture The majority (941/1252: 75.2%, 95% CI 72.7% to 77.5%) of admissions with
acute cardiopulmonary conditions were unable to produce sputum for culture. In total, 76 of the
296 sputum samples that were of acceptable quality for culture grew an organism; 10 of the 76 grew
S. pneumoniae after a median interval from specimen collection of 71.4 hours (IQR 69.15–84.0 hours).
The median TtR antimicrobial sensitivity was 133 hours (IQR 123.1–148.1 hours) for 8 out of the
10 isolates of S. pneumoniae. Altogether 129 of 294 (43.9%) patients were discharged before their
sputum cultures were reported.113
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DISCUSSION
114Ease of usel A scoring system was devised to compare the EoU of the different tests, based on 11 criteria, each
assigned a score of 1, 2 or 3. A high score (maximum possible 33) reﬂects a high level of complexity,
requiring speciﬁc expertise, equipment and facilities, etc. A score of ‘11’ identiﬁed test procedures as
being straightforward and undemanding to use; scores of ‘12–22’ identiﬁed tests as being of
moderate complexity and requirements; and scores of ‘23 and higher’ as being ‘complex’.
l The QuickVUE Inﬂuenza A&B POCT and the BinaxNOW S. pneumoniae POCT were both rated as
straightforward and undemanding to use. Blood culture was rated moderately complex. All other tests
were rated as complex, with PCR testing being the most complex.Process outcomes and cost-effectivenessl There were no statistically signiﬁcant differences in the distributions of total costs, or QALYs gained, for
the three diagnostic strategy groups, whether based on observed costs and effects, i.e. complete case
analysis or after allowing for missing data using MCMC methods.
l Average total NHS costs for the three diagnostic groups are relatively similar to one another
(near-patient group, £2159; ‘molecular’ group £1978; ‘traditional’ group £2327), with the probability
that any one strategy is the least costly not exceeding 79%.
l The overall cost proﬁle of traditional laboratory culture is the most expensive and is associated with the
lowest gain in terms of QALYs.
l The ‘near-patient’ group has the highest gain in terms of QALYs but this gain in QALYs is not offset by
its higher cost at current thresholds of willingness to pay, with an ICER of £734,717.
l In terms of cost per correct case of inﬂuenza detected, and veriﬁed by serology, both PCR and POCTs
have lower estimates of cost than traditional laboratory culture but there is considerable uncertainty
surrounding each. Overall, the cost per case detected was lowest by PCR.Conclusionsl The Quidel and BinaxNOW POCTs for inﬂuenza A and B and S. pneumoniae are straightforward and
undemanding, and do not require laboratory facilities.
l The Quidel and BinaxNOW POCTs for inﬂuenza A and B and S. pneumoniae provide results within
minutes. Their speed of use provides opportunities to inﬂuence treatment decisions well within the
median time to hospital discharge or death.
l As judged by our trial, both the Quidel POCT for inﬂuenza A and B and traditional viral culture have
low sensitivity when compared with PCR or serology as gold standard.
l Meta-analysis of studies that included both adults and children and compared the Quidel POCT for
inﬂuenza A and B with PCR produced an overall pooled sensitivity of 34%, which is similar to the
observed sensitivity in our clinical trial.
l The PCR tests are considered complex, requiring specialised equipment, reagents and expertise. The
median TtR real-time PCR results for inﬂuenza A and B (≈29 hours) limits the usefulness of PCR in
guiding treatment with NIs.
l PCR has greater sensitivity than viral culture or the Quidel POCT for inﬂuenza A and B using serology
as gold standard.
l Conventional viral culture is demanding, requiring specialist equipment, reagents and skills. The time
taken to report positive culture in our study was several-fold longer than the median duration of
hospitalisation. Conventional viral culture results cannot provide results soon enough to inﬂuence
clinical management or control of infection.
l The BinaxNOW pneumococcal POCT has suboptimal sensitivity compared with blood culture. It cannot
be used to rule out pneumococcal pneumonia.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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of sputum culture is limited by the inability to produce sputum (75% were unable to produce sputum
in our study) and TtR positive cultures (median ≈71 hours for S. pneumoniae).
l Blood culture is moderately demanding in terms of equipment, test site and expertise. Blood cultures
are often negative when the BinaxNOW pneumococcal POCT is positive. The median times to issuing a
provisional report (≈37 hours) and identifying the organism as S. pneumoniae and its antimicrobial
sensitivity (≈84 hours) further limit the usefulness of blood culture in guiding antimicrobial therapy.
l All diagnostic tests that we evaluated had limitations, including suboptimal sensitivity, complexity, test
requirements, or long turnaround time.
l Few people in our study were admitted within 48 hours of illness onset. Virus shedding declines within
days of illness onset, so diagnostic tests for inﬂuenza must be done early after illness onset and have
very low limits of virus detection.
l Few patients were prescribed NIs. The reason(s) remains speculative but delay between illness onset
and admission, the knowledge base of junior doctors (i.e. unfamiliarity with viral diagnostic tests, NIs,
and inﬂuenza and its complications) and the sensitivity and/or speed of use of the diagnostic tests are
likely factors.
l Many patients in this study were febrile on admission suggesting infection as a likely cause. The
infrequent use of single-room accommodation across all admissions for acute cardiopulmonary illness
(8.9%) and patients with inﬂuenza or RSV (11.7%) risks nosocomial transmission of infection.
l We found no evidence that POCTs for inﬂuenza or S. pneumoniae infection, or PCR tests for inﬂuenza
A and B and RSV A and B, inﬂuenced prescribing of antibiotics or NIs by clinicians providing care, or
inﬂuenced clinical outcomes (including the duration of fever, requirement for supplemental oxygen,
oxygen delivery by CPAP, admissions to ITU, ventilator support, deaths, or duration of hospitalisation)
and use of single-room accommodation.
l The total costs and QALYs for each diagnostic strategy were similar, although incrementally PCR was
the most cost-effective strategy with a probability of being so of 78.3% at a willingness-to-pay
threshold of £20,000 per QALY. Results of sensitivity analyses indicated that this conclusion appeared
to be warranted. In terms of cost per correct case of inﬂuenza detected, traditional viral culture was
the most expensive diagnostic strategy, and PCR was the least expensive.
l Overall, there was a high level of consistency between the different facets of the study. The sensitivity
of the Quidel POCT for inﬂuenza A and B was low and was in keeping with the results of our
meta-analysis when adjustments were made for the ‘gold standard’, manufacturer and age distribution
of those tested. The BinaxNOW pneumococcal test had suboptimal sensitivity that was comparable to
sensitivities reported by others. Our study identiﬁed other factors that hamper patient care, notably
the interval between illness onset and hospital admission, the limited availability of sputum, the
infrequency of positive blood and sputum cultures, and the tardiness of individual tests (apart from
the POCTs). We found no evidence that diagnostic strategy inﬂuenced clinical outcomes, or total
costs and QALYs, ﬁndings that are consistent with the various limitations outlined above.
l Our studies do not support routine use of POCTs for either inﬂuenza or pneumococcal antigen for
adults hospitalised with acute cardiopulmonary conditions.
l Our ﬁndings support the replacement of traditional viral culture by PCR – for reasons of greater
sensitivity, speed, and cost-effectiveness.Strengths and limitations of the study
Strengthsl Compared with other studies identiﬁed in our meta-analysis, the 3WS is one of the largest undertaken
on POCTs – only Ruest et al.,152 Nougairede et al.183 and Lucas et al.142 had larger sample sizes, but
clinicians in our study were blind to the nature of tests for clinical management.
l Our study was powered to enable both clinical effectiveness (in terms of length of stay) and diagnostic
performance to be evaluated with sufﬁcient power/precision.115
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Nicholson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
DISCUSSION
116l In terms of conduct, the prospective nature of 3WS meant that clinicians were blind to the results of
the test strategies to which patients were not randomised. Thus, it enabled an unbiased assessment
of the impact of the strategy to which they were randomised on the clinical management of
eligible patients.
l The research nurses who carried out the study spent most of their time on the admissions unit of the
two hospitals providing care for acute medical admissions. They interacted directly with the teams of
doctors and nurses providing initial care for the patient volunteers, particularly when patients were
recruited, and also when the results of the POCTs were entered into the case notes and when the
patients were followed up. Positive blood culture results were telephoned to the team in the usual
manner, and results of microbiological tests were uploaded on to the pathology department results’
database when they became available. We ensured that bacteriology and virology results were made
available to clinicians as soon as possible. Members of the research team and hospital microbiologists
were available to answer any queries regarding the pathogens, the tests and the results of
individual tests.Limitationsl The accuracy study for inﬂuenza and pneumococcal infection was limited primarily by the lack of an
adequate reference standard. The serological tests for inﬂuenza were relatively unhelpful because the
period between collection of acute and convalescent sera either coincided with annual vaccination
against seasonal inﬂuenza or seasonal inﬂuenza activity. Blood culture is regarded as the gold standard
for pneumococcal infection but cultures are often negative. This impacted on the cost-per-case
analysis, and, as such, the ﬁndings of this analysis, should be considered exploratory.
l It could be argued that the length of follow-up in 3WS, i.e. 28 days, was insufﬁcient to detect any
potential longer term consequences of the diagnostic strategies on the longer-term management and
clinical outcomes of these patients. However, given the age distribution and clinical presentation of the
patients in 3WS, 28 days should have enabled an appropriate assessment and evaluation of the index
admission. The main driver in terms of patient outcome (and in fact of resource use, and therefore
cost) was length of stay, and only 53 (4.2%) patient admissions had a length of stay beyond 28 days.
The main outcome that further follow-up would have enabled to be assessed was readmission,
although as 3WS covered the two acute hospitals in Leicestershire, readmissions pertaining to the
index admission would have been identiﬁed, and, indeed, of the 1172 unique patients in 3WS, only
67 (5.7%) were readmitted (and rerandomised). Of course, there may have been other patients who
were also readmitted but who declined to take any further part in 3WS. It also further brings into
question the value of conducting further decision modelling over a longer time horizon, especially
given that such an exercise would be dependent upon adequate resource use and outcome beyond
that provided by 3WS.
l This study was purposefully carried out during autumn through spring, a period that was speciﬁcally
selected because it embraced seasonal inﬂuenza, RSV activity and the distinct winter seasonality when
invasive pneumococcal disease reaches a peak. Clearly, if the study found no beneﬁt from near-patient
or molecular diagnostic tests when these pathogens peak (as occurred in this study) then it would be
extremely unlikely to be of beneﬁt during the summer months when cases of invasive pneumococcal
disease are fewer, and those of RSV and inﬂuenza effectively absent. However, had the study shown a
clear advantage of either the NPTs, or rapid molecular diagnosis, then there would be uncertainty of
the value (both clinical effectiveness and cost-effectiveness) of such a programme when disease activity
is much lower.
l The molecular tests that were used in the study evolved during the study and were updated and
implemented by a technician with considerable experience in molecular diagnostic tests, with back-up
and training from the HPA. Although it could be argued that the time to report the PCR test results
could have been shortened with a longer period of embedding the new developments into clinical
practice, the complexity and turnaround times of PCR techniques actually decreased throughout the
study. It could be argued that the study should have awaited newer developments and reconﬁguration
of the laboratory, as it is now possible to produce same day results. Indeed, this was implementedNIHR Journals Library www.journalslibrary.nihr.ac.uk
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when specimens were delivered to the laboratory by 10 AM.
l Traditional virus culture technology was used as the comparator for PCR and the Quidel Inﬂuenza
A + B POCT in this study. More rapid cell culture diagnostic techniques have been developed. Their
cost, EoU, sensitivity and speciﬁcity, and clinical effectiveness and cost-effectiveness were not assessed
in this study.
l The cost-effectiveness analysis was subject to a variety of forms of uncertainty. There were a signiﬁcant
number of missing data, which, although allowed for in the MCMC-based analysis, was a concern.
However, a series of sensitivity analyses has established that the conclusions of this report are,
apparently, robust to both the inherent uncertainty in the data and methodological uncertainty
induced by potentially different analytical approaches.Implications for practicel Our ﬁndings do not support the routine use of POCTs for pneumococcal disease for all acute
admissions with acute cardiopulmonary conditions. Indeed, the information provided by the POCT for
pneumococcal antigen is considered, on the basis of our results, to be of questionable value even in
patients with CAP. We note that at least three investigators have used the results of pneumococcal
antigen test (exclusively) prospectively to target narrow-spectrum β-lactam treatment in CAP, with
inconsistent results.161,239,240 Guchev et al.239 did a non-randomised study that evaluated a targeted
approach to antibiotic therapy, based on the results of the pneumococcal urinary antigen test in young
military recruits patients with non-severe pneumonia. Twenty-two per cent of patients with CAP had
positive urinary tests and all were treated with oral amoxicillin. Treatment failures occurred in 5 out of
48 (10.4%) patients. Falguera et al.240 treated 177 patients empirically and then randomised them into
two arms when clinically stable; 89 patients were randomised to empiric treatment, and 88 to a target
treatment study. Of the 88, 25 had positive urinary antigen tests and 63 had negative tests, i.e. 28.4%
of the 88 patients were antigen positive. The 25 patients assigned to targeted treatment showed a
statistically signiﬁcant higher risk of clinical relapse compared with the remaining population (12%
vs. 3%, p = 0.04). However, Sordé et al.161 reduced the spectrum of antibiotics in 41 patients with
positive antigen tests; pneumonia was cured in all patients. Factors for further consideration include
the proportion of patients with CAP who have S. pneumoniae infection, the sensitivity and costs of the
test, failure rate of ‘optimised’ antimicrobial therapy (i.e. step-down treatment) and whether or not
the period of hospitalisation is cut by targeted treatment. The BTS, in its 2009 guidelines,17
recommended pneumococcal antigen testing in all patients with moderate- or high-severity CAP.
l Our ﬁndings do not support the routine use of POCTs for inﬂuenza A and B throughout winter for
adults presenting with acute cardiopulmonary conditions for three main reasons: ﬁrst, the suboptimal
sensitivity of these tests, particularly with the new lineage of H1N1 virus; second, evidence that the
majority of patients present with illness duration exceeding 48 hours; and third, the lack of evidence
that those identiﬁed as inﬂuenza positive had any change in treatment or isolation status. However, if
further research substantiates preliminary evidence of beneﬁt from NI treatment of patients who begin
treatment in hospital > 48 hours after illness onset, there may be a place for using POCTs for inﬂuenza
A and B in hospitals during periods of heightened inﬂuenza activity. The data accrued from our study
and the 2009 H1N1 pandemic should facilitate modelling to identify whether this strategy might be
cost-effective.
l Our ﬁndings on the sensitivity, turnaround times, cost, and EoU of conventional diagnostic virology
suggest that this technology should be replaced by PCR. The improved performance of PCR over
conventional cell culture technology – in terms of test turnaround times and sensitivity – make PCR the
preferred option, but it is acknowledged that PCR technology remains complex and demanding in
terms of expertise and resources. We believe that laboratories should invest in developing molecular
diagnostic processes and quality systems in preparation for forthcoming automation and molecular
‘black box technology’.117
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118l Our research identiﬁed as a sizeable problem the number of admissions with febrile acute respiratory
illness who are nursed in open wards. This practice is likely to result in nosocomial transmission of
inﬂuenza and other respiratory viruses that can be life-threatening in people with underlying heart and
lung disease. Consideration must be given to one or more of the following: improving the design of
future hospitals to include more single-room accommodation; managing single-room accommodation
better than now; ensuring that all patients with acute respiratory illness follow ‘respiratory etiquette’;
and use of quantitative PCR to support the ﬂow of patients between single-roomed accommodation
and an open-ward environment.
l We are concerned that current NICE guidance70 is based on the results of double-blind RCTs that
were designed and powered to establish whether NIs ameliorate symptomatic ILI. These studies
were not powered to establish whether NI treatment prevents or ameliorates complications of
inﬂuenza. Moreover, most RCTs were done in young otherwise healthy people who are not
representative of patients who are hospitalised with inﬂuenza complications, including acute
exacerbations of COPD, asthma, cystic ﬁbrosis or heart failure. Recent publications indicate that
(1) NIs may beneﬁt patients when given > 48 hours after illness onset and (2) NIs ameliorate/prevent
life-threatening complications. These observations were not generated by RCTs, rather by observational
studies and risk being ignored.Recommendations for research1. We recommend a systematic review and meta-analysis of published data relating to the treatment of
patients hospitalised with inﬂuenza with NIs to assess the evidence in support of treatment of patients
hospitalised with inﬂuenza complications at > 48 hours after symptom onset.
2. Most patients with inﬂuenza complications in this study were unable to receive antiviral therapy
because of delayed presentation. Patients risk serious outcomes from acute respiratory illness unless
they are seen sooner. Research is needed to determine how widespread delayed presentation is, why it
occurs and whether it can be reduced.
3. Because of the high speciﬁcity of POCTs for inﬂuenza, research is needed to determine their
effectiveness in GP surgeries (or a commercial pharmacy setting) for people at risk of serious
complications due to age and chronic ill-heath, during declared outbreaks.
4. There is good evidence that inﬂuenza virus exacerbates asthma, COPD, cystic ﬁbrosis and is causally
associated with CAP and acute bronchitis. Uncertainty about the role of NI treatment of patients
presenting with these complaints during inﬂuenza outbreaks will remain until trials have shown
clear beneﬁts.
5. Controversy about the beneﬁts of treatment with neuraminidase of patients presenting to hospital at
> 48 hours (up to 6 days) after onset of symptoms will remain until clinical trials have established clear
beneﬁts. We recommend that this research include assessments of quantitative viral shedding and
biomarkers to evaluate their role in guiding patient management.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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APPENDIX 1
140All patients will be followed up for 28 days.Rationale
The purpose of this study is to determine the diagnostic accuracy and clinical- and cost-effectiveness of
rapid molecular and near-patient diagnostic tests for inﬂuenza, RSV and S. pneumoniae infections in the
elderly, and subjects aged > 18 years with chronic cardiopulmonary conditions, or pneumonia/inﬂuenza
type symptoms, in comparison to traditional laboratory culture.Objectives and hypotheses
Research objectives1. To determine the diagnostic accuracy (sensitivity, speciﬁcity, positive and negative predictive values) of
rapid molecular and near-patient diagnostic tests for inﬂuenza, RSV and S. pneumoniae infections in
comparison to traditional laboratory culture.
2. To assess the potential beneﬁts of ease of use, and speed of rapid molecular and near-patient
diagnostic tests for inﬂuenza, RSV and S. pneumoniae infections, in comparison to traditional
laboratory culture.
3. To determine whether rapid molecular and near-patient diagnostic tests for inﬂuenza, RSV and
S. pneumoniae infections have any impact on the prescription of antimicrobials.
4. To determine whether rapid molecular and near-patient diagnostic tests for inﬂuenza, RSV and
S. pneumoniae infections allow more appropriate use of isolation facilities, in comparison to
traditional laboratory culture.
5. To compare the costs of performing rapid molecular and near-patient diagnostic tests for inﬂuenza,
RSV and S. pneumoniae infections, in comparison to traditional laboratory culture.
6. To assess cost-savings associated with earlier use of narrow-spectrum antimicrobial therapy (or
avoidance or discontinuation of antibiotics) in patients whose inﬂuenza, RSV and S. pneumoniae
infections are diagnosed more rapidly by rapid molecular and near-patient diagnostic tests, in
comparison to traditional laboratory culture.
7. To compare the outcome of patients whose inﬂuenza, RSV, and S. pneumoniae is diagnosed more
rapidly by rapid molecular and near-patient diagnostic tests, compared with those who are diagnosed
by traditional laboratory culture.
8. To assess the impact that rapid molecular and near-patient diagnostic tests have on the costs
associated with an inpatient stay and on costs post-discharge up to a maximum of 28 days
after admission.
9. To assess the impact that rapid molecular and near-patient diagnostic tests have on quality-of-life, as
measured by the EuroQol, and to use this information to estimate the quality adjusted life years
(QALYs) generated during the 28 days after admission.
10. To assess the cost-effectiveness of rapid molecular and near-patient diagnostic tests in comparison to
traditional laboratory culture. This will be done on the basis of both cost per case detected and cost
per QALY.Hypotheses1. The increased diagnostic accuracy of rapid molecular and near-patient tests over traditional laboratory
methods improves patient management through better use of antimicrobials and isolation facilities.
Rapid molecular and near-patient diagnostic tests for inﬂuenza, RSV and S. pneumoniae infections are
more cost-effective than traditional laboratory diagnostic tests.
2. Rapid molecular and near-patient diagnostic tests for inﬂuenza, RSV and S. pneumoniae infections
provide beneﬁts in terms of (a) ease of use, and (b) more rapid results, in comparison to traditional
laboratory culture.
3. Rapid molecular and near-patient diagnostic tests for inﬂuenza, RSV and S. pneumoniae infections
result in earlier use of ‘narrow-spectrum’ antimicrobial therapy; an earlier switch from intravenous toNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36oral therapy; and earlier discontinuation of antibiotics in patients infected with inﬂuenza and RSV – in
comparison to traditional laboratory culture.
4. Rapid detection of inﬂuenza and RSV by rapid molecular and near-patient diagnostic tests leads to the
appropriate isolation of patients, but only in hospitals/wards having an adequate provision of cubicles.
5. The costs of performing rapid molecular and near-patient diagnostic tests for inﬂuenza, RSV and
S. pneumoniae infections, differ signiﬁcantly from the cost of traditional laboratory culture.
6. The earlier use of narrow-spectrum antimicrobial therapy (or avoidance or discontinuation of
antibiotics) in patients whose inﬂuenza, RSV and S. pneumoniae infections are diagnosed more rapidly
by rapid molecular and near-patient diagnostic tests results in signiﬁcant cost-savings, in comparison
to traditional laboratory culture.
7. A streamlining of antimicrobial prescribing that may arise from more rapid diagnosis of inﬂuenza, RSV
and S. pneumoniae infections by rapid molecular and near-patient diagnostic tests does not adversely
affect patient outcome.
8. Any increase in costs incurred by rapid molecular and near-patient diagnostic tests, in comparison to
traditional laboratory culture, are more than offset by savings that arise from either rational
antimicrobial prescribing or earlier discharge from the hospital.
9. Rapid molecular and near-patient diagnostic tests result in an improvement in quality-of-life, as
measured by the EuroQol, which arises from streamlining of antibiotics and earlier discharge into
the community.
10. Rapid molecular and near-patient diagnostic tests are more cost-effective than traditional
laboratory culture.Observational objectives1. To estimate the admission rates for inﬂuenza, RSV, and S. pneumoniae in the target population.
2. To compare the clinical characteristics and economic burden of inﬂuenza A and B and RSV A and B.
3. To review the implications of rapid diagnosis on isolation policy, and review alternate approaches to
managing the infection control issues.Hypotheses (observational)1. The admission rates in the target population are higher for S. pneumoniae than inﬂuenza A and B.
The admission rates for inﬂuenza A and B are similar to those for RSV A and B.
2. The clinical characteristics and economic burden of inﬂuenza A and B and RSV A and B are similar.
3. Rapid near-patient and/or molecular diagnostic tests will reveal more cases of inﬂuenza and RSV who
require isolation than can be isolated. Alternate approaches to managing the infection control issues,
such as the use of inﬂuenza neuraminidase inhibitors, may be pertinent.Methodology
Study design
Prospective, randomised controlled trial of the impact of diagnostic testing [(i) Group 1: rapid near-patient
diagnostic tests (inﬂuenza and pneumococcus), (ii) Group 2: rapid molecular tests (inﬂuenza and RSV), plus
laboratory pneumococcal antigen testing, and (iii) Group 3: traditional ‘laboratory culture’ (inﬂuenza, RSV,
and S. pneumoniae)] in elderly (> 65 years) and ‘high-risk’ patients, who present to Medical Admissions’
Units in Leicestershire with an acute cardio-pulmonary illness.
All tests will eventually be done on all patients who enter the study, but patients in Groups 1 and 2 will
only be provided with rapid test results relating to their randomisation group.141
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APPENDIX 1
142Number of cases
Elderly Estimated 2752 cases of acute cardio-pulmonary illness in the elderly, of whom 664 will have
pneumonia (J12.9-J18.9). An estimated 556 will have unspeciﬁed acute lower respiratory tract infections
(J22.X). About one third of the pneumonia cases will have S. pneumoniae infections (n = 221); If ∼5% of
all acute cardiopulmonary admissions have laboratory-conﬁrmed RSV and ∼10% have inﬂuenza, then
∼138 cases of RSV and ∼275 cases of inﬂuenza would be studied in the elderly.
High-risk 18- to 64-year-old An estimated 83 cases of pneumonia, with one-third (n = 28) having
S. pneumoniae infections. An estimated 93 cases of unspeciﬁed acute lower respiratory tract infections
(J22.X); 29 acute unspeciﬁed URTI’s (J06.9); and 181 cases of COPD. If ∼5% of these admissions (n = 386)
have laboratory-conﬁrmed RSV and ∼10% have inﬂuenza, then ∼19 cases of RSV and ∼38 cases of
inﬂuenza would be studied in 18 to 64 year-old high-risk patients.Demographic datal Male or female elderly, aged > 65 years of age.
l Male or female ‘high-risk’ patients with underlying heart or lung conditions, aged 18 to 64 years of
age, or with pneumonia or inﬂuenza like symptoms.Inclusion criterial Able and willing to give written informed consent, OR a relative or carer is willing to give written
informed assent for patients who are too debilitated to provide consent.
l Age > 65 years, OR age > 18 years with underlying chronic heart or lung disease including asthma; OR
with pneumonia or inﬂuenza like symptoms.
l Have an acute exacerbation of chronic cardio-pulmonary illness of < 168 hours (7 days) duration, OR
an acute cardio-pulmonary illness or inﬂuenza-like illness of < 7 days’ duration, including:
¢ Pneumonia,
¢ Inﬂuenza/inﬂuenza-like illness,
¢ Exacerbations of chronic obstructive pulmonary disease (COPD),
¢ Bronchitis,
¢ Asthma,
¢ Congestive heart failure,
¢ Cardiac arrhythmia.
l Able and willing to adhere to the procedures stated in the protocol.
l Patients should have access to a telephone.Exclusion criterial Inclusion criteria not met.
l Angina/suspected myocardial infarction.
l Were recruited to this study within 28 days of the current admission.
l Could not be recruited into the study within a 16-hour period of initial assessment by a doctor on the
Medical Admissions Unit or a ward accepting acute medical admissions.
l Enrolment in a study of antimicrobial therapy for the illness for which the patient was admitted.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Randomisation:
Patients in each centre will be randomly allocated to one of three diagnostic policy groups:
l Group 1: near-patient tests (Quidel – inﬂuenza; BinaxNOW – pneumococcus).
l Group 2: rapid molecular tests (‘ﬂu & RSV plus laboratory testing of concentrated urine in the
BinaxNOW assay); and
l Group 3: traditional laboratory culture.
using computer generated randomisation codes stratiﬁed by centre.Assessment methods:
Clinical
Impact of test result on prescribing, speciﬁcally:
(a) Earlier use of ‘narrow-spectrum’ anti-microbial therapy.
(b) Earlier switch from intravenous to oral therapy.
(c) Avoidance or earlier discontinuation of antibiotics in patients infected with inﬂuenza and RSV, and
(d) Prescriptions of inﬂuenza neuraminidase inhibitors.
Will be assessed in rapid near-patient (Group 1) and molecular diagnostic groups (Group 2) and compared
with traditional laboratory culture (Group 3).
Clinical outcomes, speciﬁcally:
(a) Length of hospital stay.
(b) Fever duration.
(c) Supplemental oxygen dependence and CPAP dependence.
(d) Admissions to Intensive Care.
(e) Ventilatory support, and
(f) Deaths.
Will be assessed in rapid near-patient (Group 1) and molecular diagnostic groups (Group 2) in comparison
to traditional laboratory culture (Group 3).
Duration of hospitalisation, until discharge or death, will be obtained from the UHL Leicester hospital
activity analysis (i.e. from computerised records).
Fever duration The participants’ temperature charts will be monitored during the ﬁrst 10 days of
hospitalisation to identify when they ﬁrst became apyrexial (temperature < 37.2 °C), and remained so for a
period of at least 24 hours.
Supplemental oxygen dependence and CPAP dependence The participants will be monitored during the
ﬁrst 10 days of hospitalisation to identify when they no longer required oxygen for a period of at least
24 hours.
Admission to Intensive care, and Ventilatory support during the ﬁrst 10 days of hospitalisation will be
identiﬁed and documented by the study nurse in the Case Report Form.
Deaths that occur within a maximum of 28 days of hospitalisation will be identiﬁed and documented by
the study nurse in the Case Report Form.143
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144Quality of life, as measured by EuroQol, and quality adjusted life years generated during the 28 days after
admission will be assessed in rapid near-patient (Group 1) and molecular diagnostic groups (Group 2) in
comparison to traditional laboratory culture (Group 3).
Appropriate use of isolation facilities The time from admission to the Medical Admissions Unit to the time
of admission into a single room (isolation cubicle) will be assessed in patients with conﬁrmed inﬂuenza and
RSV in the rapid near-patient (Group 1) and molecular diagnostic groups (Group 2) in comparison to
traditional laboratory culture (Group 3).
The study nurse will document in the CRF where the patient was nursed throughout the ﬁrst 7 days
of admission.
Discharge diagnoses will be obtained from the UHL Leicester hospital activity analysis (i.e. from
computerised records).Financial
Costs of diagnostic tests, estimated by means of an ‘ingredients’ approach where all items needed to carry
out the test are recorded and costed using appropriate local and national data, e.g., items to collect and
transport specimens, media and reagents for the test, equipment to process specimens, technical support
costs, etc. Costs will be identiﬁed for the following technologies:
(a) Rapid near-patient test for inﬂuenza (Quidel).
(b) Rapid near-patient test for pneumococcus (BinaxNOW).
(c) Molecular (multiplex PCR) tests for inﬂuenza A and B and RSV A and B.
(d) Culture (blood and sputum) for S. pneumoniae.
(e) Gram staining of sputum samples.
(f) Cell culture for inﬂuenza A and B.
(g) Cell culture for RSV A and B.
(h) Other tests that may be applied, e.g. immunoﬂuorescence.
Care costs Cost of inpatient stay will be determined using information on length of stay and hospital costs
to determine a ‘hotel’ cost of routine care. To this will be added the cost of any additional clinical care
received such as diagnostic tests, drugs, etc. For patients who are discharged within 28 days of admission,
health care resource use in the period after discharge will be recorded using a simple questionnaire
administered in a telephone interview. These will be costed using appropriate national data, for example
NHS reference costs unit costs compiled by the PSSRU at the University of Kent.
Cost-savings, which accrue from (i) a reduction in the use of resources; and (ii) earlier discharge from the
hospital, will be identiﬁed by comparison of the costs for participants in Groups 1, and 2, compared with
traditional laboratory culture (Group 3).
Economic evaluation of near-patient and rapid molecular diagnostic tests will be assessed by two main
outcomes measures –
(a) cost per case detected.
(b) cost per QALY.Laboratory
Diagnostic accuracy, (sensitivity, speciﬁcity, positive and negative predictive values) and discrepant analysis
of near-patient and molecular diagnostic tests, will be estimated in comparison with traditional and other
(e.g., serology) laboratory tests.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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traditional laboratory culture will scored independently by three investigators in terms of whether they can
be done:
On site:
l Require special laboratory facilities.
l Require special equipment.
l The number of reagents required.
l The number of steps.
l Ease of disposal/decontamination of used equipment and reagents.
l Technical competency required of the operator.
l Training period required to reliably carry out the test, and any
l Health and safety implications.
Speed of tests will be assessed in terms of the median time from specimen collection to result:
l Appearing in the case notes.
l Appearing on Pathology Department results’ database (APEX), and/or
l Being phoned to the ward.
l Being acted upon – in comparison to traditional laboratory culture.Observational
Admission rates For inﬂuenza, RSV, and S. pneumoniae in the target population, taking into consideration
the total population estimates, stratiﬁed by age, and the proportion of all patients by ICD code that
were sampled.Study procedures
Baseline (day 1)
Written informed consent from patient or assent from relative or carer, Inclusion/exclusion criteria,
l Randomisation.
l Basic demography.
l Medical history/regular medication.
l Presenting symptoms and the interval between their onset and admission.
l Clinical ﬁndings.
l Quality of Life assessment.
l Investigations ordered by the admitting physicians.
l Specimen collection (blood for antibody tests, sputum, nasopharyngeal specimen, and urine) for trial
speciﬁc diagnostic tests.
l Rapid near-patient diagnostic testing for inﬂuenza & pneumococcus (Group 1) on, or adjacent to, the
ward. Results will be delivered to the nursing and/or medical team on the MAU and entered into
the case notes. The time when the results were entered into the case notes will be recorded in the
patient’s CRF together with the results.
l Processing and transport of specimens to the laboratory of diagnostic specimens (Groups 1, 2, 3).
l Antimicrobial and antiviral treatments prescribed/dose/frequency/route.
l Isolation status.
l Information relating to the above activities will be documented in the CRF.145
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146Follow-up (days 2, 3, 4, 5, 6, 7, 8, 9, 10, and 28)
The following will be performed, updated and recorded in the CRF:
l Time when diagnostic tests were made available to the nursing/medical staff.
l Treatment, speciﬁcally the relationship between the timing/availability of diagnostic tests and changes
in antimicrobial therapy. The nature of treatment given to all patients within 10 days of admission will
be documented.
l Isolation, speciﬁcally the relationship between the timing/availability of diagnostic tests and changes in
isolation status. The isolation status of all patients throughout the ﬁrst 7 days of admission will be
carefully documented.
l Admission to ITU and ventilatory support (within 28 days of hospitalisation).
l Pyrexia – the timepoint when the patient ﬁrst became apyrexial (< 37.2 °C), and remained so for
> 24 hours (during days 1–10).
l Oxygen requirement – the timepoint when supplemental oxygen was no longer required, and was not
given for > 24 hours (during days 1–10).
l Diagnostic studies (within 28 days of hospitalisation).
l Duration of hospitalisation.
l Deaths (within 28 days of hospitalisation).
l EuroQol (days 7 and 28).
l Discharge diagnosis.
l Convalescent serum sample (days 10–90).End points:
Clinical
Impact of test result on prescribing, speciﬁcally:
(a) Time, from admission to MAU, to ﬁrst administration of ‘narrow-spectrum’ antibiotics, for patients in
Groups 1, 2, and 3, who are prescribed antibiotics.
(b) Time, from admission to MAU, to ﬁrst administration of oral antibiotics, for patients in Groups 1, 2,
and 3, who are prescribed antibiotics.
(c) Time (hours) from admission to MAU to prescription of ‘no antibiotics’ (oral or intravenous)
administered to patients in Groups 1, 2, and 3, who have inﬂuenza or RSV, and
(d) Proportion of patients with inﬂuenza in Groups 1, 2, and 3 who are prescribed neuraminidase inhibitors.
Clinical outcomes, speciﬁcally:
(a) Length of hospital stay until discharge: First, for all patients in Groups 1, 2, and 3. Second, for all
patients with (i) inﬂuenza; (ii) RSV; and (iii) S. pneumoniae infection in Groups 1, 2, and 3.
(b) Fever duration (during the ﬁrst 10 days of hospitalisation) Time from admission (hours) until the
patient ﬁrst became apyrexial (temperature < 37.2 °C), and remained so for a period of at least
24 hours: First, in all patients in Groups 1, and 2 in comparison to Group 3. Second, in patients with
S. pneumoniae in Groups 1, and 2, in comparison to Group 3.
(c) Supplemental oxygen dependence and CPAP dependence (during the ﬁrst 10 days of hospitalisation)
Times from admission (hours) until the patient required (i) no supplemental oxygen, and (ii) no CPAP,
for a period of at least 24 hours: First, in all patients in Groups 1, and 2 in comparison to Group 3.
Second, in patients with S. pneumoniae in Groups 1, and 2, in comparison to Group 3.
(d) Admissions to Intensive Care (during the ﬁrst 10 days of hospitalisation) First, the proportion of
patients with S. pneumoniae infection in Groups 1, 2, and 3. Second, to better deﬁne the burden
of inﬂuenza and RSV, the proportion of all patients with (i) inﬂuenza, and (ii) RSV who require
ITU support.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36(e) Ventilatory support (during the ﬁrst 10 days of hospitalisation): First, the proportion of patients with
S. pneumoniae infection in Groups 1, 2, and 3. Second, to better deﬁne the burden of inﬂuenza and
RSV, the proportion of all patients with (i) inﬂuenza and (ii) RSV who require ventilatory support.
(f) Deaths (within 28 days of hospitalisation): First, the proportion of patients with S. pneumoniae infection
in Groups 1, 2, and 3. Second, to better deﬁne the burden of inﬂuenza and RSV, the proportion of all
patients with (i) inﬂuenza, and (ii) RSV, who die.
Quality of life, as measured by EuroQol, and quality adjusted life years generated during the 28 days after
admission, will be assessed:
(a) In all patients in Groups 1, and 2 in comparison to Group 3.
(b) Second, in patients in patients with (i) inﬂuenza, (ii) RSV, and (iii) S. pneumoniae in Groups 1, and 2, in
comparison to Group 3.
Use of isolation facilities:
(a) The time from admission to the MAU to the time of admission to a single room (isolation cubicle) will
be compared for patients with conﬁrmed inﬂuenza or RSV in Groups 1, 2, and 3.
(b) The proportion of patients with inﬂuenza or RSV in Groups 1, 2, and 3 who are isolated at any stage
during the ﬁrst 120 hours of the admission.
(c) The proportion of patients with S. pneumoniae infection in Groups 1, 2, and 3 who are inappropriately
isolated for > 12 hours.Financial
Costs of diagnostic tests Costs will be identiﬁed for:
(a) Rapid near-patient test for inﬂuenza (Quidel).
(b) Rapid near-patient test for pneumococcus (BinaxNOW).
(c) Molecular (multiplex PCR) tests for inﬂuenza A and B and RSV A and B.
(d) Culture (blood and sputum) for S. pneumoniae.
(e) Gram staining of sputum samples.
(f) Cell culture for inﬂuenza A and B.
(g) Cell culture for RSV A and B.
(h) Other tests that may be applied, e.g., immunoﬂuorescence.
Care costs of inpatient stay (+95% CI) will be determined for:
(a) All patients in Groups 1, 2, and 3.
(b) All patients (in all groups) with (i) inﬂuenza, (ii) RSV, and (iii) S. pneumoniae infection, and,
(c) Patients with (i) inﬂuenza, (ii) RSV, and (iii) S. pneumoniae infection in Groups 1, 2, and 3.
For patients who are discharged within 28 days of admission, health care resource use in the period after
discharge will be recorded using a simple questionnaire administered in a telephone interview or by post.
Cost-savings that accrue from earlier use of narrow-spectrum antibiotics, oral therapy, or avoidance, or
discontinuation of antibiotics will be assessed in:
(a) All patients in Groups 1, 2, and 3.
(b) Patients with (i) inﬂuenza, (ii) RSV, and (iii) S. pneumoniae infection in Groups 1, 2, and 3.147
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148Economic evaluation of near-patient and rapid molecular diagnostic tests will be assessed by two main
outcomes measures:
(a) Cost per case detected.
(b) Cost per QALY.Laboratory
Diagnostic accuracy:
(a) Sensitivity.
(b) Speciﬁcity.
(c) Positive predictive value.
(d) Negative predictive value.
and discrepant analysis of near-patient and molecular diagnostic tests, will be estimated in comparison
with traditional and other (e.g. serology) laboratory tests.
Ease of use of rapid near-patient and molecular tests: molecular, near-patient, and traditional laboratory
culture diagnostic tests will scored independently for ease of use by three investigators.
Speed of tests will be assessed in terms of the median time from specimen collection to result:
(a) Appearing in the case-notes.
(b) Appearing on Pathology Department results’ database (APEX).
(c) Being phoned to the ward.
(d) Being acted upon – in comparison to traditional laboratory culture.
Speed of tests will be determined for –
(a) All patients in Groups 1, 2, and 3.
(b) Patients with inﬂuenza; RSV, and S. pneumoniae infection in Groups 1, 2, and 3.Observational
Admission rates, for:
(a) Inﬂuenza.
(b) RSV, and
(c) S. pneumoniae.Analysis
Sample size
The sample size is based on the admissions during 2002–03 and 2003–04 (September 1 – April 30) for
elderly (> 65 years old) patients with acute cardio-pulmonary conditions, excluding angina and myocardial
infarction. There were 2762 acute cardio-pulmonary admissions during September 1 – April 30 2002–03,
and 2852 during 2003–04, i.e. an average of 11.57 admissions (> 65 years) per day.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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number of eligible patients is estimated at 666 × 11.57 = 7705.6. We plan to recruit 5 days per week,
which reduces the eligible number of patients to (5 ÷ 7) × 7705.6 = 5504. We understand that two-thirds
are admitted during the period 09:00–21:00h, which reduces the evaluable pool to 3669. We estimate
that three-quarters of eligible subjects will participate, i.e. we expect to recruit 2752 elderly (> 65 years old)
patients with acute cardio-pulmonary conditions. Of these, 664 are expected to have ICD codes for
pneumonia; 556 are expected to have unspeciﬁed acute lower respiratory tract infections; 683 are
expected to have exacerbations of chronic obstructive pulmonary disease; and 735 are expected to be
admitted with heart failure.
We estimated the number of admissions in ‘high-risk’ 18–64 year-olds by extrapolation using (i) national
cardio-pulmonary hospital admission data for patients aged 15–59 years, 60–74 years, and 75 years and
older and (ii) the number of cardio-pulmonary admissions aged > 65 years in Leicester.
We assumed that half of the patients admitted with pneumonia, unspeciﬁed lower respiratory tract
infections, and exacerbations of COPD have underlying high-risk conditions. We expect to recruit 83
18–64-year old patients with pneumonia, 93 with unspeciﬁed lower respiratory tract infections, and
181 with COPD. These have not been included in the following estimates:
On the basis of historical data we expect that one-third of elderly patients with pneumonia have
pneumococcal disease (i.e. 221) but expect the number identiﬁed by the pneumococcal antigen test to
be higher. Of the 221, ∼73 should be randomly allocated to the rapid near-patient test (BinaxNOW)
(Group 1); the remainder will be randomised to the group tested by traditional methods (Groups 2 & 3).
However, as identical sample sets will be taken from each individual, diagnostic accuracy will be assessed
in a minimum of 221 subjects.
We expect that 10% of the 2752 (elderly) patients will have inﬂuenza A or B. Of the 275, one third (∼91)
will be allocated to Groups 1, 2, and 3. Identical sample sets will be taken from each individual, so the
diagnostic accuracy of the tests will be assessed in all 275 subjects.
We expect that 5% of the 2752 (elderly) patients will have RSV A or B. Of the 137, one third (∼45) will be
allocated to the rapid molecular group (Group 2); the remainder (∼90) will be allocated to the groups
tested by traditional methods (Group 1 & 3). Identical sample sets will be taken from each individual, so
the diagnostic accuracy of the tests will be assessed in all 137 subjects.
While the numbers of patients with inﬂuenza and RSV who are allocated to the ‘rapid’ near-patient or
molecular tests are comparatively small, the impact of a ‘viral’ infection (RSV or inﬂuenza) infection on
patient isolation, antimicrobial prescribing, and clinical outcomes may be compared using larger combined
groups – i.e., rapid inﬂuenza & RSV (i.e. Quickview +molecular tests) n = (91 + 91 + 45) = 227 traditional
inﬂuenza & RSV n = (91 + 45 + 45) = 182.Statistical power:
This has been estimated for one laboratory and two clinical end points for the elderly population only.Diagnostic accuracy
Assuming that the average sensitivity/speciﬁcity of the tests is 80%[90%] then allowing for a 20%
dropout rate, a sample of 2752 (2000) i.e. only 2 winters) elderly (> 65 years) patients randomised into the
trial would enable the sensitivity/speciﬁcity to be estimated to within, i.e. 2SE, 7.6% (8.9%) [5.7% (6.7%)]
for a disease prevalence of 10%, and 5.4% (6.3%) [4.0% (4.7%)] for a disease prevalence of 5%.149
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150Length of stay
2752 patients would enable a Minimum Clinically Signiﬁcant Difference (MCSD) [between diagnostic
policies] of 1 day in the mean length of stay (assuming SD = 6 days) to be detected at the 5% signiﬁcance
level with over 80% power, assuming a 20% dropout rate and adjusting for the fact that there
are 3 groups.
Appropriate isolation levels: 2752 patients would also enable a Minimum Clinically Signiﬁcant Difference
(MCSD) [between diagnostic policies] of an improvement in appropriate use of isolation facilities from 5%
to 15% to be detected at the 1% signiﬁcance level with over 95% power, assuming a 20% dropout rate
and adjusting for the fact that there are 3 groups.Statistical methods:
All analyses for both process and clinical outcomes will be based on Intention to Treat (ITT) analyses.Impact of test result on prescribing
The time to prescription of ‘narrow spectrum’, ‘oral antibiotics’ or ‘no antibiotics’ between the three
groups will be assessed using survival analysis techniques, whilst the use of neuraminidase inhibitors in
those with inﬂuenza will be assessed using chi-squared tests, together with 95% CIs. Further analyses to
allow for potential differences in patient demographics and baseline clinical characteristics between the
three diagnostic test groups, and not allowed by stratiﬁcation, will make use of Cox proportional hazards
regression modelling in the case of time to appropriate prescribing and logistic regression techniques in
the case of neuraminidase inhibitors.Length of hospital stay
Length of hospital stay in the three diagnostic groups will initially be compared using non-parametric
methods. Further analyses to allow for potential differences in patient demographics and baseline clinical
characteristics between the three diagnostic test groups, and not allowed by stratiﬁcation, will make use of
generalised linear models in order to accommodate any skewness in the data.Mortality rates
Mortality rates between the three diagnostic testing groups will be compared by means of a Log-Rank Test
and Kaplan–Meier survival curves. Adjustment for potential differences in patient demographics and
baseline clinical characteristics between the three diagnostic test groups, and not allowed by stratiﬁcation,
will make use of Cox proportional hazards regression methods.Diagnostic accuracy
Sensitivity, speciﬁcity, positive and negative predictive values of molecular and near-patient diagnostic tests
in comparison to traditional laboratory methods will be calculated together with 95% CIs. Heterogeneity
in the sensitivity and speciﬁcity with respect to patient demographics and baseline clinical characteristics
will be explored as secondary analyses using patient deﬁned sub-groups.Admission to Intensive Care
The proportions of patients in the three groups who are admitted to intensive care within the ﬁrst 10 days
of admission will be compared using chi-squared tests, together with 95% CIs. Further analyses to allow
for potential differences in patient demographics and baseline clinical characteristics between the three
diagnostic test groups, and not allowed by stratiﬁcation, will make use of logistic regression techniques.Ventilatory support
The proportions of patients in the three groups who receive ventilatory support within the ﬁrst 10 days of
admission will be compared using chi-squared tests, together with 95% CIs. Further analyses to allow for
potential differences in patient demographics and baseline clinical characteristics between the three
diagnostic test groups, and not allowed by stratiﬁcation, will make use of logistic regression techniques.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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In patients with conﬁrmed inﬂuenza or RSV the time taken from admission to the MAU to admission to a
single room (isolation cubicle) will be compared between the three diagnostic groups by means of a
Log-Rank Test and Kaplan–Meier survival curves. Adjustment for potential differences in patient
demographics and baseline clinical characteristics between the three diagnostic test groups, and not
allowed by stratiﬁcation, will make use of Cox proportional hazards regression methods.Quality of life (EQ-5D)
Quality of life in the three diagnostic groups will initially be compared using non-parametric methods.
Further analyses to allow for potential differences in patient demographics and baseline clinical
characteristics between the three diagnostic test groups, and not allowed by stratiﬁcation, will make use of
generalised linear models in order to accommodate any skewness in the data.Speed of tests
Time taken to receive test results in the three diagnostic groups will initially be compared using
non-parametric methods. Further analyses to allow for potential differences in patient demographics and
baseline clinical characteristics between the three diagnostic test groups, and not allowed by stratiﬁcation,
will make use of generalised linear models in order to accommodate any skewness in the data.Cost data
Cost data will be analysed using parametric and non-parametric statistical methods which explicitly allow
for the censoring of (indirect & total) costs at 28 days, i.e. for those patients who are not discharged from
hospital within 28 days and thus enable an unbiased assessment of potential cost differences between the
three diagnostic groups to be made. Estimation of the cost distribution over longer timescales will make
use of extrapolation techniques using time of discharge obtained from hospital information systems.151
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152Trial plan and schedule of assessmentAssessments
Study day
Admission
(day 1)
Days 2, 3, 4, 7
(±1), & 10 (±1)
Day 28
(±2)
Pre-study assessment by admitting medical team ✓
Note time of admission (CRF) ✓
Inclusion/Exclusion criteria check (CRF) ✓
Written informed Consent (or Assent) (CRF) ✓ ✓ (Consent upon recovery)
Demography/immunisation status check (CRF) ✓
Medical history/concomitant medications check (CRF) ✓
Symptom assessment (CRF) ✓
Clinical ﬁndings, including body weight and temperature (CRF).
Establish when patient ﬁrst becomes apyrexial (≤ 37.2 °C),
requires supplemental O2, and remains so for > 24 hours (CRF)
✓ ✓ (temperature, O2)
EuroQol. Quality of Life assessment (CRF) ✓ ✓ (day 7) ✓
Diagnostic studies ordered by the admitting medical team (CRF) ✓ ✓
Collection of trial speciﬁc diagnostic specimens (CRF):
Nasopharyngeal (Quidel & virus culture) ✓
Sputum (Gram stain & culture) ✓
Urine (BinaxNOW) ✓
Blood (Blood cultures, serum antibodies) ✓ ✓ (antibody, day 10)
Record time when diagnostic test results were made available
to the ward nurses, and/or admitting team (CRF)
✓ ✓
Record antimicrobials & antivirals (identity, route, dose, time
of administration) prescribed by admitting medical team (CRF)
✓
Note the time of any changes in antimicrobials & antivirals
(identity, route, dose, time of administration) prescribed by
admitting medical team (CRF)
✓
Bed location, i.e., record bay or a single room (CRF) ✓
Note time of any subsequent change in isolation status (CRF) ✓
ITU and ventilatory support: Document whether admitted or
required ventilatory support (CRF)
✓ ✓
Date of hospital discharge/Death within 28 days of
admission (CRF)
✓ ✓
Discharge diagnosis (CRF) ✓ ✓
Note: Patients WILL NOT be rerecruited if readmission occurs during the 28-day follow-up.
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nasopharyngeal specimens
The collection of nasopharyngeal specimens for this study followed guidance from the National InﬂuenzaResearch Laboratory, HPA, Colindale, London, and the manufacturer of the POCT. A good specimen for
the detection of inﬂuenza or RSV must contain a substantial number of respiratory epithelial cells, which are
mainly obtained from the nasal swab. A throat swab alone will contain mainly squamous epithelial cells in
which inﬂuenza does not replicate. In brief, collection of routine nasopharyngeal swabs was as follows:
l a single swab with cotton wool bud is inserted in one nostril and rubbed against and above the
nasal turbinates
l a second swab is used to abrade the tonsils and pharynx
l place both swabs in the same bijou bottle of virus transport medium
l break off the swab sticks (scissors may be used)
l screw lid tightly on to the bottle.161
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162Trial-specific procedures were as follows.‘Near-patient diagnostic group’ (QuickVue Inﬂuenza A + B test)
and Deferred QuickVue testl The sterile sponge tipped swab provided in the QuickVue Inﬂuenza A + B test was inserted into the
nostril that presented the most secretions under visual inspection, according to manufacturer’s
instructions.
l Using gentle rotation, the swab was gently pushed until resistance was met at the level of the
turbinates (< 1 inch into the nostril). The swab was rotated a few times against the nasal wall.
l Specimens collected from patients in the ‘near-patient diagnostic group’ were tested immediately for
the presence of Inﬂuenza A and B according to the manufacturer’s instructions.
l An identical specimen was collected from patients randomised to the molecular diagnostic group and
conventional virus culture group. These specimens were collected into virus transport medium and
were refrigerated at 4 °C until they were transported at the earliest opportunity by the hospital
transport system to the microbiology laboratory. They were processed upon receipt during normal
working hours by the QuickVue A + B test.Deferred QuickVUE inﬂuenza A + B test, prompt and deferred
molecular testing, and conventional virus culturel We collected nasal and pharyngeal swabs for molecular and conventional virus culture studies using
the opposite nostril to that used for the ‘near-patient’ and ‘deferred’ QuickVue Inﬂuenza A + B tests.
l Using gentle rotation, a dry swab with cotton wool bud was inserted into the nostril and rubbed
against and above the nasal turbinates.
l A second swab is used to abrade the tonsils and pharynx.
l The swab tips from both swabs were placed into a single bijou bottle of virus transport medium,
agitated and then cut off, or broken off, into the medium.
l These specimens were refrigerated at 4 °C until they were transported to the Microbiology Laboratory
at the earliest opportunity by the hospital transport system.
l Specimens from subjects randomised to the ‘prompt’ molecular diagnostic group were processed upon
receipt during normal working hours. Specimens for ‘deferred’ molecular diagnostic testing from
subjects who were randomised to the ‘conventional’ diagnostic group were stored at ‒20 °C
l Specimens from subjects randomised to the ‘prompt’ and ‘conventional’ diagnostic groups were
processed upon receipt during normal working hours by conventional virus isolation tests.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 38 Component EoU scores for the QuickVUE Inﬂuenza A&B POCT for the diagnosis of inﬂuenza
Categories Criteria for categorisation EoU score
Test site Is a POCT 1
Intermediate between descriptions listed for scores of 1 and 3
Requires purpose-built accommodation, ventilation systems and
dedicated space
Equipment No specialised equipment required and is readily transferred
between hospital facilities
1
Intermediate between descriptions listed for scores of 1 and 3
Specialised equipment is essential and non-portable
Materials and reagents Are stable, pre-packaged and/or pre-measured, and require no
special handling steps or storage
1
Intermediate between descriptions listed for scores of 1 and 3
May be labile, requiring special storage or require special handling
steps; their preparation requires manual steps, e.g. volumetric
measurement
Operational steps Either automatically executed or easily controlled 1
Intermediate between descriptions listed for scores of 1 and 3
Require close monitoring and control, and may require special
preparation, precise temperature control or timing, accurate
pipetting or extensive calculations
Training, experience
and knowledge
Require minimal scientiﬁc and technical knowledge and experience;
and knowledge to perform test can be obtained through on-job
instruction (commensurate with AFC Band 4, or less)
1
Intermediate between descriptions listed for scores of 1 and 3
Specialised scientiﬁc and technical knowledge essential and
substantial experience required (commensurate with AFC Band 7,
or higher)
Calibration and quality control Calibration is either automatic or not required; quality control
materials are included, or readily available, and are stable
1
Intermediate between descriptions listed for scores of 1 and 3
Calibration and quality control materials, if available, may be labile
or unavailable; or technical expertise is required for calibration
Interpretation and judgement Minimal interpretation and judgement are required, and problems
require limited interpretation, judgement and decision-making
1
Intermediate between descriptions listed for scores of 1 and 3
Extensive interpretation and judgement are required; resolution
of problems requires extensive interpretation, judgement and
decision-making
continued
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TABLE 38 Component EoU scores for the QuickVUE Inﬂuenza A&B POCT for the diagnosis of inﬂuenza
(continued )
Categories Criteria for categorisation EoU score
Test system troubleshooting
and equipment maintenance
Test system troubleshooting is automatic or self-correcting or
clearly described or requires minimal judgement
1
Intermediate between descriptions listed for scores of 1 and 3
Test system troubleshooting is not automatic or self-correcting and
requires decision-making to resolve most problems; or equipment
maintenance requires special knowledge, skills and abilities
Time to reporting of results Results are reported within 4 hours of collection of almost all
specimens
1
Intermediate between descriptions listed for scores of 1 and 3
Median time to reporting of results exceeds the median duration of
hospitalisations/time to death
Health and safety The test is completed using low levels of personal protection,
i.e. gloves
1
Intermediate between descriptions listed for scores of 1 and 3
One or more operational steps requires bio-safety level Category 3,
or higher
Storage and disposal of waste
test materials and reagents
Waste materials and reagents are stored and disposed using
medium duty ‘Clinical waste’ plastic bags and ‘Sharps’ containers,
or a sluice
1
Intermediate between descriptions listed for scores of 1 and 3
Waste materials or reagents include hazardous materials that
require special attention
Total EoU score 11
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APPENDIX 7
250TABLE 39 Component EoU scores for the BinaxNOW S. pneumoniae test POCTCategories Criteria for categorisation EoU score
Test site Is a POCT 1
Intermediate between descriptions listed for scores of 1 and 3
Requires purpose-built accommodation, ventilation systems and
dedicated space
Equipment No specialised equipment required and is readily transferred
between hospital facilities
1
Intermediate between descriptions listed for scores of 1 and 3
Specialised equipment is essential and non-portable
Materials and reagents Are stable, pre-packaged and/or pre-measured, and require no
special handling steps or storage
1
Intermediate between descriptions listed for scores of 1 and 3
May be labile, requiring special storage or require special handling
steps; their preparation requires manual steps, e.g. volumetric
measurement
Operational steps Either automatically executed or easily controlled 1
Intermediate between descriptions listed for scores of 1 and 3
Require close monitoring and control, and may require special
preparation, precise temperature control or timing, accurate
pipetting or extensive calculations
Training, experience and
knowledge
Require minimal scientiﬁc and technical knowledge and experience;
and knowledge to perform test can be obtained through on-job
instruction (commensurate with AFC Band 4, or less)
1
Intermediate between descriptions listed for scores of 1 and 3
Specialised scientiﬁc and technical knowledge essential and
substantial experience required (commensurate with AFC Band 7,
or higher)
Calibration and quality control Calibration is either automatic or not required; quality control
materials are included, or readily available, and are stable
1
Intermediate between descriptions listed for scores of 1 and 3
Calibration and quality control materials, if available, may be labile
or unavailable; or technical expertise is required for calibration
Interpretation and judgement Minimal interpretation and judgement are required, and problems
require limited interpretation, judgement and decision-making
1
Intermediate between descriptions listed for scores of 1 and 3
Extensive interpretation and judgement are required; resolution
of problems requires extensive interpretation, judgement and
decision-making
Test system troubleshooting
and equipment maintenance
Test system troubleshooting is automatic or self-correcting or
clearly described or requires minimal judgement
1
Intermediate between descriptions listed for scores of 1 and 3
Test system troubleshooting is not automatic or self-correcting and
requires decision-making to resolve most problems; or equipment
maintenance requires special knowledge, skills and abilities
continued
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ABLE 39 Component EoU scores for the BinaxNOW S. pneumoniae test POCT (continued )
Categories Criteria for categorisation EoU score
Time to reporting of results Results are reported within 4 hours of collection of almost all
specimens
1
Intermediate between descriptions listed for scores of 1 and 3
Median time to reporting of results exceeds the median duration of
hospitalisations/time to death
Health and safety The test is completed using low levels of personal protection,
i.e. gloves
1
Intermediate between descriptions listed for scores of 1 and 3
One or more operational steps requires bio-safety level Category 3,
or higher
Storage and disposal of waste
test materials and reagents
Waste materials and reagents are stored and disposed using
medium duty ‘Clinical waste’ plastic bags and ‘Sharps’ containers,
or a sluice
1
Intermediate between descriptions listed for scores of 1 and 3
Waste materials or reagents include hazardous materials that
require special attention
Total EoU score 11
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TABLE 40 Component EoU scores for semi-nested multiplex PCR for inﬂuenza A subtypes H1 and H3, inﬂuenza B,
and RSV A and B
Categories Criteria for categorisation EoU score
Test site Is a POCT
Intermediate between descriptions listed for scores of 1 and 3 2
Requires purpose-built accommodation, ventilation systems and
dedicated space
Equipment No specialised equipment required and is readily transferred
between hospital facilities
Intermediate between descriptions listed for scores of 1 and 3
Specialised equipment is essential and non-portable 3
Materials and reagents Are stable, pre-packaged and/or pre-measured, and require no
special handling steps or storage
Intermediate between descriptions listed for scores of 1 and 3 2
May be labile, requiring special storage or require special handling
steps; their preparation requires manual steps, e.g. volumetric
measurement
Operational steps Either automatically executed or easily controlled
Intermediate between descriptions listed for scores of 1 and 3
Require close monitoring and control, and may require special
preparation, precise temperature control or timing, accurate
pipetting or extensive calculations
3
Training, experience and
knowledge
Require minimal scientiﬁc and technical knowledge and experience;
and knowledge to perform test can be obtained through on-job
instruction (commensurate with AFC Band 4, or less)
Intermediate between descriptions listed for scores of 1 and 3
Specialised scientiﬁc and technical knowledge essential and
substantial experience required (commensurate with AFC Band 7,
or higher)
3
Calibration and quality control Calibration is either automatic or not required; quality control
materials are included, or readily available, and are stable
Intermediate between descriptions listed for scores of 1 and 3
Calibration and quality control materials, if available, may be labile
or unavailable; or technical expertise is required for calibration
3
Interpretation and judgement Minimal interpretation and judgement are required, and problems
require limited interpretation, judgement and decision-making
Intermediate between descriptions listed for scores of 1 and 3
Extensive interpretation and judgement are required; resolution
of problems requires extensive interpretation, judgement and
decision-making
3
continued
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ABLE 40 Component EoU scores for semi-nested multiplex PCR for inﬂuenza A subtypes H1 and H3, inﬂuenza B,
nd RSV A and B (continued )
Categories Criteria for categorisation EoU score
Test system troubleshooting
and equipment maintenance
Test system troubleshooting is automatic or self-correcting or
clearly described or requires minimal judgement
Intermediate between descriptions listed for scores of 1 and 3
Test system troubleshooting is not automatic or self-correcting and
requires decision-making to resolve most problems; or equipment
maintenance requires special knowledge, skills, and abilities
3
Time to reporting of results Results are reported within 4 hours of collection of almost all
specimens
Intermediate between descriptions listed for scores of 1 and 3 2
Median time to reporting of results exceeds the median duration of
hospitalisations/time to death
Health and safety The test is completed using low levels of personal protection,
i.e. gloves
Intermediate between descriptions listed for scores of 1 and 3
One or more operational steps requires bio-safety level Category 3,
or higher
3
Storage and disposal of waste
test materials and reagents
Waste materials and reagents are stored and disposed using
medium duty ‘Clinical waste’ plastic bags and ‘Sharps’ containers,
or a sluice
Intermediate between descriptions listed for scores of 1 and 3
Waste materials or reagents include hazardous materials that
require special attention
3
Total EoU score 30
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ABLE 41 Component EoU scores for one-step, real-time RT-PCR tests for inﬂuenza A subtypes H1 and H3,
ﬂuenza B, and RSV A and B
Categories Criteria for categorisation EoU score
Test site Is a POCT
Intermediate between descriptions listed for scores of 1 and 3 2
Requires purpose-built accommodation, ventilation systems and
dedicated space
Equipment No specialised equipment required and is readily transferred
between hospital facilities
Intermediate between descriptions listed for scores of 1 and 3
Specialised equipment is essential and non-portable 3
Materials and reagents Are stable, pre-packaged and/or pre-measured, and require no
special handling steps or storage
1
Intermediate between descriptions listed for scores of 1 and 3
May be labile requiring special storage or require special handling
steps; their preparation requires manual steps, e.g. volumetric
measurement
Operational steps Either automatically executed or easily controlled
Intermediate between descriptions listed for scores of 1 and 3 2
Require close monitoring and control, and may require special
preparation, precise temperature control or timing, accurate
pipetting or extensive calculations
Training, experience and
knowledge
Require minimal scientiﬁc and technical knowledge and experience;
and knowledge to perform test can be obtained through on-job
instruction (commensurate with AFC Band 4, or less)
Intermediate between descriptions listed for scores of 1 and 3 2
Specialised scientiﬁc and technical knowledge essential and
substantial experience required (commensurate with AFC Band 7,
or higher)
Calibration and quality control Calibration is either automatic or not required; quality control
materials are included, or readily available, and are stable
Intermediate between descriptions listed for scores of 1 and 3
Calibration and quality control materials, if available, may be labile
or unavailable; or technical expertise is required for calibration
3
Interpretation and judgement Minimal interpretation and judgement are required, and problems
require limited interpretation, judgement and decision-making
Intermediate between descriptions listed for scores of 1 and 3 2
Extensive interpretation and judgement are required; resolution
of problems requires extensive interpretation, judgement and
decision-making
continued
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TABLE 41 Component EoU scores for one-step, real-time RT-PCR tests for inﬂuenza A subtypes H1 and H3,
inﬂuenza B, and RSV A and B (continued )
Categories Criteria for categorisation EoU score
Test system troubleshooting
and equipment maintenance
Test system troubleshooting is automatic or self-correcting or
clearly described or requires minimal judgement
Intermediate between descriptions listed for scores of 1 and 3 2
Test system troubleshooting is not automatic or self-correcting and
requires decision-making to resolve most problems; or equipment
maintenance requires special knowledge, skills and abilities
Time to reporting of results Results are reported within 4 hours of collection of almost all
specimens
Intermediate between descriptions listed for scores of 1 and 3 2
Median time to reporting of results exceeds the median duration of
hospitalisations/time to death
Health and safety The test is completed using low levels of personal protection,
i.e. gloves
Intermediate between descriptions listed for scores of 1 and 3
One or more operational steps requires bio-safety level Category 3,
or higher
3
Storage and disposal of waste
test materials and reagents
Waste materials and reagents are stored and disposed using
medium duty ‘Clinical waste’ plastic bags and ‘Sharps’ containers,
or a sluice
Intermediate between descriptions listed for scores of 1 and 3
Waste materials or reagents include hazardous materials that
require special attention
3
Total EoU score 25
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ABLE 42 Component EoU scores for two-step, real-time, RT-PCR tests for inﬂuenza A subtypes H1 and H3,
ﬂuenza B, and RSV A and B
Categories Criteria for categorisation EoU score
Test site Is a POCT
Intermediate between descriptions listed for scores of 1 and 3 2
Requires purpose-built accommodation, ventilation systems and
dedicated space
Equipment No specialised equipment required and is readily transferred
between hospital facilities
Intermediate between descriptions listed for scores of 1 and 3
Specialised equipment is essential and non-portable 3
Materials and reagents Are stable, pre-packaged and/or pre-measured, and require no
special handling steps or storage
1
Intermediate between descriptions listed for scores of 1 and 3
May be labile requiring special storage or require special handling
steps; their preparation requires manual steps, e.g. volumetric
measurement
Operational steps Either automatically executed or easily controlled
Intermediate between descriptions listed for scores of 1 and 3
Require close monitoring and control, and may require special
preparation, precise temperature control or timing, accurate
pipetting or extensive calculations
3
Training, experience and
knowledge
Require minimal scientiﬁc and technical knowledge and experience;
and knowledge to perform test can be obtained through on-job
instruction (commensurate with AFC Band 4, or less)
Intermediate between descriptions listed for scores of 1 and 3 2
Specialised scientiﬁc and technical knowledge essential and
substantial experience required (commensurate with AFC Band 7,
or higher)
Calibration and quality control Calibration is either automatic or not required; quality control
materials are included, or readily available, and are stable
Intermediate between descriptions listed for scores of 1 and 3
Calibration and quality control materials, if available, may be labile
or unavailable; or technical expertise is required for calibration
3
Interpretation and judgement Minimal interpretation and judgement are required, and problems
require limited interpretation, judgement and decision-making
Intermediate between descriptions listed for scores of 1 and 3 2
Extensive interpretation and judgement are required; resolution
of problems requires extensive interpretation, judgement and
decision-making
continued
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ABLE 42 Component EoU scores for two-step, real-time, RT-PCR tests for inﬂuenza A subtypes H1 and H3,
ﬂuenza B, and RSV A and B (continued )
Categories Criteria for categorisation EoU score
Test system troubleshooting
and equipment maintenance
Test system troubleshooting is automatic or self-correcting or
clearly described or requires minimal judgement
Intermediate between descriptions listed for scores of 1 and 3 2
Test system troubleshooting is not automatic or self-correcting and
requires decision-making to resolve most problems; or equipment
maintenance requires special knowledge, skills
and abilities
Time to reporting of results Results are reported within 4 hours of collection of almost all
specimens
Intermediate between descriptions listed for scores of 1 and 3 2
Median time to reporting of results exceeds the median duration of
hospitalisations/time to death
Health and safety The test is completed using low levels of personal protection,
i.e. gloves
Intermediate between descriptions listed for scores of 1 and 3
One or more operational steps requires bio-safety level Category 3,
or higher
3
Storage and disposal of waste
test materials and reagents
Waste materials and reagents are stored and disposed using
medium duty ‘Clinical waste’ plastic bags and ‘Sharps’ containers,
or a sluice
Intermediate between descriptions listed for scores of 1 and 3
Waste materials or reagents include hazardous materials that
require special attention
3
Total EoU score 26
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ABLE 43 Component EoU scores for virus culture for the diagnosis of inﬂuenza A and B, and RSV
Categories Criteria for categorisation EoU score
Test site Is a POCT
Intermediate between descriptions listed for scores of 1 and 3 2
Requires purpose-built accommodation, ventilation systems and
dedicated space
Equipment No specialised equipment required and is readily transferred
between hospital facilities
Intermediate between descriptions listed for scores of 1 and 3
Specialised equipment is essential and non-portable 3
Materials and reagents Are stable, pre-packaged and/or pre-measured, and require no
special handling steps or storage
Intermediate between descriptions listed for scores of 1 and 3
May be labile requiring special storage or require special handling
steps; their preparation requires manual steps, e.g. volumetric
measurement
3
Operational steps Either automatically executed or easily controlled
Intermediate between descriptions listed for scores of 1 and 3
Require close monitoring and control, and may require special
preparation, precise temperature control or timing, accurate
pipetting or extensive calculations
3
Training, experience and
knowledge
Require minimal scientiﬁc and technical knowledge and experience;
and knowledge to perform test can be obtained through on-job
instruction (commensurate with AFC Band 4, or less)
Intermediate between descriptions listed for scores of 1 and 3 2
Specialised scientiﬁc and technical knowledge essential and
substantial experience required (commensurate with AFC Band 7,
or higher)
Calibration and quality control Calibration is either automatic or not required; quality control
materials are included, or readily available, and are stable
1
Intermediate between descriptions listed for scores of 1 and 3
Calibration and quality control materials, if available, may be labile
or unavailable; or technical expertise is required for calibration
Interpretation and judgement Minimal interpretation and judgement are required, and problems
require limited interpretation, judgement and decision-making
Intermediate between descriptions listed for scores of 1 and 3
Extensive interpretation and judgement are required; resolution
of problems requires extensive interpretation, judgement and
decision-making
3
continued
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TABLE 43 Component EoU scores for virus culture for the diagnosis of inﬂuenza A and B, and RSV (continued )
Categories Criteria for categorisation EoU score
Test system troubleshooting
and equipment maintenance
Test system troubleshooting is automatic or self-correcting or
clearly described or requires minimal judgement
Intermediate between descriptions listed for scores of 1 and 3 2
Test system troubleshooting is not automatic or self-correcting and
requires decision-making to resolve most problems; or equipment
maintenance requires special knowledge, skills and abilities
Time to reporting of results Results are reported within 4 hours of collection of almost
all specimens
Intermediate between descriptions listed for scores of 1 and 3
Median time to reporting of results exceeds the median duration of
hospitalisations/time to death
3
Health and safety The test is completed using low levels of personal protection,
i.e. gloves
Intermediate between descriptions listed for scores of 1 and 3 2
One or more operational steps requires bio-safety level Category 3,
or higher
Storage and disposal of waste
test materials and reagents
Waste materials and reagents are stored and disposed using
medium duty ‘Clinical waste’ plastic bags and ‘Sharps’ containers,
or a sluice
Intermediate between descriptions listed for scores of 1 and 3 2
Waste materials or reagents include hazardous materials that
require special attention
Total EoU score 26
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ABLE 44 Component EoU scores for the BacT/ALERT 3D blood culture system
Categories Criteria for categorisation EoU score
Test site Is a POCT
Intermediate between descriptions listed for scores of 1 and 3 2
Requires purpose-built accommodation, ventilation systems and
dedicated space
Equipment No specialised equipment required and is readily transferred
between hospital facilities
Intermediate between descriptions listed for scores of 1 and 3
Specialised equipment is essential and non-portable 3
Materials and reagents Are stable, pre-packaged and/or pre-measured, and require no
special handling steps or storage
1
Intermediate between descriptions listed for scores of 1 and 3
May be labile requiring special storage or require special handling
steps; their preparation requires manual steps, e.g. volumetric
measurement
Operational steps Either automatically executed or easily controlled 1
Intermediate between descriptions listed for scores of 1 and 3
Require close monitoring and control, and may require special
preparation, precise temperature control or timing, accurate
pipetting or extensive calculations
Training, experience and
knowledge
Require minimal scientiﬁc and technical knowledge and experience;
and knowledge to perform test can be obtained through on-job
instruction (commensurate with AFC Band 4, or less)
Intermediate between descriptions listed for scores of 1 and 3 2
Specialised scientiﬁc and technical knowledge essential and
substantial experience required (commensurate with AFC Band 7,
or higher)
Calibration and quality control Calibration is either automatic or not required; quality control
materials are included, or readily available, and are stable
Intermediate between descriptions listed for scores of 1 and 3 2
Calibration and quality control materials, if available, may be labile
or unavailable; or technical expertise is required for calibration
Interpretation and judgement Minimal interpretation and judgement are required, and problems
require limited interpretation, judgement and decision-making
Intermediate between descriptions listed for scores of 1 and 3 2
Extensive interpretation and judgement are required; resolution
of problems requires extensive interpretation, judgement and
decision-making
continued
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ABLE 44 Component EoU scores for the BacT/ALERT 3D blood culture system (continued )
Categories Criteria for categorisation EoU score
Test system troubleshooting
and equipment maintenance
Test system troubleshooting is automatic or self-correcting or
clearly described or requires minimal judgement
1
Intermediate between descriptions listed for scores of 1 and 3
Test system troubleshooting is not automatic or self-correcting and
requires decision-making to resolve most problems; or equipment
maintenance requires special knowledge, skills and abilities
Time to reporting of results Results are reported within 4 hours of collection of almost all
specimens
Intermediate between descriptions listed for scores of 1 and 3 2
Median time to reporting of results exceeds the median duration of
hospitalisations/time to death
Health and safety The test is completed using low levels of personal protection,
i.e. gloves
Intermediate between descriptions listed for scores of 1 and 3 2
One or more operational steps requires bio-safety level Category 3,
or higher
Storage and disposal of waste
test materials and reagents
Waste materials and reagents are stored and disposed using
medium duty ‘Clinical waste’ plastic bags and ‘Sharps’ containers,
or a sluice
Intermediate between descriptions listed for scores of 1 and 3 2
Waste materials or reagents include hazardous materials that
require special attention
Total EoU score 20
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TABLE 45 Component EoU scores for sputum culture
Categories Criteria for categorisation EoU score
Test site Is a POCT
Intermediate between descriptions listed for scores of 1 and 3
Requires purpose-built accommodation, ventilation systems and
dedicated space
3
Equipment No specialised equipment required and is readily transferred
between hospital facilities
Intermediate between descriptions listed for scores of 1 and 3 2
Specialised equipment is essential and non-portable
Materials and reagents Are stable, pre-packaged and/or pre-measured, and require no
special handling steps or storage
Intermediate between descriptions listed for scores of 1 and 3 2
May be labile requiring special storage or require special handling
steps; their preparation requires manual steps, e.g. volumetric
measurement
Operational steps Either automatically executed or easily controlled 1
Intermediate between descriptions listed for scores of 1 and 3
Require close monitoring and control, and may require special
preparation, precise temperature control or timing, accurate
pipetting or extensive calculations
Training, experience and
knowledge
Require minimal scientiﬁc and technical knowledge and experience;
and knowledge to perform test can be obtained through on-job
instruction (commensurate with AFC Band 4, or less)
Intermediate between descriptions listed for scores of 1 and 3 2
Specialised scientiﬁc and technical knowledge essential and
substantial experience required (commensurate with AFC Band 7,
or higher)
Calibration and quality control Calibration is either automatic or not required; quality control
materials are included, or readily available, and are stable
1
Intermediate between descriptions listed for scores of 1 and 3
Calibration and quality control materials, if available, may be labile
or unavailable; or technical expertise is required for calibration
Interpretation and judgement Minimal interpretation and judgement are required, and problems
require limited interpretation, judgement and decision-making
Intermediate between descriptions listed for scores of 1 and 3
Extensive interpretation and judgement are required; resolution
of problems requires extensive interpretation, judgement and
decision-making
3
continued
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TABLE 45 Component EoU scores for sputum culture (continued )
Categories Criteria for categorisation EoU score
Test system troubleshooting
and equipment maintenance
Test system troubleshooting is automatic or self-correcting or
clearly described or requires minimal judgement
Intermediate between descriptions listed for scores of 1 and 3
Test system troubleshooting is not automatic or self-correcting and
requires decision-making to resolve most problems; or equipment
maintenance requires special knowledge, skills and abilities
3
Time to reporting of results Results are reported within 4 hours of collection of almost all
specimens
Intermediate between descriptions listed for scores of 1 and 3 2
Median time to reporting of results exceeds the median duration of
hospitalisations/time to death
Health and safety The test is completed using low levels of personal protection,
i.e. gloves
Intermediate between descriptions listed for scores of 1 and 3
One or more operational steps requires bio-safety level Category 3,
or higher
3
Storage and disposal of waste
test materials and reagents
Waste materials and reagents are stored and disposed using
medium duty ‘Clinical waste’ plastic bags and ‘Sharps’ containers,
or a sluice
Intermediate between descriptions listed for scores of 1 and 3
Waste materials or reagents include hazardous materials that
require special attention
3
Total EoU score 25
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TABLE 46 Component EoU scores for sputum Gram stain and microscopy
Categories Criteria for categorisation EoU score
Test site Is a POCT
Intermediate between descriptions listed for scores of 1 and 3
Requires purpose-built accommodation, ventilation systems and
dedicated space
3
Equipment No specialised equipment required and is readily transferred
between hospital facilities
Intermediate between descriptions listed for scores of 1 and 3 2
Specialised equipment is essential and non-portable
Materials and reagents Are stable, pre-packaged and/or pre-measured, and require no
special handling steps or storage
Intermediate between descriptions listed for scores of 1 and 3 2
May be labile requiring special storage or require special handling
steps; their preparation requires manual steps, e.g. volumetric
measurement
Operational steps Either automatically executed or easily controlled
Intermediate between descriptions listed for scores of 1 and 3 2
Require close monitoring and control, and may require special
preparation, precise temperature control or timing, accurate
pipetting or extensive calculations
Training, experience and
knowledge
Require minimal scientiﬁc and technical knowledge and experience;
and knowledge to perform test can be obtained through on-job
instruction (commensurate with AFC Band 4, or less)
Intermediate between descriptions listed for scores of 1 and 3
Specialised scientiﬁc and technical knowledge essential and
substantial experience required (commensurate with AFC Band 7,
or higher)
3
Calibration and quality control Calibration is either automatic or not required; quality control
materials are included, or readily available, and are stable
1
Intermediate between descriptions listed for scores of 1 and 3
Calibration and quality control materials, if available, may be labile
or unavailable; or technical expertise is required for calibration
Interpretation and judgement Minimal interpretation and judgement are required, and problems
require limited interpretation, judgement and decision-making
Intermediate between descriptions listed for scores of 1 and 3 2
Extensive interpretation and judgement are required; resolution
of problems requires extensive interpretation, judgement and
decision-making
continued
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ABLE 46 Component EoU scores for sputum Gram stain and microscopy (continued )
Categories Criteria for categorisation EoU score
Test system troubleshooting
and equipment maintenance
Test system troubleshooting is automatic or self-correcting or
clearly described or requires minimal judgement
Intermediate between descriptions listed for scores of 1 and 3 2
Test system troubleshooting is not automatic or self-correcting and
requires decision-making to resolve most problems; or equipment
maintenance requires special knowledge, skills and abilities
Time to reporting of results Results are reported within 4 hours of collection of almost
all specimens
Intermediate between descriptions listed for scores of 1 and 3 2
Median time to reporting of results exceeds the median duration of
hospitalisations/time to death
Health and safety The test is completed using low levels of personal protection,
i.e. gloves
Intermediate between descriptions listed for scores of 1 and 3
One or more operational steps requires bio-safety level Category 3,
or higher
3
Storage and disposal of waste
test materials and reagents
Waste materials and reagents are stored and disposed using
medium duty ‘Clinical waste’ plastic bags and ‘Sharps’ containers,
or a sluice
1
Intermediate between descriptions listed for scores of 1 and 3
Waste materials or reagents include hazardous materials that
require special attention
Total EoU score 23
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DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36Appendix 8 Sample of WinBUGS code usedA. WinBUGS code (model A)# 3 WS: Cost-effectiveness analysis
*************1 = costs, 2 = QALYs***************
*************group: 1 = POCT, 2 = PCR, 3 = culture*****Modelmodel {
for(j in 1:N) {
y[j, 1:2] ∼ dmnorm(mu[group[j],], tau[group[j],,])
}
# Prior distributions
for (i in 1:3) {
mu[i,1] ∼ dnorm(0.0,1.0E-8)
mu[i,2] ∼ dnorm(0.0,100)
tau[i,1:2,1:2] ∼ dwish(A[,], f)
}}Data – original scalelist(N = 1252)
group[] y[,1] y[,2]
1 1042.02 NA
1 8763.113 0.0037973
2 959.1775 0.0068849
2 529.565 NA
3 NA NA267
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APPENDIX 8
2681 1240.867 0.0042
3 1011.275 0.0025507
2 NA 0.0084479
.
.
.
.
.
2 NA 0.0084671
1 NA 0.0006808
3 NA 0.016474
ENDSpecifying prior distributions for Wishart distributionlist(f = 2)
# Covariance matrix prior estimate
A[,1] A[,2]
10000 0
0 0.01
ENDNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 36B. Markov chain Monte Carlo sensitivity analysesTable 47 displays the results of various sensitivity analyses exploring the impact of length of ‘burn-in’ and
sample, different initial/starting values, and changing the prior distributions used in terms of their impact
on the posterior mean costs and QALYs for the three patient groups.TABLE 47 Markov chain Monte Carlo sensitivity analyses
Parameter Traditional PCR POCT
Base case (model A)
Costs (£) 2327 (1989 to 2664) 1978 (1743 to 2165) 2159 (1828 to 2485)
QALYs 0.007588
(0.006334 to 0.008854)
0.007779
(0.006555 to 0.008983)
0.008035
(0.006772 to 0.009280)
Burn-in/sample
10k/20k
Costs (£) 2327 (1992 to 2661) 1977 (1739 to 2216) 2160 (1831 to 2491)
QALYs 0.007596
(0.006337 to 0.008882)
0.007776
(0.006553 to 0.008990)
0.008030
(0.006786 to 0.009286)
50k/100k
Costs (£) 2326 (1991 to 2663) 1977 (1741 to 2215) 2160 (1833 to 2487)
QALYs 0.007599
(0.006330 to 0.008877)
0.007776
(0.006563 to 0.008988)
0.008033
(0.006789 to 0.009281)
Alternative priors
Costs (£) 1786 (1478 to 2091) 1724 (1500 to 1947) 1682 (1384 to 1979)
QALYs 0.007322
(0.004132 to 0.010550)
0.007682
(0.004706 to 0.010670)
0.007853
(0.004968 to 0.010750)
Alternative starting values
Chain 1
Costs (£) 2327 (1994 to 2664) 1977 (1739 to 2213) 2159 (1834 to 2485)
QALYs 0.007597
(0.006310 to 0.008866)
0.007771
(0.006557 to 0.008987)
0.008037
(0.006787 to 0.009286)
Chain 2
Costs (£) 2327 (1989 to 2666) 1977 (1741 to 2215) 2160 (1837 to 2485)
QALYs 0.007598
(0.006326 to 0.008882)
0.007770
(0.006568 to 0.008983)
0.008035
(0.006776 to 0.009284)
Chain 3
Costs (£) 2326 (1990 to 2662) 1978 (1739 to 2216) 2161 (1835 to 2487)
QALYs 0.007602
(0.006330 to 0.008873)
0.007783
(0.006565 to 0.009009)
0.008039
(0.006793 to 0.009295)
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mu[1,1] chain 1
Iteration
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Iteration
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1.00E+3
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2.00E+3
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mu[1,2] chain 1
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mu[2,1] chain 1
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0.008
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0.012
mu[3,1] chain 1
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IGURE 23 Markov chain Monte Carlo history plots for mean costs and QALYs.
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mu[1,1] chains 1 : 3
Iteration
20,001 40,000 60,000
0.0
0.5
1.0
Iteration
20,001 40,000 60,000
0.0
0.5
1.0
Iteration
20,001 40,000 60,000
0.0
0.5
1.0
mu[1,2] chains 1 : 3
mu[2,1] chains 1 : 3
FIGURE 24 Brooks–Gelman–Rubin plots for chains 1, 2 and 3, representing three different sets of
starting/initial values.
mu[1,1] chain 1
Lag
0 20 40
– 1.0
– 0.5
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0.5
1.0
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0 20 40
– 1.0
– 0.5
0.0
0.5
1.0
Lag
0 20 40
– 1.0
– 0.5
0.0
0.5
1.0
mu[1,2] chain 1
mu[2,1] chain 1
FIGURE 25 Markov chain Monte Carlo autocorrelation plots for mean costs and QALYs.
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272C. Alternative model (model B) – WinBUGS and R codeWinBUGS code# 3 WS – Gamma/Logit cost-effectiveness model
*************1 = costs, 2 = QALYs***************
*************group: 1 = POCT, 2 = PCR, 3 = culture*****Modelmodel {
for(j in 1:N) {
y[j,1] ∼ dgamma(eta[group[j]], lambda0[j])
lambda0[j] <- eta[group[j]]/phi0[j]
y[j,2] ∼ dnorm(mu.e[group[j]],tau[group[j]])
phi0[j] <- mu.c[group[j]] + beta[group[j]]*(y[j,2] – mu.e[group[j]])
}
# Priors
for (i in 1:3) {
tau[i] <- pow(sigma.e[i],–2)
sigma2.e[i] <- pow(sigma.e[i],2)
eta[i] ∼ dunif(1,100)
mu.c[i] ∼ dunif(1,50000)
mu.e[i] ∼ dnorm(0.0,0.001)
sigma.e[i] ∼ dnorm(0.0,1)I(0,)
beta[i] ∼ dnorm(0.0,0.001)}
}Datagroup[] y[,1] y[,2]
1 1042.02 NA
1 8763.113 –5.569660463NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18360 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 362 959.1775 –4.971515961
2 529.565 NA
3 NA NA
1 1240.867 –5.468461909
3 1011.275 –5.968833489
3 2585.17 –5.38489336
.
.
.
.
.
2 NA –4.763064064
1 NA –7.291560949
3 NA –4.089360693
ENDStarting valueslist(beta = c(0,0,0), eta = c(40,40,40), sigma.e = c(0.5,0.5,0.5), mu.c = c(2000,2000,2000),
mu.e = c(–5,–5,–5))R codeMatrices mu.e and sigma.e (which are on the logit(QALY) scale) are obtained from WinBUGS model above
using ﬁles wb.output and wb2.output.
# Read data in
mu.e <- cbind(wb.output[60001:80000,2],wb.output[80001:100000,2],wb.output[100001:120000,2])
sigma.e <- cbind(wb.output2[1:20000,2],wb.output2[20001:40000,2],wb.output2[40001:60000,2])
# Create matrices to store results
m.e <- array(NA,c(20000,3))
e.pred <- array(NA,c(1000,20000,3))
estar.pred <- e.pred273
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274# Undertake MC simulations
for (t in 1:3) {
for (s in 1:20000) {
estar.pred[,s,t] <- rnorm(1000,mu.e[s,t],sigma.e[s,t])
e.pred[,s,t] <- exp(estar.pred[,s,t])/(1 + exp(estar.pred[,s,t]))
}
m.e[,t] <- apply(e.pred[,, t],2,mean)
}
# Calculate means on original scale
mean(m.e[,1])
mean(m.e[,2])
mean(m.e[,3])NIHR Journals Library www.journalslibrary.nihr.ac.uk
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